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ABSTRACT 
 
 
The prevailing lifestyle pattern in western society results in humans spending the majority of 
non-sleeping hours in the postprandial state. Given that impaired postprandial metabolism 
may have adverse consequences for health, interventions that positively influence the 
postprandial milieu are pertinent considering the global rise in prevalence of chronic 
metabolic disorders. The aim of this thesis was to investigate whether consumption of whey 
protein, which has reported beneficial properties relevant to metabolic health, could impact 
favourably upon acute and second-meal postprandial metabolic and appetite responses. More 
specifically, a series of studies was designed to establish the conditions under which a 
rationale for whey protein supplementation may be strongest, through investigation of co-
ingestion with other macronutrients, timing of supplementation and interactions with low-
moderate intensity exercise.  
 
Study one revealed that consuming whey (20 g) alongside a high-carbohydrate or high-fat 
breakfast significantly augmented the plasma insulin response to that meal in physically 
active, normal-weight males, without significantly affecting postprandial glycaemia, 
lipaemia or subjective appetite. Whey protein consumption at breakfast did not affect second 
meal responses or 24-hour glycaemia when co-ingested with either macronutrient. Study two 
compared the effects of the same dose of protein administered before, during or after a mixed-
macronutrient breakfast in centrally-obese males. Consuming whey as a preload 15 minutes 
prior to breakfast significantly reduced postprandial glycaemia compared to consuming it 
afterwards or not at all, with evidence indicating that insulin-independent mechanisms may 
iv 
 
be responsible. Again, prior whey consumption, irrespective of timing, did not influence 
glycaemic, insulinaemic or appetite profiles following a standard lunch meal. The final study 
investigated the effects of a post-exercise whey protein preload on postprandial metabolism 
and appetite in physically inactive, centrally-obese males. Postprandial glycaemia was 
moderately impaired following brisk walking exercise without supplemental protein, 
however this effect was negated when exercise was followed by a whey preload, with a 
reduced peak glycaemic excursion observed compared to other conditions. Ad libitum energy 
intake, assessed at lunch, did not differ between conditions. 
 
This thesis has shown that whey protein supplementation at breakfast may acutely influence 
postprandial glycaemia in centrally-obese individuals, however this beneficial effect is not 
carried over to subsequent meal occasions. Timing of protein intake appears to be important, 
and this effect is not diminished by prior walking exercise in previously sedentary 
individuals. Further studies to investigate the effects of whey protein supplementation at 
multiple meals are required to determine whether this may be a worthwhile strategy to 
prevent day-long elevated glycaemic exposure. 
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CHAPTER 1 
 
Introduction 
 
1  
1.1 Introduction 
 
The impact of impaired metabolic health is increasingly a global concern which is driven 
largely by increased prevalence of obesity. In a systematic report published in The Lancet 
using data from 1.9 million participants residing in 199 countries, Finucane et al. (2011) 
estimated that there are 502 million adults with obesity globally. Further reports indicate that 
prevalence is rapidly increasing in developing countries (Misra & Khurana, 2008) (see Figure 
1.1), and the effects of an ‘obesity epidemic’, which began in the USA over 40 years ago 
(Malik et al., 2013), are recognised by the World Health Organisation (WHO) (James, 2008). 
According to the most recent Health Survey for England (Bridges et al., 2015) 25.6% of the 
adult population are obese (body mass index (BMI) > 30 kg∙m-2).  
 
The consistently high prevalence of obesity has far-reaching effects on society, and the health 
burden is largely driven by the increased risk of developing type 2 diabetes mellitus (T2DM), 
cardiovascular disease (CVD) and some forms of cancer (Wang et al., 2011). In line with 
increasing obesity, it follows that T2DM and metabolic syndrome, a clustering of inter-
related metabolic risk factors (Kassi et al., 2011), are becoming more prevalent worldwide 
(Halcox & Misra, 2015; Nolan et al., 2011). Current estimates predict that the global 
prevalence of T2DM will rise to 334 million patients by 2025 (Gillett et al., 2012), with 
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accompanying increases in young people (Elder et al., 2015). Moreover, there are 
approximately 316 million individuals with impaired glucose tolerance (IGT) who are at high 
risk of progression to T2DM (Verma & Hussain, 2016). The impact of such disorders upon 
quality of life, in addition to the health care burden (treatment and management of diabetes 
and its ensuing complications accounts for approximately 10% of National Health Service 
spending per annum (Diabetes UK, 2014; Hex et al., 2012)), underscores the importance of 
implementing strategies to avert the progression from normal to impaired metabolism.  
 
 
 
 
Figure 1.1 The prevalence of obesity in adult women (a) and men (b) in 1980 and 2008 from different world regions. 
Adapted from Finucane et al. (2011) and Malik et al. (2013). 
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Pharmacological agents such as metformin and thiazolidinediones can be effective in 
lowering blood glucose and reducing the risk of metabolic diseases, with possible favourable 
cardiovascular effects, however their efficacy over the long term is uncertain and side effects 
limit their use (Tahrani et al., 2011; Tahrani et al., 2010). The role of lifestyle change in the 
prevention of onset and deterioration in metabolic health is therefore paramount, and remains 
the cornerstone in prevention and management of insulin resistance (Altaf et al., 2015). 
Evidence demonstrating that many chronic diseases are preventable through lifestyle is 
compelling (Diabetes Prevention Program Research Group, 2002; Salas-Salvadó et al., 2011; 
Tuomilehto  et al., 2001), thus health promotion strategies are necessary in improving quality 
of life and reducing the burden on health care systems (Slawson et al., 2013). A key part of 
this is identifying dietary practices as well as foods or food components which facilitate 
reduced risk of metabolic health deterioration.  
 
Epidemiological studies have demonstrated an inverse relationship between dairy product 
consumption and incidence of obesity (Mirmiran et al., 2005; Rautiainen et al., 2016), 
metabolic syndrome (Drehmer et al., 2015a) and T2DM (Aune et al., 2013; Díaz-López et 
al., 2016). It has been proposed that dairy proteins, particularly whey protein, may be 
responsible for driving this association. Whey protein comprises approximately 20% of 
bovine milk protein and was historically seen as a waste by-product of the cheese 
manufacturing process, where the solid curds (casein protein constituting the remaining 80%) 
are removed from milk leaving the soluble whey proteins behind (Bansal & Bhandari, 2016). 
It contains a heterogeneous group of protein fractions, a number of which have been shown 
to exert biological effects in vitro (Lacroix & Li-Chan, 2014) and in animal models (Shi et 
al., 2012). Whey is now recognised as a high-quality protein and a valuable co-product of 
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casein production for use as a functional food ingredient (Luhovyy et al., 2007), with an 
increasing number of experimental studies investigating the effects of whey consumption on 
metabolic regulation, satiety and food intake. However, many questions remain regarding the 
effectiveness of whey protein to augment meal responses, and knowledge of beneficial 
strategies for its supplementation which have ‘real world’ application may be important when 
evaluating the efficacy of whey protein to help prevent the progression of metabolic 
impairment.  
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CHAPTER 2 
 
Literature Review 
 
2  
2.1 Introduction 
 
Given the vast global burden of poor metabolic health on both society and healthcare systems, 
it is prudent to consider lifestyle and dietary interventions to prevent or manage the 
deterioration of metabolic processes associated with the onset of obesity and related 
metabolic disorders. The following review of literature therefore presents an overview of 
normal metabolic and appetite regulatory processes, how they are impaired in declining 
metabolic health, and strategies to prevent or manage this decline.  
 
2.2 Normal metabolism 
 
2.2.1 Carbohydrate metabolism 
 
Carbohydrate metabolism involves coordinated regulation of glucose intake, storage, 
mobilisation and breakdown (Efeyan et al., 2015). Synchronised adjustments are made to 
rates of glucose appearance (from exogenous and endogenous pathways) into and 
disappearance (tissue uptake and storage) from the blood, to manipulate glucose flux and 
thus maintain blood glucose concentration within the typical range.  
 
6 
 
In the postabsorptive state, typically represented by an overnight fast, glucose turnover 
decreases to its nadir within the 24-hour cycle, and plasma glucose concentration is relatively 
stable (Shrayyef & Gerich, 2010). The greatest test of glucoregulation occurs when this 
situation is challenged by ingestion of a meal (particularly a high carbohydrate meal), and 
gives way to the postprandial state. This period of 4-7 hours immediately following meal 
ingestion involves nutrient assimilation and metabolism (Gerich, 1993; Monnier, 2000). 
Dietary carbohydrates are digested via progressive hydrolysis in the intestinal lumen and a 
number of enzymes located within the brush-border of enterocytes, in order to liberate free 
monosaccharides (Monnier, 2000). These are conveyed into the enterocyte via transport 
proteins, and ultimately enter the circulation into the hepatic portal vein.  
 
Blood glucose concentration is noticeably increased within 15 minutes of ingestion of a 
mixed meal, and peaks at around 30-60 minutes (Frayn, 2010). The size of postprandial 
glycaemic excursions from postabsorptive levels has become a prominent area of interest for 
researchers, as postprandial hyperglycaemia is considered a precursor for T2DM and an 
independent risk factor for CVD (Gerich, 2006). The extent of circulating glucose excursions 
following meal ingestion may depend on a number of factors. Firstly, the rate of gastric 
emptying is known to account for up to 35-50% of the variation in peak blood glucose 
following ingestion of glucose in healthy individuals (Horowitz et al., 1993; Woerle et al., 
2008), and can be altered by aspects such as meal size and the amounts of complex 
carbohydrate, fibre and simple sugars in the meal (Russell et al., 2016). Other factors include 
whether the meal is in solid or liquid form, and the accompanying amounts of protein and 
fat, both of which delay gastric emptying (Gerich, 1993).  
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Insulin is a key metabolic regulator, acting primarily to lower plasma glucose concentration 
via suppression of endogenous glucose production from the liver and kidneys, promotion of 
glucose uptake into muscle and adipose tissue and inhibition of release of non-esterified fatty 
acids (NEFA) into the circulation. Insulin synthesis and secretion occurs within pancreatic 
β-cells and glucose concentration is the main regulator of its secretion (Stumvoll, 2004), with 
a three- to fourfold increase in plasma insulin from basal level observable within 30-60 
minutes of meal ingestion (Shrayyef & Gerich, 2010). Glucose enters β-cells via glucose 
transport proteins (GLUT1-3) at a rate determined by its concentration (Yang, 2014). 
 
Insulin acts to restrain hepatic glucose output indirectly by inhibiting glycogen 
phosphorylase while simultaneously promoting glycogen synthase, thus a switch in emphasis 
from glycogen breakdown to glycogen storage occurs (Frayn, 2010). This is a relatively slow 
process, and in order to promote a reduction in plasma glucose, uptake into other tissues is 
required. Muscle and adipose glucose uptake is dependent upon the transport of glucose into 
cells, which is mediated by insulin-sensitive glucose transporter type 4 (GLUT4). An 
increase in circulating insulin following a meal leads to binding of insulin to its receptor on 
the cell surface, generating a complex signalling-cascade which induces rapid translocation 
of GLUT4 to via membrane fusion (Yang, 2014).  
 
As time since meal ingestion proceeds, and an individual begins to advance back into the 
postabsorptive state, plasma insulin levels decline and glucagon levels rise. Counter-
regulation of glucose is assisted by increased release of the catecholamines adrenaline and 
noradrenaline during stress or hypoglycaemia, with cortisol and growth hormone becoming 
important with more severe or prolonged hypoglycaemia (Mitrakou et al., 1991).  
8 
 
2.2.2 Lipid metabolism 
 
The majority of fat consumed in the diet is in the form of triglyceride. Digestion and 
absorption of dietary fat results in monoglycerides and fatty acids being taken up into 
enterocytes where re-esterification occurs, forming new triglyceride molecules. (Hussain, 
2014). These are packaged with phospholipids, cholesterol and apolipoprotein-B48 
(ApoB48) to produce large lipoprotein molecules (Ansar et al., 2011). In contrast to absorbed 
carbohydrate, these triglyceride-rich chylomicrons initially bypass splanchnic tissues by 
exiting absorptive cells via exocytosis into the lacteals, ultimately entering the general 
circulation at the thoracic duct (Hussain, 2014). This chylomicron pathway is considerably 
slower than glucose absorption, with peak plasma triglyceride occurring 3-4 hours following 
a meal containing a moderate amount of fat (Silva et al., 2005), however short and medium-
chain fatty acids (10 carbons or fewer (Bonham et al., 2013)) escape re-esterification and 
enter the portal circulation directly in the form of NEFA (Bugaut, 1987).  
 
Following an overnight fast plasma NEFA levels are usually at their highest in the 24-hour 
cycle (around 0.4-1.0 mmol∙l-1 (Kruszynska, 1997)). Despite the lower basal concentration 
in comparison to glucose, NEFA is the predominant fuel in the postabsorptive state when 
considering the relative rate of turnover and energy yield of each substrate (Frayn, 2010). 
NEFA enters the plasma predominantly from the hydrolysis of triglyceride within the 
adipocyte (Karpe et al., 2011) which occurs as part of a constant cycle of lipolysis and re-
esterification. The hydrolysis of triglyceride is carried out by a series of lipases, including 
hormone-sensitive lipase (HSL) which is potently inhibited by insulin (Saponaro et al., 
2015). Consumption of a typical breakfast meal almost maximally suppresses lipolysis 
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(Chowdhury et al., 2015). In concert with inhibition of HSL activity, the milieu of increasing 
insulin and glucose concentrations seen postprandially also stimulates adipose tissue glucose 
uptake and oxidation, with a resultant production of glycerol 3-phosphate (Saponaro et al., 
2015). When this is readily available the rate of re-esterification of NEFA will be high, thus 
the rate of release of NEFA into the circulation is reduced (Goodman, 2009), and there is a 
subsequent switch to the use of glucose as the predominant fuel (Frayn, 2010).  
 
Insulin also has a role in promoting fat storage following consumption of a mixed meal. The 
majority of triglyceride is removed from the circulation by adipose tissue, facilitated by 
lipoprotein lipase (LPL) which adheres to the epithelium of its associated capillaries 
(Goodman, 2009). Insulin stimulates adipose LPL, mediated via amplified transcription and 
increased export to endothelial cells, indicating that this is not an immediate effect. 
Consequently, LPL activity is greatest after several hours of insulin stimulation (Czech et al., 
2013) which coincides with chylomicron entry into the plasma, allowing rapid clearance and 
emphasising the coordination of insulin secretion with lipid metabolism (Frayn, 2010).  
 
2.2.3 Protein metabolism 
 
Proteins are fundamental to both the architecture and the activity of living cells, functioning 
as structural and contractile elements as well as hormones, enzymes, transport proteins, 
antibodies and numerous other physiological roles (Gropper & Smith, 2013). In the 
postabsorptive state, there is net breakdown of protein in muscle, which can largely be 
attributed to the low insulin concentration. Insulin is perhaps the most important regulator of 
protein metabolism and has a net anabolic effect, promoting protein synthesis in the setting 
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of adequate amino acid availability (Biolo et al., 1999). Following a meal containing protein, 
plasma amino acids enter the circulation within 15-30 minutes and the concentration typically 
rises for several hours before returning to basal levels (Frayn, 2010). Up to a third of dietary 
amino acids are metabolised by splanchnic tissues (Soultoukis & Partridge, 2016), however 
branched-chain amino acids (BCAAs) typically remain in the circulation. Indeed, despite 
making up ~20% of dietary protein intake, BCAAs account for ~70% of amino acids leaving 
the liver following a meal (Kruszynska, 1997).  
 
The utilisation of amino acids is largely influenced by hormonal control. Following a mixed 
meal containing glucose, it is clear that plasma insulin will rise to affect this change in protein 
metabolism, however amino acids are also able to stimulate insulin secretion from β-cells 
(Newsholme et al., 2005), although the various mechanisms for this effect remain to be fully 
elucidated. This effect is noteworthy when considering individuals with T2DM, who have a 
blunted insulin response to increases in plasma glucose concentration, but amplified insulin 
secretion following amino acid ingestion (van Loon et al., 2003). This insulinotrophic effect 
appears greater following protein and carbohydrate coingestion rather than consumption of 
either macronutrient alone (Gropper & Smith, 2013).  
 
2.2.4 Acute effects of aerobic exercise on subsequent metabolism 
 
Regular aerobic exercise is considered an effective strategy in the prevention of metabolic 
health impairment, partly due to the transient effects on postprandial metabolism which can 
last upwards of 48 hours following the most recent bout (Colberg et al., 2010). Acute exercise 
is known to significantly impact lipid metabolism. Whilst triglyceride levels may remain 
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unchanged or slightly increase during exercise in the fasting state (Maraki & Sidossis, 2013), 
studies have consistently reported a reduction in triglyceride response following a high-fat 
meal after prior exercise (Freese et al., 2014). The effect of aerobic exercise on postprandial 
lipaemia appears to be related to the energy deficit created by exercise (Gill et al., 2002), 
independent of the duration or intensity of exercise, and the effects are attenuated when 
expended energy is replaced following exercise (Burton et al., 2008). The mechanisms 
responsible remain uncertain, however it is likely that increased clearance of triglyceride-
rich lipoprotein particles via enhanced muscle LPL activity plays a part, driven by the need 
to replenish intramuscular triglyceride stores depleted by exercise (Maraki & Sidossis, 2013). 
When individuals who have undergone a 12 week brisk walking programme were challenged 
to a high-fat meal, the postprandial lipaemic response did not differ from controls when 
administered 48 hours after exercise (Aldred et al., 1995), indicating that the effects of 
exercise on triglyceride metabolism appear to be transient and quickly reversed.  
 
It is well established that a single bout of aerobic exercise is sufficient to increase insulin 
sensitivity (Horowitz, 2007; Nelson & Horowitz, 2014), however the specific effects on 
subsequent postprandial glycaemic control are less well known. Whilst it would be expected 
that an increase in post exercise muscle glucose uptake would lead to improvements in post-
exercise glycaemia, responses to a mixed meal or oral glucose tolerance test (OGTT), 
assessed close to cessation of exercise, have included improvements (Hasson et al., 2010), 
no change (Gonzalez et al., 2013) or decrements (Rose et al., 2001) in glucose tolerance. 
Differences are likely to be affected by the fitness and prior nutritional state of the participant, 
exercise modality, and the timing and method of glucose tolerance assessment. An increase 
in whole body glucose uptake, indicated by a 24% greater increase in rate of glucose 
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disappearance in an OGTT following prior exercise (Rose et al., 2001), is likely due to the 
drive for muscle glycogen repletion, mediated by the residual effects of contraction-induced 
GLUT4 translocation (Borghouts & Keizer, 2000). Enhancement in the rate of glucose 
appearance from meal-derived carbohydrate appears to also be elevated in the postprandial 
period following prior exercise, and may supersede the rate of disappearance leading to 
greater rises plasma glucose (Rose et al., 2001), with greater post-exercise intestinal 
absorption a likely mediator (Gonzalez, 2014). Knudsen et al. (2014) recently established 
that the effect of an acute bout of moderate-intensity exercise appears to influenced by 
underlying glycaemic control, with an immediate increase in the postprandial glucose 
response observed in normoglycaemic participants, contrasting with preservation of glucose 
tolerance in those with IGT and T2DM. The mechanisms underlying such an effect remain 
unclear however, and the effect of altering post-exercise nutritional intake is uncertain. 
 
Ultimately, the relative significance of the acute effects of exercise on subsequent glycaemia 
may depend on whether an acute bout of exercise is followed up by further repeated exercise. 
Regular exercise training is commonly accompanied by alterations in aerobic fitness and 
body mass which have an independent influence on glucose metabolism (Coker et al., 2009). 
In sedentary non-diabetic individuals who are unlikely to undertake frequent bouts of 
exercise or physical activity, adjusting post-exercise macronutrient intake may be a prudent 
strategy to modulate post-exercise glycaemia.  
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2.3 Appetite and energy intake 
 
Control of appetite involves the complex processing of a series of homeostatic and hedonic 
stimuli regulating the initiation and maintenance of food ingestion (Berthoud, 2006). In 
addition to internal signals generated by physiological processes, external cues related to 
food and the food consumption environment exert effects on subjective perceptions of hunger 
and satiety through psychological processes (Mela, 2006). Total daily energy intake is a 
function of both the number of eating events and meal size (Benelam, 2009). Satiation, 
defined as the process leading to termination of eating, and satiety, defined as the process 
leading to inhibition of further eating (Benelam, 2009; Blundell et al., 2010), therefore play 
important roles in influencing the amount consumed at, and the time period between, each 
meal occasion.  
 
The numerous stimuli modulating satiation and satiety are presented in Figure 2.1. Here, 
satiation and early satiety are influenced largely by several sensory and cognitive factors 
relating to prior associations and aspects of meal quality. As meal contents progress into the 
stomach, increased gastric volume induces distension of the stomach which is communicated 
to the brain via activation of vagal afferents (Badman & Flier, 2005; Wang et al., 2008), 
enhancing satiation, while the presence of nutrients in the intestinal lumen stimulates 
secretion of satiety-promoting gastrointestinal hormones (Tremblay & Bellisle, 2015) 
(discussed further in section 2.3.1). A plethora of intracellular and extracellular nutrient-
sensing mechanisms exist throughout the body to detect changing metabolite levels (Efeyan 
et al., 2015) and following absorption these provide information about nutrient status which 
may also affect satiety (Benelam, 2009). The influence of blood glucose on appetite has long 
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been debated since the development of the ‘glucostatic theory’ by Mayer (1953), however 
evidence for a role of circulating glucose on appetite regulation under normal physiologic 
conditions is equivocal (Flint et al., 2007; Schultes et al., 2016). Longer term signals, 
including insulin and the adipokine leptin provide information regarding energy status (see 
section 2.3.2) in order to influence energy balance (Woods & D'Alessio, 2008).  
 
 
 
Figure 2.1 The 'Satiety Cascade' illustrating the cognitive and physiological processes influencing satiation and satiety. 
CCK, cholecystokinin; GLP-1, glucagon-like peptide; PYY, peptide tyrosine-tyrosine. Adapted from Blundell et al. (2010). 
 
 
Whilst the predominant focus of this thesis is on postprandial metabolic responses, 
modulation of appetite responses may clearly be of importance in the context of metabolic 
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health and subsequent energy intake. Physiologic changes in homeostatic appetite signals 
were not measured as part of this work, however considering their importance in the 
regulation of appetite, it is pertinent to briefly discuss their various functions in post-ingestive 
control of energy intake. 
 
2.3.1 Episodic appetite hormones 
 
A number of hormones act in the short term as episodic satiation or satiety signals, so-called 
because they act in unison with episodes of eating (Stensel, 2010), and these are summarised 
in Table 2.1. Of these, ghrelin is the only orexigenic (hunger stimulating) hormone currently 
identified and its suppression is relevant to the onset of satiety (Benelam, 2009). Levels of 
circulating ghrelin rise during fasting and immediately prior to meals but fall rapidly 
following meal intake (Cummings et al., 2004; Cummings et al., 2001), with suppression 
proportional to the caloric load ingested (Callahan et al., 2004).  
 
In contrast to the orexigenic effects of ghrelin, several gastrointestinally-derived peptides are 
known to have anorexigenic (appetite suppressing) effects. Glucagon-like peptide-1 (GLP-1) 
is secreted from the L-cells of the intestinal mucosa following direct contact with nutrients, 
in proportion to the caloric load and glucose in particular (Ahrén et al., 2010). A meta-
analysis of nine datasets (Verdich et al., 2001) identified a dose-dependent link between 
GLP-1 infusion, reductions in food intake and enhanced satiety in lean and obese participants, 
although obese individuals may be less responsive to its actions (Holst, 2007). The presence 
of nutrients in the duodenum and jejunum initiates rapid release of cholecystokinin (CCK) 
into circulation, particularly in response to fat- or protein rich meals which acts to suppress 
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intake during meals (Woods & D'Alessio, 2008). Peptide tyrosine-tyrosine (PYY) is co-
secreted from L cells in the distal gut alongside GLP-1 (Suzuki et al., 2012) and inhibits food 
intake, shown by a dose-dependent reduction in subsequent meal size following exogenous 
infusion (Muurahainen et al., 1988). An attenuated meal-stimulated PYY response is 
observed in obesity, with higher energy intake required to achieve similar postprandial PYY 
concentrations (Batterham et al., 2006).  
 
 
 
Table 2.1 Summary of relevant episodic appetite hormones and their actions. Adapted from Benelam (2009) and Suzuki et 
al. (2010). 
Hormone Primary sites of secretion Effect on  
appetite 
Mechanism Additional effects 
 
Ghrelin 
 
Stomach 
 
↑ Hunger 
 
Via ghrelin receptors in the  
brain 
 
Long-term effect on energy balance 
Growth hormone secretion 
CCK Duodenum and jejunum ↑ Satiation Via vagus nerve Delays gastric emptying 
Stimulates pancreatic enzyme 
secretion 
Stimulates gall bladder contraction 
Acts as a neurotransmitter 
GLP-1 L-cells of intestine and brain ↑ Satiety Via GLP-1R in brain Incretin (stimulates insulin 
production) 
Slows gastric emptying 
PYY 3-36 Ileum, colon and rectum ↑ Satiety Via Y2 receptors in brain Slows gastric emptying 
Delays intestinal transport 
Reduces gastric secretions 
Glucagon Pancreatic α-cells ↑ Satiety Via vagus nerve Increases blood glucose levels and 
insulin secretion 
CCK, cholecystokinin; GLP-1, glucagon-like peptide-1; PYY, peptide tyrosine-tyrosine; GLP-1R, glucagon-like peptide-1 
receptor. 
 
 
 
2.3.2 Tonic appetite hormones 
 
Longer term regulation of appetite is influenced by tonic signals of adiposity which act at the 
arcuate nuclei in the hypothalamus. These signals provide a background tone that determines 
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the sensitivity of the brain to satiation signals, thereby subtly influencing energy intake at a 
given meal (Woods & D'Alessio, 2008). The discovery of Leptin by Zhang et al. (1994) was 
instrumental in developing understanding of adipose tissue as an endocrine organ. It is 
secreted by white adipose tissue, with circulating levels that are proportional to fat mass in 
weight-stable individuals (Considine  et al., 1996), but are reduced by weight loss (Hussain 
& Bloom, 2013). Leptin inhibits orexigenic neurons and activates anorexigenic neurons 
(Suzuki et al., 2012). These express leptin receptors, and subsequent interactions have the 
net effect of reducing food intake and increasing energy expenditure (Park & Ahima, 2015). 
Leptin deficiency is associated with severe obesity, however obese individuals commonly 
present with high levels of leptin, leading to the concept of leptin resistance (Neary et al., 
2004). Thus treatment of individuals with exogenous leptin is of limited benefit to those who 
do not suffer from congenital lipid deficiency (Farr et al., 2015; Mantzoros & Flier, 2000). 
 
Insulin is a key regulator of energy homeostasis and primarily acts to lower elevated plasma 
glucose as described in section 2.2.1, however it also acts as a tonic signal of energy status 
in the central nervous system (CNS). Both fasting and postprandial levels of insulin are 
proportional to the fat mass of the individual (Neary et al., 2004). Insulin receptors populate 
similar neuronal populations within the brain as leptin (Arora & Anubhuti, 2006), hence these 
neurons receive feedback indicating the adequacy of energy stores within the body from both 
hormones (Blundell et al., 2015).  Insulin resistance is characteristic of the obese state 
(Woods & D'Alessio, 2008), thus the strength of tonic inhibition of fat mass on food intake 
is weakened (Blundell et al., 2015), indicated by the association between insulin and appetite 
reported in healthy volunteers being blunted in overweight individuals (Flint et al., 2007).  
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2.3.3 Measurement of appetite 
 
The physiological regulators of appetite provide a variety of internal signals which are 
interpreted as subjective feelings associated with hunger and satiety (Bilman et al., 2015; 
Stubbs et al., 2000), These feelings are commonly measured using visual analogue scales 
(VAS) to quantify different aspects of appetite. These consist of unipolar unstructured line 
scales anchored with descriptive statements of opposing meaning (Blundell et al., 2010) to 
capture sensations of appetite-related aspects such as hunger, fullness, satiety and prospective 
food consumption. This method is easy to administer and imposes little burden upon the 
participant, however several theoretical issues are associated with their use. By definition, 
appetite sensations are subjective constructs making comparison between participants 
difficult to interpret (Livingstone et al., 2000), however use of within-subject designs can 
overcome such inter-individual differences. In free-living conditions people do not just eat 
when ‘metabolically hungry’, indeed it is common for individuals to initiate feeding in the 
absence of hunger and in spite of large fat reserves (Berthoud, 2011), often linked to cognitive 
and emotional factors, and VAS should therefore not be considered as a proxy for measures 
of energy intake. Whilst the association with food intake has been described as modest 
(Benelam, 2009), variation in subjective appetite measures has previously been associated 
with subsequent intake (Drapeau et al., 2007; Flint et al., 2000; Parker et al., 2004).  
 
To provide further insight into the impact of an intervention on appetite and feeding 
behaviour, measurements of food intake are often taken alongside subjective appetite 
responses (Stubbs et al., 2000). Laboratory assessments of ad libitum energy intake at a single 
meal can be quantified using a free choice buffet or a fixed meal of known macronutrient 
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composition. Too much choice may undermine physiological satiety signals (Livingstone et 
al., 2000), thus current recommendations advise the avoidance of buffet style test meals 
unless there is a specific hypothesis relating to food choice (Blundell et al., 2010). The 
laboratory setting enhances the efficacy of both methods by eradicating extraneous 
influences on satiety that are encountered in the free-living setting (Benelam, 2009). 
Alternatively, the use of self-reported weighed or estimated food diaries theoretically 
increases external validity by assessing intake under normal conditions (Blundell et al., 
2010), however the associated lack of control over the environment in which food is 
consumed can make interpretation of data problematic. This method is exposed to bias and 
misreporting, and underestimation of energy intake is common (Livingstone et al., 2000; 
Livingstone & Black, 2003). A 12% underrecording bias has been observed in obese men 
when comparing estimated food intake against the doubly labelled water technique (Goris et 
al., 2000). The use of self-reported food diaries is therefore often reserved for monitoring of 
pre-trial dietary standardisation or for longer term (24 hour or 7 day) periods of dietary 
assessment.  
 
2.4 Impaired metabolism 
 
2.4.1 Metabolic disease states 
 
Regulation of blood glucose concentration within a relatively narrow range is a fundamental 
physiological process, however its derangement over time may lead to progressive states of 
metabolic impairment and ultimately manifest as T2DM (Stumvoll, 2004). This complex 
metabolic and endocrine disorder is characterised by hyperglycaemia and altered lipid 
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metabolism (Nolan et al., 2011) and, if poorly controlled, can lead to a number of 
complications. These include microvascular disease encompassing nephropathy, neuropathy 
and retinopathy (Altaf et al., 2015) in addition to macrovascular disorders such as CVD, 
stroke or peripheral vascular disease (Gillett et al., 2012). The diagnosis of T2DM may be 
made based on plasma glucose concentration in addition to glycated haemoglobin (HbA1c) 
and clinical judgement of risk factors such as family history. Plasma glucose during fasting 
or following an OGTT may be compared to standardised cut-off values (Table 2.2) to assess 
whether glycaemia falls within normal, impaired or diabetic regions (American Diabetes 
Association, 2016).  
 
 
  
Table 2.2 Criteria for the diagnosis of diabetes and categories of increased risk. Data adapted 
from American Diabetes Association (2016). 
Category 
Plasma glucose concentration (mmol·l-1)* 
Fasting 2 hour 
Normoglycaemic < 5.6 < 7.8 
Impaired fasting glucose 5.6 - 6.9 - 
Impaired glucose tolerance - 7.8 - 11.0 
Diabetes mellitus ≥ 7.0 ≥ 11.1 
*Fasting, no caloric intake for at least 8 hours; 2 hour, following 75 g oral glucose tolerance test. 
 
 
The long-established belief that T2DM is a progressive condition that can be managed and 
decelerated, but not reversed, has been challenged in recent years. Studies using hypocaloric 
diets have demonstrated normalisation of β-cell function and hepatic insulin sensitivity in 
T2DM of short duration (Lim et al., 2011) and fasting glucose in 50% of participants with 
T2DM of longer duration (Steven & Taylor, 2015). However, the extreme nature of these 
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interventions (maintaining an ~2.5 MJ (600 kcal) per day diet regimen for at least 8 weeks) 
suggests that this may not be a realistic option for all individuals (Taylor, 2013), and serves 
to emphasise the significance of preventing the decline in metabolic health from normal to 
impaired, and subsequently to T2DM. 
 
Individuals who present with plasma glucose levels that are higher than normal, but not 
elevated to diabetic levels, have been termed ‘pre-diabetic’ (American Diabetes Association, 
2016). Whether or not this constitutes a disease state in itself is the subject of much debate 
(Grundy, 2012). Regardless of the terminology, those with impaired fasting glucose (IFG) 
and/or IGT (Table 2.2) display an increased risk of future development of T2DM and CVD. 
Such impairments in glycaemic control are indicative of insulin resistance (Grundy, 2012), 
indeed pre-diabetes is associated with the presence of both insulin resistance and early β-cell 
dysfunction, abnormalities that often transpire prior to the detection of noticeable changes in 
blood glucose (Tabák et al., 2012). Insulin resistance is frequently accompanied by visceral 
obesity, dyslipidaemia and hypertension and this clustering of interrelated CVD risk factors, 
first postulated by Reaven (1988) as ‘syndrome X’, is now termed ‘metabolic syndrome’. 
 
Several organisations have previously produced diagnostic criteria for metabolic syndrome 
(Alberti & Zimmet, 1998; Alberti et al., 2005; Grundy et al., 2005; National Cholesterol 
Education Program, 2002), however some discrepancies in their sensitivity have been 
recognised (Hunt et al., 2004) and efforts to form a consensus have since resulted in a 
harmonised set of criteria (Alberti et al., 2009). An additive effect of increasing metabolic 
syndrome components on risk is beginning to be recognised (O'Neill & O'Driscoll, 2015), 
such that when metabolic syndrome is combined with pre-diabetes (i.e. the number of 
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abnormal components is increased), the risk of incident T2DM is even higher (Ford et al., 
2008), suggesting the importance of efforts to improve metabolic health before this 
progression has taken place (Phillips, 2014).  
 
2.4.2 The progression of impaired fuel metabolism 
 
Insulin sensitivity fluctuates throughout the normal life course, and insulin resistance may 
occur during puberty, pregnancy and as part of ageing (Kahn et al., 2006). However, by far 
the most prevalent cause, particularly in developed countries, is obesity (Boden, 2011). The 
presence of insulin resistance, decreased β-cell secretory capacity and concomitant 
hyperglycaemia in the context of prolonged fat excess has been well established, however 
the precise mechanisms underpinning the effect of such lipotoxicity on impaired glucose 
metabolism are the subject of much investigation. The deposition of lipid in insulin target 
tissues other than adipose tissue, often termed ‘ectopic fat’, may provoke lipid-induced 
disruption of insulin signalling pathways, and has been proposed as a theory explaining the 
decrease in insulin action associated with obesity (Shulman, 2014). This is based on the 
finding that an increase in plasma NEFA leads to intramyocellular and intrahepatic 
accumulation of triglyceride and NEFA metabolites (Boden et al., 2001), caused by a 
spillover of  energy storage from adipose tissue to other organs following prolonged periods 
where energy intake exceeds energy expenditure (Shulman, 2014).  
 
Recent evidence also suggests that insulin resistance is related to a state of chronic, low-
grade inflammation and macrophage infiltration in adipose tissue, with increased circulating 
concentrations of pro-inflammatory cytokines associated with obesity (Kwon & Pessin, 
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2013; Ouchi et al., 2011). In this respect, the distribution of adipose may be important since 
visceral fat tissue expresses higher levels of many cytokines than subcutaneous depots (Fried 
et al., 1998). In addition, the rate of lipolysis is higher in visceral adipocytes (Bano, 2013), 
thus the liver is directly exposed to high levels of both NEFA and pro-inflammatory factors 
released from visceral fat into the portal vein. The so called ‘portal theory’ dictates that this 
effect directly leads to elevated hepatic triglyceride and consequent deleterious effects on 
hepatic insulin sensitivity (Item & Konrad, 2012).  
 
In addition, the overwhelming of storage available in adipocytes leads to spillover of NEFA 
into plasma which, in concert with cytoplasmic triglyceride, inhibits insulin-stimulated 
glucose uptake into the muscle and impairs glucose disposal (Miranda et al., 2005). Insulin 
resistance in adipose tissue also limits postprandial suppression of NEFA mobilisation, with 
consequent day-long elevation in plasma NEFA (Abdul-Ghani & DeFronzo, 2010; Nolan et 
al., 2011). The prolonged exposure of β-cells to elevated levels of NEFA and its metabolites 
(e.g. acetyl coenzyme A) is considered the underlying cause of declining β-cell function 
(Taylor, 2013). Furthermore, total possible insulin secretion is limited via β-cell apoptosis 
which is stimulated by chronic exposure to NEFA metabolites (Cnop, 2008). Thus, in 
susceptible individuals, a vicious cycle is established whereby development of insulin 
resistance increases the demand for insulin secretion on β-cells however, as β-cell function 
declines, circulating concentrations of glucose, NEFA and other metabolites increase, 
exacerbating the cellular damage and further impairing insulin action (Bano, 2013).  
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2.4.3 The significance of postprandial hyperglycaemia 
 
In the years that precede the development of T2DM, a progressive transition from normal 
glucose tolerance (NGT) to IGT occurs, characterised by a decline in both insulin action and 
early phase insulin secretion (Monnier et al., 2007). Hyperglycaemia ensues, with 
postprandial rather than fasting glucose appearing to deteriorate first (Monnier et al., 2007; 
Woerle et al., 2004). Evidence suggests a considerable number of individuals with normal 
fasting glucose will have an abnormal postprandial glucose level (DECODE Study Group, 
2001; Gerstein, 2001) and postprandial hyperglycaemia has been identified as an independent 
and continuous risk factor for CVD in diabetic and non-diabetic populations (Bianchi et al., 
2008; Coutinho et al., 1999; Gerich, 2003), even when fasting glucose is in the normal range 
(Ning et al., 2012). In non-diabetic individuals it appears that increased postprandial glucose 
is a stronger predictor of HbA1c than increased fasting glucose (Fava, 2008), and also carries 
a greater risk of CVD (Bianchi et al., 2008; Gerich, 2003).  
 
The mechanisms responsible for the increase in risk of CVD are not fully understood, 
however endothelial dysfunction has been proposed as a likely facilitator. Glucose enters 
endothelial cells via insulin-independent GLUT1, making them vulnerable to the deleterious 
effects of hyperglycaemia in individuals with IGT (Fava, 2008). Large postprandial 
excursions are thought to be a risk factor even after correcting for mean blood glucose 
(Colette & Monnier, 2007). Glycaemic exposure and variability, both features of IGT, may 
contribute towards the development of atherosclerosis through generation of atherogenic 
particles via glycosylation of proteins in addition to the triggering of endothelial dysfunction 
and oxidative stress (Bianchi et al., 2008; Ceriello et al., 2008).  
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IGT is associated with a blunted insulin response to a meal, however it is not necessarily 
impaired β-cell function that is fully responsible, since a loss of efficiency of the incretin 
response has been observed previously in individuals with IGT. This long recognised effect 
describes the phenomenon whereby oral glucose ingestion provokes a greater insulin 
secretory response than intravenous delivery of the same glucose load (Elrick et al., 1964).  
In addition, GLP-1 inhibits glucagon secretion and delays gastric emptying (Nadkarni et al., 
2014), thereby influencing postprandial metabolism via multiple pathways. Whilst IFG is 
associated with normal insulin secretion but resistance to insulin action, in IGT both secretion 
and sensitivity are impaired (Bock et al., 2006), leading to reduced disposal of exogenous 
glucose with exaggerated and prolonged increases in plasma glucose concentration.  
 
Postprandial hyperglycaemic excursions may be both a self-perpetuating cause, and a 
function of, the deterioration in fuel homeostasis which increases the risk of CVD and, if left 
unchecked, commonly leads to development of T2DM. In this context, and considering that 
progression from NGT to T2DM can occur rapidly (Elder et al., 2015), there is an evident 
requirement for satisfactory strategies to reduce postprandial glucose excursions in healthy 
and at-risk individuals, which may also produce secondary improvements in insulin 
sensitivity and hypertriglyceridemia (Fava, 2008).  
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2.5 Strategies to improve metabolic health 
 
2.5.1 Breakfast consumption  
 
One area which has received much attention in recent years is the breakfast meal and the 
effect of its consumption or omission on energy intake and other health parameters. There 
does not appear to be a universally accepted definition of breakfast (Betts et al., 2016; Timlin 
& Pereira, 2007), making comparisons between associational studies difficult. Furthermore, 
there is no consensus on the optimal composition, timing and amounts of energy and nutrients 
that define a healthful breakfast (O'Neil et al., 2014). Despite this, evidence from a plethora 
of cross sectional studies has demonstrated the association between breakfast consumption 
and reduced incidence of overweight or obesity (Kapantais et al., 2011; Ma et al., 2003; Song 
et al., 2005) and improved cardiometabolic risk profile (Deshmukh-Taskar et al., 2012; 
Reutrakul et al., 2014). Moreover, consumption of breakfast appears to be in decline (Kant 
& Graubard, 2015; Leidy et al., 2016), a trend which has occurred concomitant to the 
increased global prevalence of obesity (Finucane et al., 2011).  
 
This positive effect of breakfast consumption on obesity and other health parameters is 
presumed and widely posited by media and public health officials (Brown et al., 2013), 
however evidence from randomised controlled trials to explain the causality of such 
associations remains limited. Interactions between breakfast consumption and other 
behaviours, such as lower levels of smoking and alcohol intake and higher levels of physical 
activity (Timlin & Pereira, 2007), does not preclude the possibility that residual confounding 
has occurred.  
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2.5.1.1 Short term effects on metabolism, appetite and energy intake 
 
It has been proposed that skipping breakfast may be detrimental to appetite control, such that 
energy intake is higher at subsequent meals. In an acute crossover design, Astbury et al. 
(2011) found that in regular breakfast consumers, energy intake at lunch was 17% greater 
after skipping breakfast, whilst energy intake over the observation period was not different, 
indicating full compensation for the omitted breakfast. This is in contrast to the findings of 
Gonzalez et al. (2013), who observed that eating breakfast did not influence energy intake at 
lunch compared to when breakfast was omitted in healthy participants, despite significantly 
higher hunger ratings in the no breakfast trial. Levitsky and Pacanowski (2013) reported that 
intake at lunch was increased following breakfast skipping, however not by enough to fully 
compensate for the breakfast meal resulting in a net caloric deficit (408 kcal) by the end of 
the day. A similar effect was observed by Clayton et al. (2015), where only partial 
compensation of energy intake occurred following omission of a standard breakfast, with 24-
hour energy intake consequently 19 ± 5% higher during the breakfast trial. If repeated on a 
regular basis, the energy deficit created following omission of breakfast could generate 
weight loss effects, as reported by Geliebter et al. (2014) who conducted a 4-week 
intervention where daily breakfast skipping induced a reduction in body mass 
(1.18 ± 1.16 kg). In a longer term intervention (16 weeks) conducted in overweight or obese 
adults who were attempting to lose weight, no difference in weight loss was observed in the 
breakfast, no breakfast or control (no intervention) groups (Dhurandhar et al., 2014).  
 
Regardless of its impact on body composition, skipping breakfast is likely to be detrimental 
for insulin sensitivity and glucose tolerance (Dhurandhar, 2016). Compared to the same 
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period of breakfast omission, 14 days of breakfast consumption resulted in reduced insulin 
response to a mixed-macronutrient test meal in healthy females (Farshchi et al., 2005), 
however other measures of insulin sensitivity were not different. This outcome is supported 
by the findings of Chowdhury et al. (2016) who observed reduced post-OGTT insulinaemia 
in obese adults following 6 weeks of breakfast consumption. No differences in glycaemia 
were observed in the aforementioned study, however greater glucose variability (Coefficient 
of variation (CV%): 3.9%, 95% CI: 0.1-7.8%) was detected in the fasting group in the 
afternoon and evening when the same methods were conducted in lean participants (Betts et 
al., 2014). Indications that changes in glucose homeostasis may persist over a longer period 
are supported by Kobayashi et al. (2014), who identified increased 24-hour mean glycaemia 
(recorded using CGM) following omission of breakfast in healthy males. The mechanisms 
responsible for improvements in subsequent glucose homeostasis are still not fully 
understood, however it is generally accepted that prior consumption of a carbohydrate load 
leads to improved glucose tolerance at a later meal, an effect known as the ‘second meal 
effect’, which is discussed further in section 2.5.1.2. 
 
2.5.1.2 Second meal effect 
 
Many acute nutritional intervention studies investigate the postprandial effects of a single 
bolus of nutrients, however prior meal consumption can affect the handling of a subsequent 
meal. Such an effect was first noted almost a century ago by Hamman and Hirschman (1919), 
who observed that tolerance to a glucose load was improved following prior consumption of 
glucose. This second meal effect was labelled the ‘Staub–Traugott effect’ after confirmation 
of these findings by Staub (1921) and Traugott (1922), and is of considerable interest as 
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postprandial hyperglycaemia has deleterious metabolic effects and is an important risk factor 
for T2DM and CVD as discussed in section 2.4.3.  
 
Whilst the mechanisms responsible for reduced second meal glycaemia are still not fully 
understood, likely mediators include changes in NEFA concentration (Tigges & Heer, 2013), 
as well as altered rates of muscle glycogen synthesis (Jovanovic et al., 2009b) and hepatic 
glucose production (Bonuccelli et al., 2009). Preprandial NEFA concentration may explain 
up to half of the variation in postprandial glucose response (Wolever et al., 1995), an affect 
that may be attributable to the link between elevated NEFA levels and reduced whole-body 
insulin sensitivity and insulin-stimulated glucose uptake (Boden, 2011). In this context, 
improved insulin sensitivity is likely to contribute to the Staub–Traugott effect, accentuated 
by a priming influence of previous exposure on insulin-stimulated processes (Frayn, 2010).  
 
Consumption of pure glucose loads outside of the laboratory setting is uncommon, however 
the effect of improved glucose tolerance following a second meal appears to be preserved 
following consumption of mixed-macronutrient meals (Astbury et al., 2011; Jovanovic et al., 
2009a; Jovanovic et al., 2009b), enhancing the validity of interpreting such findings in a ‘real 
world’ context. This is likely to be mediated by a reduction in the rate of gastric emptying 
following prior consumption of protein (Ma et al., 2009) and fat (Gentilcore et al., 2006). 
This effect may have implications when considering the efficacy of breakfast consumption 
on daily glycaemic excursions, and manipulation of breakfast macronutrient content may be 
an effective strategy to investigate in terms of promoting substantial health benefits. 
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2.5.2 Protein supplementation 
 
Dietary strategies including modification of complex carbohydrate intake or consuming low 
glycaemic index (GI) diets may be beneficial in improving metabolic health outcomes 
(Raben, 2014), however compliance may be difficult to maintain in the long term (Brekke et 
al., 2004). Modulation of dietary protein intake is an alternative dietary strategy which shows 
promise in prevention of obesity-related disorders (Astrup et al., 2015). Inadequate protein 
intake is linked to negative health outcomes including weight gain and loss of skeletal muscle 
mass (Pasiakos, 2015), which may be particularly detrimental to quality of life in older adults. 
The World Health Organization (2011) recommends a daily dietary protein intake of 
0.83 g∙kg-1 body mass, however it is recognised that intakes above this level may be 
beneficial for specific populations including athletes (Kreider et al., 2010) and the elderly 
(Deutz et al., 2014).  
 
Recent evidence associates consumption of higher levels of protein with positive health 
outcomes beyond just maintenance of muscle mass, with potential implications for the 
prevention or management of obesity and related co-morbidities. In a cross-sectional 
analysis, protein intake was inversely associated with BMI and waist circumference, while 
habitual consumption of protein above recommended levels was associated with higher HDL 
cholesterol (Pasiakos et al., 2015). This supports the findings of a recent meta-analysis where 
a small but significant inverse association of protein intake and fat mass was observed in 
overweight or obese individuals adhering to a higher protein diet for at least 1 year following 
weight loss (Clifton et al., 2014b).  
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In addition to evidence linking increased habitual protein consumption with improved body 
weight management (Astrup et al., 2015; Leidy et al., 2015a; Wycherley et al., 2012), 
evidence suggests that acute protein ingestion is associated with favourable postprandial 
responses including greater satiety (Bonnema et al., 2016; Potier et al., 2009), increased 
postprandial fat oxidation and energy expenditure (Baum et al., 2015; Neumann et al., 2016), 
with some evidence of improved glycaemia (El Khoury et al., 2014; Park et al., 2015). In 
addition to the quantity of protein in meals and the wider diet, much interest centres on the 
impact of protein quality on markers of metabolic health. Protein quality concerns the 
essential amino acid (EAA) content of a protein in addition to rates of digestion and 
absorption. Animal proteins are generally considered to be higher quality proteins than plant-
based sources, due to increased levels of all EAAs (Pasiakos, 2015). Of these, dairy proteins 
are perhaps the highest quality source, and an increasing body of evidence is suggestive of a 
role for such proteins in improving health outcomes (Comerford & Pasin, 2016; Fekete et al., 
2016; McGregor & Poppitt, 2013; Ricci-Cabello et al., 2012).  
 
2.5.2.1 Dairy products and proteins 
 
A wealth of epidemiological evidence associates increased dairy consumption with reduced 
risk of metabolic disease. An inverse relationship has been demonstrated between dairy 
consumption and glycaemia (Da Silva et al., 2014; Drehmer et al., 2015b) as well as 
incidence of obesity (Mirmiran et al., 2005; Rautiainen et al., 2016), metabolic syndrome 
(Drehmer et al., 2015a) and T2DM (Aune et al., 2013; Díaz-López et al., 2016). The 
relationship between dairy intake and metabolic health is not fully understood however, and 
although the majority of evidence supports a beneficial effect, this is by no means a universal 
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observation (Crichton et al., 2011). Struijk et al. (2013) found no association between total 
dairy or consumption of individual dairy products and incidence of T2DM in a prospective 
analysis of ~6000 Danish adults, whilst Snijder et al. (2008) did not detect an association 
between dairy intake and a number of cardiometabolic risk factors in an elderly Dutch cohort. 
Such inconsistencies may have arisen due to the considerable heterogeneity of the study 
designs implemented in this area, where there is extensive variation in study populations, 
methods of dietary assessment, follow-up duration, diagnostic criteria and control of 
confounding variables. In addition, many studies report limited information regarding dairy 
intake criteria, such as the type, quantity and fat content of dairy products included.   
 
The interaction between the various constituents of dairy products also makes delineation of 
the specific effects of certain components problematic. Milk and other dairy products are 
complex and diverse foods containing a number of key nutrients and bioactive components 
which may synergistically contribute to reduction of disease risk (Lovegrove & Givens, 
2016), including dairy proteins, oligosaccharides, medium-chain triglycerides, conjugated 
linoleic acids, calcium and magnesium. It may therefore be prudent to consider the effect of 
isolated components in randomised controlled trials. In terms of the components mentioned, 
dairy proteins appear to play a key role in the potential influence of dairy consumption on 
metabolic regulation, with an accumulating body of evidence supporting the beneficial 
effects of whey protein consumption in particular (Mignone et al., 2015; Pal & Radavelli-
Bagatini, 2013; Zhang et al., 2016). 
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2.5.2.2 Potential role of whey protein supplementation in metabolic health 
improvement 
 
Bovine milk protein comprises of two distinct types of proteins, namely whey (~20%) and 
casein (~80%). Both whey and casein are complete proteins (i.e. they contain all of the EAAs) 
and have high EAA content, however whey is a considerably richer source of the BCAAs 
leucine, isoleucine and valine (Hall et al., 2003), which may have important metabolic 
consequences which shall be discussed further below (section 2.5.2.2.4). Their respective 
physicochemical properties result in differential effects on gastric emptying and kinetics of 
digestion and absorption. Casein is precipitated in the stomach by gastric acid resulting in 
coagulation and slowing of gastric emptying, initiating a small but prolonged postprandial 
amino acid release (Fekete et al., 2016). In contrast, whey proteins are acid-soluble and are 
therefore rapidly emptied from the stomach and delivered to the small intestine intact (Pal & 
Radavelli-Bagatini, 2013), leading to whey being described as a ‘fast protein’ in comparison 
to the ‘slow protein’ casein (Boirie et al., 1997). This results in a greater increase in amino 
acids in the plasma which may be important in terms of augmenting the postprandial 
response, and may be responsible for the greater satiety effect of whey compared to casein 
proteins (Pal et al., 2014). The proportions of the constituent protein fractions of whey and 
their various actions are presented in Table 2.3. The hydrolysis of whey protein during 
digestion releases bioactive peptides which are thought to be responsible for a number of 
potential functional benefits of whey protein on human health (Adams & Broughton, 2016).  
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Table 2.3 Composition of whey. Adapted from Pal and Radavelli-Bagatini (2013), Krissansen (2007) and Sousa et al. 
(2012). 
Constituent 
Approximate 
Proportion  
(% of Energy) 
Actions 
β-Lactoglobulin 35 
Has high branched chain amino acid (~25%) content. 
Captures hydrophobic molecules, participating in the 
reduction of intestinal absorption of lipids. 
α-Lactalbumin 12 
Has highest content of tryptophan (6%) of all dietary 
proteins. It is rich in lysine, leucine, threonine, and cysteine. 
It has the ability to bind to minerals such as Ca and Zn, 
positively affecting their absorption. 
Glycomacropeptide 12 
Formed from the digestion of κ-casein during coagulation of 
cheese. It is high in EAAs, particularly BCAAs. 
Proteose peptone 3 12 Foaming and emulsifying properties. 
Immunoglobulin 8 
Four classes of immunoglobulins are present: IgG, IgA, IgM, 
and IgE. It functions as an antioxidant and increases 
immunity. 
Bovine serum albumin 5 
Good amino acid profile with the function of binding to 
lipids. 
Lactoferrin 1 
Inhibits the production of pro-inflammatory cytokines and 
protects against the development of hepatitis. 
Lactoperoxidase 0.5 Important antimicrobial properties 
Other components (lactose) 
and minor proteins 
~15  
Vitamins and minerals  
(Ca, Fe, K, P, Mg, Zn) 
Variable  
Traces of milk fat Variable  
Ca, calcium; BCAA, branched-chain amino acid; EAA, essential amino acid; Fe, iron; K, potassium; Mg, magnesium; 
P, phosphorus; Zn, zinc. 
 
 
 
The number of published acute studies investigating the effects of whey protein consumption 
on postprandial responses has increased considerably in recent years. A summary of these 
studies in normal-weight, overweight/obese and T2DM populations is provided in Table 2.4, 
followed by discussion of these effects, potential mechanisms and limitations of the current 
body of research.
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Table 2.4 Summary of acute randomised trials investigating the effect of whey protein consumption on metabolic and appetite responses. 
Reference Participants Design Treatment Comparison Key Outcomes 
NORMAL-WEIGHT PARTICIPANTS     
Abou-Samra et 
al. (2011) 
Healthy: males (n=32) 
Age: 25 ± 4 years 
BMI: 24.0 ± 0.4 kg∙m-2 
Randomised, single-blind, crossover design.  
Six sessions scheduled at least 2 days apart. Six 
preloads (20 g added to 250 ml water) served 30 
minutes prior to ad libitum breakfast meal. 
Whey protein (20 g) 
- Pea protein 
- Casein  
- Egg albumin (all matched for protein) 
- Maltodextrin (matched for energy) 
- Control (water) 
- Food intake was lower only after casein and pea protein compared to water. 
- Feelings of satiety were significantly higher after casein and pea protein 
compared to other preloads. 
- Blood glucose response was lower after whey compared to other preloads. 
Akhavan et al. 
(2010) 
Healthy: males (n=16) 
Age: 22 ± 1 years 
BMI: 22.6 ± 0.4 kg∙m-2 
 
Healthy: 9 females, 12 males 
(n=21) 
Age: 22 ± 1 years 
BMI: 22.1 ± 0.5 kg∙m-2 
Randomised, crossover design.  
Participants consumed preloads with 300 ml water. 
After 30 minutes: 
 
Experiment 1: Ad libitum pizza meal 
Experiment 2: Standard pizza meal 
Experiment 1:  
Whey protein (10, 20, 30, 
40 g) 
 
Experiment 2:  
Whey protein (5, 10, 20, 40 
g) 
Experiment 1:  
- Control (isovolumetric flavoured 
water) 
 
Experiment 2:  
- Control (isovolumetric flavoured 
water) 
- Whey protein hydrolysate (10 g) 
Experiment 1:  
- 20-40g whey protein supressed food intake and 10-40g reduced post-meal blood 
glucose concentration and AUC. 
 
Experiment 2:  
- 10-40g whey protein, but not whey protein hydrolysate, reduced post-meal BG 
AUC and insulin AUC in a dose-dependent manner.  
Akhavan et al. 
(2014) 
Healthy: males (n=10) 
Age: 18-29 years 
BMI: 18.5-29.4 kg∙m-2 
Randomised, single-blind, crossover design.  
Participants consumed preloads with 300 ml water. 
Standardised pizza meal eaten 30 minutes after 
preload.  
Whey protein (10, 20 g) 
- Glucose (10, 20 g) 
- Control (isovolumetric flavoured 
water) 
- Whey protein slowed pre-meal gastric emptying vs control and 10g glucose. 
- Both whey protein and glucose (10 and 20 g) reduced post-meal glycaemia with 
similar CCK, amylin, ghrelin and GIP responses. 
- For total duration (0-230 minutes), whey protein resulted in lower mean plasma 
glucose, insulin and C-peptide but higher GLP-1 and PYY compared to glucose 
preloads. 
Anderson et al. 
(2004) 
Healthy: males (n=13) 
Age: 22 ± 3 years 
BMI: 22.1 ± 0.7 kg∙m-2 
 
Healthy: males (n=22) 
Age: 22 ± 1 years 
BMI: 22.8 ± 0.4 kg∙m-2 
 
Healthy: males (n=10) 
Age: 18-35 years 
BMI: 20-27 kg∙m-2 
Randomised, single-blind, crossover designs.  
Participants consumed test drinks as 400 ml 
preloads.  
 
An ad libitum pizza buffet meal was served 60 
minutes post-preload in experiments 1 and 2, and 
120 minutes post-preload in experiment 3. 
Experiment 1:  
Whey protein (0.65g·kg-1 
body mass) 
 
 
Experiment 2:  
Whey protein (50 g) 
 
Experiment 3: 
Whey protein (50 g) 
- Sucrose 
- Egg albumin 
- Soy protein (all isoenergetic) 
- Control (water) 
 
- Egg albumin (isoenergetic) 
- Control (water) 
 
- Whey protein hydrolysate (10 g) 
- Control (water) 
- Compared to control, preloads (45-50g) of whey and soy protein, but not egg 
albumin, supressed food intake at a pizza meal consumed 1 hour later. 
- Suppression of food intake after whey protein, consumed as intact protein or 
peptides, extended to 2 hours.  
Astbury et al. 
(2010) 
Healthy: 12 females, 12 males 
(n=24) 
Age: 30 ± 9 years 
BMI: 23.0 ± 2.4 kg∙m-2 
 
Healthy: 13 females, 13 males 
(n=26) 
Age: 25 ± 5 years 
BMI: 22.8 ± 2.5 kg∙m-2 
Randomised, single-blind, crossover designs.  
Participants completed 4 visits in each study, 
separated by at least 3 days.  
 
 
Liquid preloads (400 ml) were provided, followed 
90 minutes later by ad libitum pasta meal. 
 
 
Experiment 1 (all 1675kJ): 
Whey protein (12.9g) 
12.5% of energy  
Whey protein (25.4g) 25% 
Whey protein (50.4g) 50% 
 
Experiment 2 (all 1047kJ): 
Whey protein (6.8g) 10% 
of energy  
Whey protein (13.1g) 20% 
Whey protein (25.4g) 40% 
Experiment 1: 
- Control (isovolumetric flavoured 
water) 
 
 
Experiment 2: 
- Control (isovolumetric flavoured 
water) 
 
Experiment 1: 
- Energy intake after control was significantly higher than after test preloads. 
- Intake following 12.5% protein was significantly higher than after 25% and 50% 
preloads.  
- There were no differences in subjective appetite ratings between preloads. 
 
Experiment 2: 
- Energy intake after control was significantly higher than after test preloads, with 
no difference in energy intake between protein containing preloads. 
- There were no differences in subjective appetite ratings between preloads. 
Chungchunlam 
et al. (2015) 
Healthy: females (n=18) 
Age: 22 ± 1 years 
BMI: 22.7 ± 0.4 kg∙m-2 
Randomised, single-blind, crossover design. 
Four visits separated by at least 3 days. Liquid 
preloads (300 ml) consumed at lunchtime on each 
occasion followed after 120 minutes by ad libitum 
fried rice meal. 
Whey protein (45 g) 
- Maltodextrin (45 g) 
 
(Energy matched) 
- Energy intake was reduced following whey protein. 
- No effect of preload on subjective appetite responses. 
- Total amino acid and BCAA concentration were increased after whey protein. 
Gunnerud et al. 
(2012a) 
Healthy: 3 females, 6 males 
(n=9) 
Age: 22-30 years 
BMI: 25.8 ± 3.4 kg∙m-2 
Randomised, crossover design. 
Five visits separated by at least 2 days. Test meals 
served as breakfast on each occasion. Samples taken 
120 minutes postprandially. 
Whey protein (16.2 g) 
 
(with 25 g lactose) 
- White wheat bread (control) 
- Casein (16.8 g) 
- Bovine milk 
- Human milk 
(all carbohydrate matched) 
- Glucose iAUC was reduced after all protein meals compared to control.  
- The insulin response was significantly higher after whey protein. 
- Early phase plasma amino acids were correlated to insulin and incretin secretion. 
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Reference Participants Design Treatment Comparison Key Outcomes 
Gunnerud et al. 
(2012b) 
Healthy: 9 females, 5 males 
(n=14) 
Age: 20-28 years 
BMI: 21.9 ± 0.6 kg∙m-2 
Randomised, single-blind, crossover design. 
Seven visits separated by ~7 days. Fed standard 
breakfast (ham sandwich – 50 g carbohydrate, 13 g 
protein) with different drinks (served immediately 
pre-meal). Samples taken 180 minutes 
postprandially. 
Whey protein (9 g) 
- Whey protein +5 amino acids 
- Whey protein +6 amino acids 
- Soy protein 
- Soy protein +5 amino acids 
- Soy protein +6 amino acids 
(all energy matched) 
- Control (water) 
- All protein drinks reduced the glycaemic response in the first 60 minutes. 
- No differences for insulinaemic indices. 
- The early insulin response (0-15min iAUC) correlated positively with plasma 
amino acids, GLP-1, GIP and glycaemic profile. 
Gunnerud et al. 
(2013) 
Healthy: 7 females, 5 males 
(n=12) 
Age: 20-23 years 
BMI: 22.9 ± 0.7 kg∙m-2 
Randomised, single-blind, crossover design. 
Four visits separated by ~7 days. Different test 
drinks (250 ml) served as breakfast on each 
occasion. Samples taken 120 minutes 
postprandially. 
Whey protein (4.5, 9, 18 g) 
 
(combined with 25 g 
glucose) 
- Control (water + 25 g glucose) 
- Linear dose-response relationships found between whey protein 
supplementation and postprandial glycaemia, insulinaemia and amino acids. 
- 18 g and 9 g whey protein significantly reduced glycaemia. 
- 18 g increased insulin response. 
- Amino acids responded in dose-dependent manner. 
Hursel et al. 
(2010) 
Healthy: 18 females, 17 males 
(n=35) 
Age: 21 ± 2 years 
BMI: 23.0 ± 2.1 kg∙m-2 
Randomised, single-blind, crossover design. 
Three visits separated by ~7 days. Test breakfasts 
served and samples taken 240 minutes 
postprandially. 
Whey protein yoghurt 
drink, 41% energy from 
protein 
- Control (normal protein yoghurt 
drink), 15% energy from protein 
- α-lactalbumin-enriched whey protein 
yoghurt drink, 41% energy from 
protein (all matched for energy) 
- Both high protein breakfasts increased thermogenesis more 
than normal protein. 
- α-lactalbumin suppressed hunger more than whey or control. 
Hutchison et al. 
(2015) 
Healthy: males (n=18) 
Age: 25 ± 1 years 
BMI: 21.6 ± 0.5 kg∙m-2 
Randomised, double-blind, crossover design. 
Three visits separated by 7-11 days. Test drinks 
(~450 ml) served and samples taken 180 minutes 
postprandially, followed by ad libitum buffet meal. 
Whey protein (30 g) 
Whey protein (70 g) 
 
Matched for osmolarity 
- Control (saline) 
 
Matched for osmolarity 
- Gastric emptying was comparable between protein drinks. 
- Energy intake was suppressed similarly by both protein loads. 
- Glucose was modestly reduced following the high whey protein load. 
Nilsson et al. 
(2007) 
Healthy: 6 females, 6 males 
(n=12) 
Age: 20-30 years 
BMI: 22.4 ± 0.6 kg∙m-2 
Randomised, crossover design. 
Five visits separated by at least 1 week. Drinks (250 
ml) were provided as breakfast. Postprandial blood 
samples taken for 120 minutes. 
Whey protein (18 g) 
 
(combined with 25 g 
glucose) 
- Lysine and threonine 
- Leucine, isoleucine and valine 
- Leucine, isoleucine, valine, lysine and 
threonine 
(all combined with 25 g glucose) 
- Control (25 g glucose)  
- Drink with leucine, isoleucine, valine, lysine and threonine mimicked the 
glycaemic and insulinaemic responses seen after whey ingestion.  
- Consumption of whey resulted in 56% smaller glucose AUC and 60% larger 
insulin AUC than reference drink. 
- Whey drink gave 80% greater GIP response, whereas drinks containing free 
amino acids did not significantly affect GIP secretion. 
Silva Ton et al. 
(2014) 
Healthy: 6 females, 4 males 
(n=10) 
Age: 25 ± 1 years 
BMI: 22.0 ± 0.8 kg∙m-2 
Randomised, crossover design. 
Four visits separated by at least 1 day. Test drinks 
consumed as preloads 30 minutes prior to 
consumption of 25 g glucose. Postprandial blood 
samples taken for 120 minutes.  
Whey protein (0.5g·kg-1 
body mass) 
- Control (isovolumetric flavoured 
water) 
- Soy protein (0.5 g·kg-1 body mass) 
- Egg albumin (0.5g·kg-1 body mass) 
- Whey and soy protein reduced glucose iAUC by 56.5% and 44.4% compared to 
control, respectively. 
NORMAL-WEIGHT AND OVERWEIGHT/OBESE PARTICIPANTS    
Bowen et al. 
(2006a) 
Healthy (25) and overweight 
(47): males (n=72) 
Age: 55 ± 3 years 
BMI: Healthy – 23.3 ± 0.2, obese 
– 30.1 ± 0.5 kg∙m-2 
Randomised, single-blind, crossover design. 
Four visits separated by 7 days. Liquid preloads 
(450 ml) consumed on each occasion followed after 
180 minutes by ad libitum buffet meal. 
Whey protein (50 g) 
- Soy (50 g) 
- Gluten (50 g) 
- Glucose (63 g) control 
 
(All energy matched) 
- Energy intake was equally reduced after whey, soy or gluten: all 10% lower than 
after glucose in both lean and obese. 
- Fasting and postprandial GLP-1 was higher in overweight participants.  
Hoefle et al. 
(2015) 
 
Healthy (15) and prediabetes 
(15): 5 females, 25 males (n=30) 
Age: Healthy – 26 ± 1, 
prediabetes – 62 ± 2 years 
BMI: Healthy – 23.9 ± 0.5, 
prediabetes – 29.0 ± 1.5 kg∙m-2 
 
Randomised, single-blind, crossover design. 
Three visits separated by at least 2 days. Test drinks 
served and samples taken 240 minutes 
postprandially. 
Whey protein (50 g) 
 
(combined with 50 g 
maltodextrin) 
- Control (50 g maltodextrin) 
- Casein (50 g + maltodextrin 50 g) 
 
 
- Whey protein and casein similarly reduced postprandial glucose excursions in 
healthy and prediabetic participants.  
- Both proteins increased plasma insulin despite simultaneous increases in 
glucagon concentrations. 
 
 
 
Zafar et al. 
(2013) 
Healthy: females (n=12) 
Age: 22 ± 5 years 
BMI: 22.6 ± 2.4 kg∙m-2 
 
Healthy (15) and overweight 
(15): females (n=30) 
Age: 22 ± 5 years 
BMI: Healthy – 21.5 ± 2.1, 
overweight – 30.7 ± 2.5 kg∙m-2 
Randomised, crossover design.  
Four visits scheduled ~1 week apart. Sweetened 
beverages (300 ml) consumed followed after 180 
minutes by ad libitum pizza meal. 
 
Randomised, crossover design. 
Three visits scheduled ~1 week apart. Sweetened 
beverages (300 ml) consumed, samples taken for 
120 minutes. 
Whey protein (25 g) 
- Whey protein (25 g) + glucose (50 g) 
- Glucose (50 g) 
- Glucose (75 g) 
 
 
- Whey protein (25 g) + glucose (25 g) 
- Glucose (25 g) 
- Peak blood glucose and iAUC was reduced after whey protein and whey protein 
supplemented glucose in both normal weight and overweight participants. 
- Energy intake was reduced after both WP drinks, with or without glucose. 
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Reference Participants Design Treatment Comparison Key Outcomes 
OVERWEIGHT/OBESE PARTICIPANTS     
Bowen et al. 
(2006b) 
Overweight: males (n=19) 
Age: 53 ± 6 years 
BMI: 32.1 ± 3.7 kg∙m-2 
Randomised, single-blind, crossover design. 
Four visits separated by 7 days. Liquid preloads 
consumed on each occasion followed after 180 
minutes by ad libitum buffet meal. 
Whey protein (55 g) 
- Casein (55 g) 
- Lactose (56 g) 
- Glucose (56 g) control 
 
(matched for energy) 
- Acute appetite and energy intake were equally reduced after whey, casein or 
lactose, all 10% lower than after glucose. 
- CCK was 71% higher 90 minutes after protein preloads compared to glucose and 
lactose, which predicted appetite at 180 minutes. 
- There was a small increase in BCAAs after whey compared to casein, but this 
was independent of appetite and energy intake. 
Bowen et al. 
(2007) 
Obese: males (n=28) 
Age: 57 ± 2 years 
BMI: 32.5 ± 0.6 kg∙m-2 
Randomised, double-blind, crossover design. 
Four visits separated by 7 days. Liquid preloads 
consumed on each occasion followed after 240 
minutes by ad libitum buffet meal. 
Whey protein (50 g) 
- Fructose (25 g) + Whey protein (25 g) 
- Fructose (50 g) 
- Glucose (50 g) control 
 
(matched for energy) 
- There was no difference in energy intake between the preloads. 
- Whey protein produced a prolonged suppression of ghrelin and elevations of 
GLP-1 and CCK that were reduced when combined with fructose.  
Pal et al. 
(2010b) 
Overweight and obese:  
females (n=20) 
Age: <66 years 
BMI: 25-40 kg∙m-2 
Randomised, single-blind, crossover design. 
Three visits separated by 1 week. Test drinks (~400 
ml) consumed alongside mixed macronutrient 
breakfast and postprandial blood samples taken for 
360 minutes. 
Whey protein (45 g) 
- Sodium caseinate (45 g) 
- Control (glucose 45 g) 
 
(matched for energy) 
- Appearance of triglycerides in the blood decreased after the whey meal 
compared to control and casein by 21% and 27% respectively. 
- Glucose was reduced after whey and casein compared to control. 
- There was a reduction in the AUC for triglyceride:ApoB48 ratio after whey 
compared to glucose and casein, reflecting reduced exposure to triglyceride-rich 
lipoproteins.  
Petersen et al. 
(2009) 
Obese: 3 females, 7 males (n=10) 
Age: 44 ± 9 years 
BMI: 33.6 ± 4.8 kg∙m-2 
Randomised, crossover design. 
Visits separated by at least 1 day. Drinks (250 ml) 
were provided as breakfast. Postprandial blood 
samples taken for 120 minutes. 
5, 10, 20 g Intact whey 
protein + peptides  
(all combined with 50 g 
glucose) 
- Control (50 g glucose) 
- Increasing doses of intact whey and peptides decreased blood glucose iAUC in 
a dose-dependent manner. 
T2DM PARTICIPANTS     
Clifton et al. 
(2014a) 
Prediabetes (11) and T2DM (13): 
11 females, 13 males (n=24) 
Mean age: 60 years 
Mean BMI: 32 kg∙m-2 
Randomised, crossover design. 
Four visits, including 2 test days and 2 placebo days; 
data from both days was averaged. Liquid preloads 
(150 ml) followed after 15 minutes by standardised 
carbohydrate-based breakfast. 
Whey protein (17 g) with 
5 g added fibre (guar) 
- Control (water) 
- Peak glucose was reduced by 2.1 mmol∙l-1 at 45 min. 
- Mean glucose over 3 hours was reduced by 0.8 mmol∙l-1.  
- There was no difference between those with diabetes or prediabetes or those on 
medication or not on medication. 
Frid et al. 
(2005) 
T2DM:  
6 females, 8 males (n=14) 
Age: 27-69 years 
BMI: 26.2 ± 3.1 kg∙m-2 
Randomised, crossover design. 
Two visits separated by at least 7 days. High GI 
breakfast (white bread) and lunch (mashed potato 
and meatballs) 4 hours post breakfast, were served 
on both occasions, with trial-dependent addition of 
whey or ham and lactose.   
Whey protein (18.2 g) with 
both meals = 36.4 g in total 
- Ham and lactose 
 
(matched for protein and carbohydrate 
content) 
- Insulin AUC was 31% higher after breakfast and 57% higher after lunch when 
whey was included.  
- Glucose AUC was similar after breakfast but reduced by 21% after lunch with 
whey protein ingestion.  
- No difference in GLP-1 after both meals. 
- GIP response was higher after whey ingestion. 
Jakubowicz et 
al. (2014) 
T2DM:  
6 females, 9 males (n=15) 
Age: 64 ± 1 years 
BMI: 26.7 ± 1.2 kg∙m-2 
Randomised, crossover design. 
Test drinks (250 ml) consumed as a preload 30 
minutes prior to a high GI breakfast and samples 
taken 180 minutes postprandially. 
Whey protein (50 g) - Control (water) 
- Blood glucose levels were reduced by 28% after whey protein preload, with a 
uniform reduction in early and late phases. 
- Insulin and GLP-1 responses were significantly higher following whey protein. 
- DPP-IV activity was not different between trials. 
Ma et al. 
(2009) 
T2DM:  
7 females, 1 males (n=8) 
Age: 58 ± 3 years 
BMI: 28.6 ± 1.3 kg∙m-2 
Randomised, crossover design. 
Preload administered 30 minutes before mashed 
potato + glucose meal (59.1 g carbohydrate). Whey 
protein added to preload, meal, or not added. 
Whey protein in preload 
(55 g) 
Whey protein in meal 
(55 g) 
- Control 
- Gastric emptying was slowest after the whey preload, and slower after whey in 
meal than control. 
- Glucose iAUC reduced for whey preload and whey meal compared to control. 
- GIP, insulin and CCK were higher during both whey trials than control. 
- GLP-1 was only higher after the whey preload. 
ApoB48, apolipoprotein-B48; AUC, area under the curve; BCAA, branched-chain amino acids; BMI, body mass index; CCK, cholecystokinin; DPP-IV, dipeptidyl peptidase IV; GI, 
glycaemic index; GIP, glucose-dependent insulinotrophic polypeptide; GLP-1, glucagon-like peptide-1; iAUC, incremental area under the curve; PYY, peptide tyrosine-tyrosine; T2DM, 
type 2 diabetes mellitus. 
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2.5.2.2.1 Effect on glycaemia 
 
Studies in a variety of populations have identified the capacity of whey protein to augment 
the postprandial insulinaemic response, with potential concomitant effects on glycaemia. 
Studies with overweight or T2DM populations are fewer in number than those with healthy 
sample groups, and it remains unclear whether the magnitude of the insulinotrophic effect 
following whey supplementation is sufficient to consistently reduce postprandial glycaemia 
in insulin resistant individuals, where hyperinsulinaemia may be commonplace. When lean 
ham and lactose were substituted by the equivalent amount (18.2 g) of whey protein in high 
GI meals given to individuals with T2DM, the insulin response was significantly increased 
following both breakfast (18%) and lunch (49%), however glycaemia was similar following 
the breakfast meal, and only reduced after lunch (21%) (Frid et al., 2005). It is possible that 
the post-breakfast increase in circulating insulin was not sufficient to overcome the greater 
insulin resistance observed in the postabsorptive state (Plat et al., 1996). The post-lunch 
reduction in glycaemia was not insignificant however, and is comparable with the 28% 
reduction in glucose area under the curve (AUC) observed alongside a simultaneous 105% 
increase in insulin AUC by Jakubowicz et al. (2014). This study compared 50 g whey protein 
consumption with a control (water) drink before a high GI breakfast in participants with 
T2DM. The higher dose of protein and the fact that it was administered as a preload 30 
minutes prior to the breakfast meal in the latter study, in addition to the fact that it was a 
single meal test, means that these findings are not directly comparable. Despite this, the effect 
observed on postprandial glycaemia in both studies was greater than that detected over the 
same time period (180 minutes) following administration of nateglinide, a pharmacologic 
rapid-acting insulin secretagogue (Gribble et al., 2001), emphasising the potential of dietary 
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strategies for glycaemic management in individuals with impaired glucose metabolism. In a 
further study in participants with T2DM, similar reductions in post-meal glycaemia were 
observed whether 55 g whey was given before (30 minutes) or alongside a high GI meal 
compared with no supplementation (Ma et al., 2009). Rate of gastric emptying was also 
measured as part of this protocol and was inhibited by the presence of whey, however there 
was no evidence that the difference in emptying rates between the whey preload and whey in 
meal trials was reflected in postprandial glycaemia.  
 
A limited number of studies have assessed the glycaemic response following whey 
supplementation in non-diabetic overweight or obese populations. A significant reduction in 
glucose AUC was observed over 180 minutes following consumption of a 55 g liquid protein 
preload in comparison to lactose and glucose controls in overweight or obese men (BMI 
ranging from 26.8 to 40.4 kg∙m-2), however changes in insulin concentrations were not 
affected by condition (Bowen et al., 2006b). Data for whey and casein protein preloads were 
pooled together however, and the differential effects of whey and casein supplementation on 
a variety of markers (Boirie et al., 1997; Hall et al., 2003) makes comparison with other whey 
supplementation protocols difficult. Nevertheless, the findings of Pal et al. (2010b) support 
the observations described above. This group reported a 16% reduction in post-meal 
glycaemia over 360 minutes in a group of overweight or obese post-menopausal females 
following 45 g whey protein compared to an energy-matched glucose control. Similarly to 
above, this intervention did not influence post-meal insulinaemia, indicating that milk-
derived proteins may influence plasma glucose via insulin-independent mechanisms or via 
temporal changes in insulin sensitivity. Key differences exist between the design of these 
studies however, which may influence any direct comparisons. Pal et al. (2010b) 
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administered protein alongside a mixed macronutrient breakfast meal, simulating the effect 
of consuming a realistic breakfast meal (bread roll with margarine and spread) with additional 
protein, which may be a more ecologically valid method than the provision of a test beverage 
only (Bowen et al., 2006b). The control arm did consist of 45 g glucose however, therefore 
a direct effect of adding protein to the meal in comparison with adding no additional nutrients 
cannot be established.  
 
Only one acute study has focussed on the glycaemic response to whey protein in both normal-
weight and overweight participants. Zafar et al. (2013) investigated the effects of 25 g whey 
protein or glucose, or a combination of both (50 g), on postprandial glycaemia for 120 
minutes in 15 normal-weight and 15 overweight young females. Whey protein was effective 
in reducing postprandial glycaemia compared to glucose and glucose with whey, while the 
latter condition supressed blood glucose compared to control. Glucose AUC was 16% higher 
following the pure glucose drink in overweight compared to normal-weight participants, 
however this disparity in glucose tolerance between groups was corrected when whey protein 
was administered, with glucose attenuated to similar levels in both groups following whey 
protein beverages. The authors hypothesise that such an effect may be due to an enhancement 
of insulin sensitivity by whey protein in overweight participants, however insulin 
concentrations were not assessed in this study, making this a speculative assumption. Such 
an effect has, however, been observed following chronic whey protein consumption in both 
rats (Belobrajdic et al., 2004) and humans (Pal et al., 2010a). 
 
A dose-response relationship between whey protein load and post-meal glucose reduction 
has been observed in a number of studies in normal weight (Akhavan et al., 2010; Gunnerud 
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et al., 2013) and obese populations (Petersen et al., 2009). Both studies in lean healthy 
individuals observed a linear effect of glucose reduction with glucose loads ranging from 5-
40 g (Akhavan et al., 2010) and 4.5-18 g (Gunnerud et al., 2013), however differential 
patterns in insulin response were reported between studies. In the former, post meal insulin 
was reduced in a dose-dependent manner, however when pre-meal (post-preload) values 
were included there was no difference between conditions in cumulative insulin AUC. In the 
latter, a dose-dependent increase in insulin AUC was reported, with all whey doses resulting 
in higher insulin AUC compared to control, albeit only significantly higher following the 
highest dose (18 g). Such a contrast may be the result of a number of fundamental differences 
in study design, since Akhavan et al. (2010) administered whey as a preload 30 minutes 
before consumption of a mixed-macronutrient pizza meal, as a standalone supplement in 
flavoured water, whereas Gunnerud et al. (2013) did not use a preload design, and 
administered whey as a breakfast beverage combined with 25 g glucose. The addition of 18 g 
whey to 25 g glucose has previously been investigated by the same group and found to 
significantly reduce glycaemia with a concomitant increase in insulin AUC (Nilsson et al., 
2007), and it has been proposed that amino acid availability may potentiate the increased 
insulin response. This is an attractive theory since plasma amino acids also increased in a 
dose-dependent manner in this study, while a previous investigation revealed that a 
combination of whey and free amino acids induced a rapid insulinogenic effect which 
influenced early glycaemia (Gunnerud et al., 2012b). Plasma amino acids were not measured 
by Akhavan et al. (2010), however they argue that insulin alone cannot be the only cause of 
reduced post-meal glycaemia since they observed such reductions in the presence of reduced 
post-meal and similar cumulative insulin concentrations.  
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2.5.2.2.2 Effect on lipid metabolism 
 
Fasting levels of blood lipids are commonly used in the clinical setting as a markers of CVD 
risk, however the importance of the postprandial milieu, and of post-meal 
hypertriglyceridaemia in particular, as a determinant of CVD risk is increasingly being 
recognised by researchers (Kolovou et al., 2011). Evidence from acute trials assessing the 
effect of whey protein on markers of lipaemia is limited and has shown mixed results.  
 
The effects of 45 g of whey, casein or glucose served alongside a mixed macronutrient meal 
on glycaemia were described above, however the study by Pal et al. (2010b) was primarily 
designed to investigate effects on lipaemic markers in overweight and obese females. No 
condition-dependent differences were detected for total, LDL or HDL cholesterol, NEFA or 
ApoB48, however triglyceride AUC was reduced by 21% and 27% following whey 
consumption compared to glucose and casein respectively. In addition AUC for 
triglyceride:ApoB48 ratio was significantly reduced following whey protein compared to 
casein and glucose, reflecting decreased exposure to smaller triglyceride-rich chylomicron 
particles. This is currently the only acute study that has compared whey protein consumption 
with a non-protein control in the context of investigating postprandial lipaemia, however 
other studies have compared the same 45 g dose with different protein types or whey protein 
fractions. Mortensen et al. (2009) compared the effects of whey with casein and non-dairy 
proteins (cod and gluten) alongside a high fat meal on postprandial lipaemia in participants 
with T2DM. Similarly to above, whey protein reduced triglyceride AUC in comparison to 
casein, and also appeared to outperform other proteins in terms of modulating the triglyceride 
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response, in addition to promoting greater suppression of plasma NEFA for 6 hours 
postprandially.  
 
In contrast to the findings above, Mariotti et al. (2015) reported that triglyceride AUC was 
increased following consumption of whey or α-lactalbumin-enriched whey protein compared 
with casein protein alongside a high fat meal. Such a discrepancy may partly be explained 
by the different populations. Overweight but otherwise healthy young men were included in 
this study, whereas the population in the study of Pal et al. (2010b) consisted of post-
menopausal women and Mortensen et al. (2009) included 12 T2DM participants with mean 
age of 65 years. Nine of that group were taking lipid-lowering medication which would likely 
interrupt lipoprotein and fatty acid metabolism compared to healthy volunteers. In addition, 
the protein was not completely mixed with the other macronutrients in the test meal served 
in the above two studies, whereas Mariotti et al. (2015) served a homogenised test drink 
containing cream, sucrose and the supplemental protein. This may have had implications for 
nutrient interaction during digestion.  
 
Notwithstanding this, in a study from the same group using an identical test meal as 
Mortensen et al. (2009), in an obese non-diabetic population, postprandial plasma 
triglyceride concentrations were more favourable following the addition of whey to the meal 
(Holmer-Jensen et al., 2013). Triglyceride AUC was 61% higher after cod protein and 66% 
higher after gluten protein, although values were not different compared to casein after 6 
hours. Whey and casein also showed significantly greater suppression of NEFA during this 
period, although this was not significant over the full 8-hour postprandial period.  
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Current evidence provides a mixed picture regarding the potential of whey protein to improve 
markers of dyslipidaemia. Studies have shown that measures of HDL and LDL cholesterol 
tend to remain stable following consumption of dairy proteins with high fat meals, however 
there is evidence that whey may have important influences on other circulating lipids. The 
mechanisms underpinning these interactions are currently not well understood however, and 
further studies are required to investigate the effects that whey protein may have when 
consumed with test meals that better reflect those consumed in daily living, in both lean and 
overweight individuals. 
 
2.5.2.2.3 Effect on satiety and energy intake 
 
Whilst it is generally accepted that protein ingestion can strongly influence satiety and food 
intake (Potier et al., 2009), the type of protein may be an important factor in determining the 
magnitude of this effect. Whey protein may increase satiety (Veldhorst et al., 2009) and 
reduce food intake (Hall et al., 2003) compared to casein, and has also been shown to produce 
favourable effects on hunger and energy intake compared to non-dairy proteins in some 
studies (Pal & Ellis, 2010), but not others (Abou-Samra et al., 2011). In normal-weight young 
males, preloads (45-50 g) of whey and soy protein, but not egg, reduced ad libitum energy 
intake at a pizza buffet meal 1 hour later compared to a water control (Anderson et al., 2004). 
In contrast Bowen et al. (2006a) found that although energy intake was reduced by 10% 180 
minutes post ingestion of 50 g whey compared with glucose control, this was not different 
from soy and gluten preloads, and the same effect was observed in both lean and obese 
participants. There was also no difference in subjective measures of hunger and prospective 
food consumption between trials or by participant weight status. It is speculated that obese 
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participants may have reduced sensitivity to the appetite suppressing effects of GLP-1, as 
postprandial levels of this hormone were higher in the obese group, without affecting energy 
intake. The effect on behavioural responses of mixing groups of lean and obese participants 
during the ad libitum buffet meal may also be responsible for the lack of difference between 
participant groups.  
 
Another study by the same group in overweight and obese participants reported that ad 
libitum energy intake was reduced by 493 kJ (~10%) at a buffet meal 180 minutes following 
consumption of 55 g whey protein compared to an energy-matched glucose control, however 
this reduction was similar to that observed for lactose and casein preloads (Bowen et al., 
2006b), with a similar effect observed in average appetite ratings. In a different design, there 
were no differences in subjective appetite responses and similar amounts of energy were 
consumed at a buffet meal 4 hours post ingestion of 50 g preloads of whey, fructose, a 
combination of these ingredients, or glucose (Bowen et al., 2007). This was despite the fact 
that whey produced contrasting post-ingestion profiles of ghrelin, CCK and GLP-1, an effect 
that was attenuated when 50% of the whey was replaced by fructose. It could be speculated 
that obese individuals may require greater doses of whey protein to promote satiety, as similar 
amounts to those administered in this studies have produced positive effects on satiety in 
normal-weight individuals (Pal & Ellis, 2010), indeed there is evidence of a dose-response 
relationship in such individuals, with multivariate analysis predicting a 24 kJ reduction in 
subsequent energy intake for every 1 g increase in whey protein content of the preload.  
 
Astbury et al. (2010) reported stepwise reductions in lunchtime energy intake with increasing 
whey protein content of mixed macronutrient preloads served 90 minutes prior to the meal 
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in 24 healthy young adults. Consumption of a 1675 kJ preload with whey protein constituting 
12.5% of energy resulted in reduced food intake when compared to control (0 kJ), but greater 
intake than after 25% and 50% preloads. Interestingly there were no differences in subjective 
appetite responses between trials in this study, indicating that adjustments in preload 
macronutrient composition may have resulted in physiological changes that were sufficient 
to reduce energy intake without affecting subjective feelings. The lack of physiological 
response data makes speculation of such mechanisms difficult, however. In another dose-
response study, preloads containing doses of whey above 10 g (20-40 g) were adequate in 
reducing energy intake at a subsequent ad libitum pizza buffet meal in healthy young males, 
with the largest reduction occurring after a 40 g protein preload (Akhavan et al., 2010). The 
fact that the lowest preload dose, which is comparable to the lowest dose in the above study, 
did not significantly augment subsequent intake may be a result of the smaller time period 
(30 minutes) between preload and buffet meal. This may also have influenced the degree of 
energy compensation at the meal, as cumulative intake (preload+meal) was not different 
between trials. Notwithstanding this, the 78 kcal reduction observed following the 10 g 
preload was predicted to be significant if the sample size was increased to 40 participants, 
therefore statistical power may also have been an issue. Similarly to above, there were no 
effects of condition on subjective appetite ratings prior to the meal. In contrast, evidence of 
a dose-response effect on energy intake is not supported by the similar reduction in intake 
observed 180 minutes post ingestion of 30 g and 70 g whey preloads in healthy males 
(Hutchison et al., 2015). The use of a 70 g dose represents a load over and above that which 
may be obtained from usual serving sizes however. Taken together with the evidence from 
previous studies (Akhavan et al., 2010; Astbury et al., 2010), these findings are indicative of 
~30-40 g protein representing a threshold after which greater loads do not result in further 
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suppression in subsequent intake. This may be a result of plasma amino acids exceeding a 
threshold level (Veldhorst et al., 2009).  
 
When studies have assessed the impact of protein content rather than type (i.e. a non-protein 
comparator was used), findings have generally confirmed the satiating effect of protein 
consumption. A 45 g whey protein preload drink reduced food intake after 120 minutes in 
comparison to an energy-matched maltodextrin preload in healthy females (Chungchunlam 
et al., 2015),  however differences in subjective appetite were not apparent. Addition of 25 g 
whey protein to 50 g glucose reduced energy intake at a pizza buffet meal 180 minutes later 
by 21% (279 kcal) in healthy young females (Zafar et al., 2013), although differences in 
subjective appetite were only detected at the 180 minute time point. When the energy content 
of the preload is taken into account, intake was still 11% lower after addition of whey, 
although this finding was not statistically significant. This does however, emphasize the 
potential for investigating supplementation strategies whereby whey protein is an addition to 
a meal or preload, rather than a substitution for other nutrients, which may be a more realistic 
approach for individuals to adhere to. 
 
2.5.2.2.4 Potential mechanisms underlying the effects of whey protein 
supplementation 
 
It is likely that several interconnected mechanisms interact to affect postprandial responses, 
as depicted in Figure 2.2, with evidence suggesting that whey lowers glucose via insulin-
dependent and insulin-independent mechanisms (Akhavan et al., 2014).  
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Figure 2.2 Putative mechanisms by which whey protein may influence postprandial glycaemia. Adapted from Mignone et 
al. (2015). GLP-1, glucagon-like peptide 1; GIP, glucose-dependent insulinotrophic polypeptide; CCK, cholecystokinin; 
PYY, peptide YY; DPP-Ⅳ, dipeptidyl peptidase-Ⅳ. 
 
 
Although not fully understood, evidence suggests that whey protein enhances postprandial 
insulinaemia via direct and indirect pathways. It is well established that protein, or more 
specifically amino acids, stimulate insulin secretion (Floyd et al., 1966), an effect that is 
present in both healthy individuals (Nilsson et al., 2004) and those with T2DM (van Loon et 
al., 2003). Whey protein is a rich source of EAAs, known to be potent insulin secretagogues 
(Floyd et al., 1970). This is particularly the case for the BCAAs leucine, isoleucine and 
valine, of which whey protein has a high content (Ha & Zemel, 2003). Leucine is of particular 
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interest in this regard, as it can directly stimulate insulin secretion from pancreatic β-cells via 
inhibition of ATP-sensitive potassium channels, leading to depolarisation of the β-cell 
membrane and subsequent insulin secretion (Gao et al., 2003). When intact whey protein or 
a mixture of amino acids including BCAAs were administered to healthy individuals 
(combined with 25 g glucose), both drinks raised insulin concentrations similarly, suggesting 
that the action of whey on postprandial glycaemia is largely associated with its BCAA 
content (Nilsson et al., 2007). However, the GIP response was 80% greater following intact 
whey compared to glucose control, whereas it was not different for the amino acid mixtures. 
This is indicative of bioactive peptides present in intact whey, or formed during digestion, 
influencing the incretin response. Indeed, whey also stimulates GLP-1 release in healthy 
males (Akhavan et al., 2014). Both hormones have strong insulinotrophic effects (Adams & 
Broughton, 2016), therefore whey stimulated incretin release may be responsible for an 
indirect influence on the insulin response, an effect observed in vitro (Salehi et al., 2012). 
 
The efficacy of the incretin hormone response is diminished by rapid degradation to inactive 
forms by the dipeptyl peptidase-IV (DPP-IV) enzyme (Power et al., 2014). Dairy proteins, 
including whey, have emerged as potential endogenous inhibitors of DPP-IV, however 
evidence in humans is limited. Administration of whey has been associated with a significant 
reduction in DPP-IV activity in mice (Gunnarsson et al., 2006), while a peptide identified 
from whey β-lactoglobulin hydrolysate is associated with moderate DPP-IV inhibition in 
vitro (Tulipano et al., 2011). In humans with T2DM, consuming 50 g whey protein compared 
with water prior to a high GI breakfast reduced postprandial glycaemia while stimulating 
insulin and GLP-1 responses, however no differences in DPP-IV activity were detected 
(Jakubowicz et al., 2014). One explanation may be that DPP-IV inhibition in the small 
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intestine may not have been detectable in the plasma, with the possibility that this is another 
indirect mechanism where whey exerts an effect on insulin secretion.  
 
The most likely mediator of insulin-independent actions of whey on glycaemia is a result of 
modulation of gastric emptying, since slowing of gastric emptying can diminish postprandial 
glucose excursions (Horowitz et al., 1993). The coagulation of casein in the stomach is partly 
responsible for its effect of slowing gastric emptying (Adams & Broughton, 2016), however 
Calbet and Holst (2004) observed similar rates of gastric emptying following whey and 
casein ingestion. The addition of whey protein to a carbohydrate load reduces postprandial 
glucose while displaying delayed gastric emptying (Hoefle et al., 2015), and addition of whey 
to a preload has been reported to slow gastric emptying of a subsequent meal in  healthy 
(Akhavan et al., 2010) and diabetic (Ma et al., 2009) populations. The gastric emptying and 
incretin related properties of whey consumption in the context of attenuating postprandial 
glucose excursions appear to be interdependent, as GLP-1 also slows gastric emptying and 
suppresses glucagon secretion (Mignone et al., 2015). 
 
The effects of whey protein on satiety or subsequent food intake are thought to be mediated 
predominantly by gut hormones, specifically via stimulation of GLP-1, CCK and PYY, in 
addition to suppression of ghrelin, however findings are currently inconsistent. Commercial 
whey products contain 15-20% caseinomacropeptide which is associated with CCK release 
(Anderson et al., 2004), and CCK has been reported to increase following whey protein 
consumption in some (Bowen et al., 2007; Bowen et al., 2006b), but not all (Akhavan et al., 
2014) studies. Bowen et al. (2006a) reported prolonged suppression of ghrelin as well as 
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elevated GLP-1 and CCK following whey, soy and gluten preloads compared to glucose, 
which resulted in a significant reduction in subsequent food intake.  
 
A direct effect of elevated plasma amino acids may also be involved in enhancing satiety 
with whey ingestion. Intracerebroventricular injection of leucine has been documented to 
suppress food intake in rats (Morrison et al., 2007), indicating a potential central effect of 
whey protein on appetite. There is also evidence that whey influences the other side of the 
energy balance equation through an increase in diet-induced thermogenesis. Acheson et al. 
(2011) observed that whey produced favourable effects on postprandial energy expenditure 
compared to either casein or soy when contributing 50% of meal energy. Hursel et al. (2010) 
reported greater thermogenesis following a high protein yoghurt (41% of energy) with 
additional whey protein versus an energy-matched normal protein yoghurt (15% of energy). 
In addition to directly affecting energy balance, energy expenditure from thermogenesis has 
been proposed to induce satiety (Westerterp-Plantenga et al., 1999). 
 
The mechanisms explaining the effect of whey protein on postprandial lipaemia remain 
unclear, however it has been suggested that the reduction in circulating triglyceride-rich 
chylomicrons following whey supplementation may be related to the relatively fast rates of 
digestion and absorption of whey and subsequent appearance of BCAA in the plasma (Pal et 
al., 2010b). It has also been speculated that whey may lead to reduced production of 
chylomicrons in addition to greater clearance through stimulation of LPL by insulin 
(Mortensen et al., 2009), however further work is required here.  
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2.5.2.2.5 Limitations of the current evidence 
 
Currently, many studies have utilised high GI, carbohydrate-rich test meals such as powdered 
potato with (Ma et al., 2009) or without  (Frid et al., 2005) additional glucose, or have mixed 
glucose into a whey protein beverage (Gunnerud et al., 2013; Nilsson et al., 2007; Petersen 
et al., 2009) served as a test breakfast. This enables assessment of the efficacy of whey to 
attenuate greatly elevated postprandial glycaemia, however it may be valuable to investigate 
the response following consumption of whey with realistic breakfast-type foods. The 
consumption of test beverages in place of solid foods may also have implications when 
assessing appetite, since satiation is initially affected by sensory features (Benelam, 2009).  
 
There is a dearth of studies investigating the pure addition of whey to a meal as a 
supplemental strategy. A number of well controlled studies have matched comparison 
treatments for energy (Bowen et al., 2006a; Chungchunlam et al., 2015) or macronutrient 
content (Gunnerud et al., 2012a; Mortensen et al., 2012), however adherence in a naturalistic 
setting may be easier when adding protein before or alongside a meal, rather than substituting 
it for other nutrients in that meal. Similar designs have supplemented whey by adding it to 
glucose (Petersen et al., 2009; Zafar et al., 2013) or maltodextrin (Hoefle et al., 2015), but 
examples of addition to mixed-macronutrient meals are lacking.  
 
The balance between providing an efficacious dose to reduce postprandial hyperglycaemia, 
ensuring palatability, and avoiding overconsumption of excess energy, should be carefully 
considered when designing studies. Studies in overweight/obese non-diabetic populations 
have all supplemented 45-55 g protein. A 45 g whey protein preload, as administered by Pal 
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et al. (2010b), contains ~180 kcal which, if consumed regularly, may have a detrimental 
impact on energy balance.  
 
To the author’s knowledge, only one study (Ma et al., 2009) has investigated the effect of 
timing of whey protein before or alongside a meal on subsequent metabolic responses. 
Several studies have administered whey at a set time before a standardised or ad libitum meal 
under all conditions, while fewer studies have administered whey protein alongside or 
immediately prior to a test meal. The large variation in preload timings (15-180 minutes) 
makes direct comparison of the most efficacious supplementation strategy problematic. 
Furthermore, no studies have investigated whether consumption of whey following a meal, 
would be beneficial. In addition, there are currently no studies that have investigated the 
effects of whey protein consumption on postprandial responses beyond a single isolated meal. 
Frid et al. (2005) examined post breakfast and post lunch responses, however whey was given 
with both meals meaning that interpretation of any second meal effects of prior whey 
consumption is confounded by subsequent whey ingestion. Given that a high (non-dairy) 
protein breakfast has been reported to attenuate postprandial glucose excursions following a 
standard lunch meal in participants with T2DM (Park et al., 2015), this may be novel area to 
investigate.  
 
An area of great interest in recent years has been the consumption of whey protein following 
resistance exercise, due to its stimulatory effect on muscle protein synthesis (Witard et al., 
2014). However, an area of great paucity in the literature concerns the influence of whey 
protein supplementation following aerobic exercise, particularly regarding subsequent 
postprandial responses. Studies have investigated the effects milk (Rumbold et al., 2015) or 
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whey protein (Clayton et al., 2014) consumption after moderate-intensity cycling exercise 
on food intake responses 60 minutes later, reporting reduced ad libitum energy intake 
compared to an energy-matched carbohydrate drink (Rumbold et al., 2015) or low energy 
placebo (Clayton et al., 2014). However, considering that a single bout of exercise produces 
divergent responses in subsequent glucose tolerance (see section 2.2.4), the impact of post 
exercise whey consumption on postprandial metabolic responses warrants attention, 
particularly in sedentary individuals.  
 
2.6 Summary 
 
A large body of evidence has associated consumption of dairy products, or more specifically 
dairy proteins, with reduced prevalence of obesity, metabolic syndrome and T2DM. 
Furthermore, a growing number of studies provides acute evidence of favourable metabolic 
and appetite-related effects of whey protein consumption at breakfast, which may be 
responsible for driving this association. Despite some inconsistencies, the majority of 
evidence suggests a beneficial effect of consuming whey protein before or with a meal on 
the subsequent glycaemic response in healthy and diabetic populations. These effects are 
indicative of the potential for whey protein supplementation to be effective in the prevention 
or management of declining metabolic health in healthy individuals, and those at risk of 
developing metabolic disorders. 
 
Previous studies show considerable variation regarding the timing and dosing of 
supplemental whey, in addition to the method of co-ingestion with other macronutrients, 
while it is not known whether the acute beneficial effects extend beyond breakfast to a 
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subsequent meal. Furthermore, the ability of supplemental whey protein to augment the 
postprandial milieu following prior aerobic exercise is unclear. Therefore, the aim of this 
thesis is to investigate practical strategies for the efficacious supplementation of whey protein 
to positively augment postprandial meal handling in normal-weight and obese populations. 
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CHAPTER 3 
 
General Methods 
 
 
Methods that were repeated across multiple chapters within this thesis are described below. 
Ethical approval for all studies was granted by the Faculty of Health and Life Sciences 
Research Ethics Committee at Northumbria University.  
3  
3.1 Participants 
 
Participants were recruited from the local community in addition to the student and staff 
population at Northumbria University, Newcastle Upon Tyne, UK. Methods of recruitment 
included email, poster advertisement and oral presentation. Individuals who responded to 
initial recruitment calls were sent written information in the form of a participant information 
sheet (see Appendix A for an example participant information sheet), detailing the nature of 
the study and comprehensive details of the time commitment and demands involved, as well 
as any potential risks and benefits of participation.  
 
Prospective volunteers who registered an interest were subsequently screened against the 
relevant inclusion/exclusion criteria (Table 3.1). During this screening visit a full verbal 
explanation of the study was given, and volunteers completed an informed consent form 
(Appendix B) and a health questionnaire (see Appendix C for example health questionnaire). 
Anthropometric measurements were taken as described in section 3.6.1.  
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 Table 3.1 Inclusion and exclusion criteria for participants across all experimental chapters. 
 Chapters 4a and 4b  Chapters 5 and 6 
Inclusion 
Male  Male 
Aged 18-40 years  Aged 18-55 years 
Regularly physically active  Low level of physical activity 
BMI: 20-30 kg∙m-2  BMI > 30 kg∙m-2 
  Waist circumference > 102 cm 
Exclusion 
Taking medication that may influence metabolism or digestion 
Recent or current smoker 
Cardiovascular, metabolic or renal disease 
Current illness 
Regular breakfast skipper 
Known food allergies or intolerances 
Eating disorder 
Inadequate venous access 
 
 
 
In Chapters 4a and 4b, young males who were habitually physically active were recruited, 
defined as those who regularly completed at least 30 minutes of structured exercise 5 times 
per week, assessed by self-report. In Chapters 5 and 6, centrally-obese males who were not 
regularly physically active but otherwise considered healthy (i.e. no reported cardiovascular 
or metabolic conditions) were recruited. Central obesity is considered an important aspect in 
the pathogenesis of metabolic syndrome (O'Neill & O'Driscoll, 2015), and is more strongly 
associated with increased risk of insulin resistance, metabolic syndrome and CVD than BMI 
alone (Nedungadi & Clegg, 2009). Participants were therefore screened for elevated waist 
circumference using the WHO threshold associated with the greatest risk of metabolic 
complications in males (Alberti et al., 2009). For these studies, prospective participants 
completed the International Physical Activity Questionnaire (Appendix D) (Hagströmer et 
58 
 
al., 2006) during screening, and were deemed to meet the inclusion criteria if they were 
considered to have a “low” physical activity level after analysis using the categorical scoring 
method. Participants were considered to be ‘breakfast skippers’ if they self-reported as 
consuming breakfast on two or less occasions in the previous 7 days, and considered 
themselves as someone who was not a regular breakfast eater (Reeves et al., 2015).  
 
The sample sizes recruited within each study were calculated using data for a difference in 
the primary outcome of glucose AUC, and its typical error variance, from relevant previous 
studies. Based on the reduction in glucose AUC observed in normal-weight participants 
following addition of whey to a standard meal (Gunnerud et al., 2012b), a sample size of 
nine was deemed sufficient to provide statistical power above 80% with an alpha level of 
0.05. When taking dropouts into account, the recruitment of 11 participants was targeted in 
Chapter 4. Based on the findings of a 16% reduction in glucose AUC following consumption 
of whey protein with a mixed-macronutrient breakfast in an overweight/obese population 
(Pal et al., 2010b), it was calculated that a sample size of 11 would provide statistical power 
above 80%, with an alpha level of 0.05. When taking dropouts into account, a total of 13 
participants was targeted in Chapters 5 and 6.  
 
3.2 Experimental design 
 
A single-blind crossover design was implemented in all studies presented within this thesis, 
whereby participants completed all experimental arms in a randomised, counterbalanced 
order. An online randomisation tool for researchers (http://www.randomization.com/) was 
used to create a set of balanced treatment order regimens by inputting the number of 
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experimental arms and expected sample size. Participant identification numbers were then 
randomly assigned to a treatment schedule using the ‘=RAND()’ function in Microsoft Excel 
to determine the order of trial completion.  
 
Studies were designed to assess the effects of whey protein supplementation and/or exercise 
manipulation at breakfast time on acute and second meal postprandial metabolic and appetite 
responses. Prior to all experimental visits, diet and physical activity was standardised as 
described in section 3.3. All trials were conducted within the clinical research laboratories at 
Northumbria University, commencing at the same time (~08:00 am) where possible and 
separated by at least 3 (Chapters 4 and 5) or 7 (Chapter 6) days.  
 
In Chapter 4 participants completed five trials, comprising four experimental conditions and 
one control condition. To present appropriate comparisons between conditions, data from 
this study are presented in two sub-chapters. Chapter 4a describes data collected in trials 
where a carbohydrate-rich breakfast was consumed alongside the control (no breakfast) trial. 
Chapter 4b presents data from trials which involved ingesting a fat-rich breakfast, alongside 
the same control dataset.  
 
3.3 Pre- and post-trial diet and physical activity standardisation 
 
Prior to each experimental visit participants were provided with verbal and written 
instructions regarding diet and physical activity control measures. For 24 hours prior to 
arrival participants were instructed to avoid caffeine and alcohol consumption as well as 
strenuous physical activity. A mixed-macronutrient meal was provided before each visit in 
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all studies (Table 3.2), and participants were instructed to consume this as their evening meal, 
approximately 12 hours prior to their arrival time, in order to standardise macronutrient and 
energy intake as far as possible. Following ingestion of this meal participants were instructed 
to consume only water (for the remainder of the evening and the following morning), 
ensuring that they arrived at the laboratory having fasted for approximately 12 hours. In 
addition, participants were asked to travel to the lab using automated transport where 
possible, to avoid excessive pre-trial exertion.  
 
 
 
 
 
Table 3.2 Composition of pre-trial evening meals. 
Chapter 
Macronutrient Composition (% energy) Energy 
(kJ) 
Ingredients and 
Manufacturer CHO FAT PRO 
4a, 4b 44.2 33.7 20.8 3171 
Pasta Bolognese (Heinz, 
USA), Chocolate pot dessert 
(Cadbury, UK). 
5, 6 37.3 43.7 18.9 3501 
Beef Lasagne (Tesco Stores 
Ltd, UK), Nature Valley oats 
and honey bar (General Mills, 
USA). 
 
 
 
In Chapters 4a and 4b participants were provided with a self-reported estimated food diary 
(Appendix E) during their first visit and asked to record all food and beverage intake for 18 
hours after leaving the laboratory, concomitant to the recording of interstitial glucose 
concentrations. Dietary intake during this period was subsequently replicated after leaving 
the laboratory following the other experimental visits.  
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3.4 Preparation of test meals 
 
A standardised breakfast meal of porridge oats was consumed in Chapters 5 and 6 which was 
designed to represent a frequently consumed meal amongst breakfast eaters in the UK 
(Reeves et al., 2013), providing 1960 kJ of energy (70% carbohydrate, 17% fat, 13% protein) 
with a GI of 63. To prepare each meal, 54 g rolled porridge oats (Quaker, UK) combined 
with 260 ml semi-skimmed milk (Tesco Stores Ltd, UK) was cooked in a microwave 
(900 W) for 130 seconds. After heating, 42.5 g clear honey (Tesco Stores Ltd, UK) was 
stirred into the semi-liquid porridge mixture which was served to the participant alongside 
250 ml of drinking water. Participants were encouraged to consume this meal within 10 
minutes.  
 
A standardised lunch meal was administered to test for second meal effects of breakfast 
interventions in Chapters 4 and 5. This pasta-based meal provided 3446 kJ of energy (50% 
carbohydrate, 36% fat, 14% protein) with a GI of 54. A 125 g portion of dried fusilli pasta 
(Tesco Stores Ltd, UK) was combined with 1000 ml water and heated in a microwave 
(900 W) for 13 minutes, then drained and mixed with 170 g of a tomato-based sauce (Dolmio 
Tomato and Basil Pasta Sauce, Mars, USA). Grated cheddar cheese (40 g) (Tesco Stores Ltd, 
UK) was added, along with 15 g olive oil (Tesco Stores Ltd, UK), before mixing thoroughly. 
The resulting homogenous meal was heated for a further 2 minutes before being served to 
the participant alongside 350 ml of drinking water. Participants were again instructed to 
finish the entire meal within 10 minutes. To assess energy intake in the final study of this 
thesis (Chapter 6), a pasta meal of similar macronutrient composition was served ad libitum. 
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Information regarding the preparation and composition of this meal is presented in section 
6.2.5. 
 
The GI of test meals was calculated using the method of Wolever and Jenkins (1986) for 
calculation of GI for mixed meals, after calculation of the GI contribution of each meal 
component using published tables (Atkinson et al., 2008). 
 
3.5 Whey protein isolate powder 
 
In all studies, whey protein isolate powder was combined with water to provide a 
supplemental beverage of the desired protein content. This was provided by Arla Foods 
Ingredients Group, Viby, Denmark (Chapters 4a and 4b: PSNU27600; Chapters 5 and 6: 
Lacprodan SP-9225 Instant). Both batches of product were provided as a ready-to-use dry 
mix powder which was soluble in water and provided a neutral taste, however all beverages 
were flavoured using energy-free flavouring (FlavDrops, Myprotein, UK) in an attempt to 
blind participants to the treatment (flavour-matched water was served in placebo trials). 
Details regarding the specific doses of supplement administered during each study are 
presented within Chapters 4-6. Full chemical specifications and amino acid profiles of these 
supplements are provided in Appendix F.  
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3.6 Data Collection 
 
3.6.1 Anthropometry 
 
Stature was measured to the nearest 0.1 cm using a fixed stadiometer (602VR, Holtain Ltd, 
UK), and body mass was determined to the nearest 0.05 kg using a digital scale (Seca 704, 
Seca Ltd, Germany), after ensuring that participants had removed footwear and were wearing 
lightweight clothing. These values were used to determine BMI by dividing body mass in 
kilograms by the square of stature in metres (kg∙m-2). In Chapters 5 and 6 waist and hip 
circumference were measured to the nearest 0.1 cm using a steel anthropometric tape (Lufkin 
W606PM, Lufkin, USA) according to International Society for the Advancement of 
Kinanthropometry (ISAK) guidelines (Stewart et al., 2011). The waist measurement was 
taken at the narrowest point between the lower costal border and the illiocristale, or the mid-
point between these landmarks if no obvious narrowing was apparent. Hip circumference 
was recorded over light clothing at the level of the greatest posterior protuberance. Waist-hip 
ratio was calculated by dividing waist circumference by hip circumference. 
 
3.6.2 Subjective appetite ratings 
 
Subjective ratings of appetite were captured at baseline and periodically throughout all 
studies using VAS (Appendix G). The reproducibility of within-subject responses and the 
sensitivity to experimental manipulations for this technique have previously been established 
(Flint et al., 2000; Stubbs et al., 2000). Paper-based 100 mm scales were used to record 
perceptions of hunger, fullness, satisfaction and prospective food consumption (PFC). Each 
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scale was anchored with statements representing the theoretical minimum and maximum 
values on the continuum for that aspect of subjective appetite. For example, in order to 
capture sensations of hunger, participants were asked the question “how hungry do you feel” 
and were presented with a scale anchored at either end with the statements “I am not hungry 
at all” and “I have never been more hungry”. Participants marked a vertical line on each scale 
indicating their feelings at that time point, and were blinded to their ratings at previous time 
points. The distance in mm between the extreme left of the scale and this mark was measured 
to provide a quantitative estimate of appetite sensations. Scales were measured independently 
by two researchers with the mean value recorded.  
 
3.6.3 Blood sampling 
 
Approximately 10 minutes after arrival, a cannula (Chapters 4a and 4b: Venflon 20G, Becton 
Dickinson, USA; Chapters 5 and 6: Vasofix 22G, B.Braun Melsungen AG, Germany) was 
inserted into a vein in the antecubital fossa while participants remained in a semi-supine 
position. A 10 cm connecting tube (Connecta, Becton Dickinson, USA) with three-way tap 
was attached to the cannula in Chapters 4a and 4b (Figure 3.1a), which was kept patent by 
flushing with 0.9% (w/v) sodium chloride solution (Posiflush, Becton Dickinson, USA). To 
ensure that samples were not contaminated by saline the first ~2.5 ml of blood was discarded 
at each sample point. In Chapters 5 and 6 sterile stylets (22G, B.Braun Melsungen AG, 
Germany) were inserted to keep the cannula patent between blood samples (Figure 3.1b).  
 
To control for any postural changes in plasma volume participants were instructed to remain 
in a seated position throughout the protocol where possible. Care was taken to ensure that 
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participants remained in this position 5 minutes prior to, and during, each blood sample, 
except for the sample which immediately followed 30 minutes of treadmill walking in 
Chapter 6. It was assumed that plasma volume would not be influenced significantly by the 
low-moderate intensity exercise prescribed in Chapter 6 (~50% V̇O2peak), as studies have 
indicated that plasma volume does not significantly change when exercise bouts of greater 
intensity and duration were employed (Broom et al., 2007; Burns et al., 2007). 
Concentrations of all analytes in plasma are therefore presented as uncorrected values.  
 
At each sample point, 10 ml of whole blood was drawn into a syringe from the cannula 
(Figure 3.1c). A 20 µl sodium heparinised capillary tube was filled with whole blood in 
Chapter 4 for immediate determination of glucose concentration. The remaining blood was 
transferred into a 10 ml Ethylenediaminetetraacetic acid (EDTA) coated tube (Vacutainer, 
Becton Dickinson, USA) and immediately centrifuged at 1734 g and 4˚C for 10 minutes 
(Allegra X-22R, Beckman Coulter, USA). Plasma was aliquoted into separate microtubes 
and stored at -80˚C for subsequent analysis.  
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Figure 3.1 Images of venous blood sampling equipment used in Chapters 4a and 4b (a) and Chapters 5 and 6 (b). Blood 
was drawn into a 10 ml syringe at each sample point (c). 
 
 
 
In Chapters 5 and 6, capillary blood samples (20 µl) were collected immediately following 
each venous blood draw using the finger-prick technique. Additional samples were collected 
at 5 and 10 minutes post meal in order to increase the resolution of the blood glucose curve 
during the period where rapid changes may occur. After cleaning the fingertip, a single-use 
lancet (Accu-Chek Safe-T Pro Plus, Roche, Switzerland) was used to prick the skin and 
induce bleeding (Figure 3.2a). After wiping the first drop of blood with a tissue, the sample 
was drawn into a 20 µl sodium heparinised capillary tube (EKF Diagnostics, UK) (Figure 
3.2b) which was placed in  haemolysing solution (Figure 3.2c) for immediate analysis of 
glucose as described in section 3.6.4.1.  
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Figure 3.2 Images of capillary blood sampling technique. A single-use lancet is used to prick the fingertip (a), a capillary 
tube is filled (b) and placed in haemolysing solution (c). 
 
 
Whilst venous blood is widely used to determine glucose concentration, metabolism at 
tissues within the forearm characteristically results in lower values than either capillary or 
arterial blood (Eriksson et al., 1983; Liu et al., 1992), particularly in the post-meal milieu 
where glucose uptake may be stimulated. Postprandial glycaemia was the primary outcome 
of interest in the studies presented in this thesis, therefore it was felt that using capillary blood 
offered a suitable method of sampling which provides values that do not differ markedly 
from arterial blood (Liu et al., 1992), without the practical constraints associated with 
collecting arterial blood. This design also allows for simultaneous measurement of venous 
and capillary blood in Chapters 5 and 6. Whilst there may be absolute differences between 
glucose values collected from these compartments, it should be noted that the pattern of 
response is similar, indicating that the use of venous blood glucose in Chapter 4 still provides 
a valid method of assessing changes of within-subject blood glucose between conditions.  
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3.6.4 Blood sample analysis 
 
3.6.4.1 Glucose 
 
Capillary tubes filled with whole blood (20 µl) were placed into microtubes and combined 
with 1 ml haemolysing solution prior to analysis. Glucose concentrations were determined 
simultaneously using the Biosen C_line analyser (EKF Diagnostics, UK) (Figure 3.3). The 
accuracy and precision of this analyser has been previously validated against a reference 
instrument (Nowotny et al., 2012). This utilises the enzymatic-amperometric method, 
whereby glucose oxidase catalyses the conversion of glucose to gluconic acid. Hydrogen 
peroxide is produced which is oxidised at the electrode generating electrons, and the resulting 
current is proportional to the initial glucose concentration. 
  
 
 
Figure 3.3 Biosen C_line analyser for determination of blood glucose concentration. 
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3.6.4.2 Insulin 
 
Plasma insulin concentration was determined using a solid-phase enzyme-linked 
immunosorbent assay (ELISA) based on the sandwich principle (IBL International, 
Hamburg, Germany). All reagents were stored and prepared according to manufacturer 
instructions. Samples were thawed at room temperature and shaken using a vortex mixer 
prior to assaying. Aliquots of sample were incubated, along with an anti-insulin antibody 
conjugated with biotin, in microplate wells coated with monoclonal antibody. After washing 
off unbound conjugate, a second incubation period was initiated where streptavidin 
horseradish peroxidase (HRP) enzyme complex binds to the biotin-anti-insulin antibody. 
After a further washing step, the amount of bound HRP complex is proportional to insulin 
concentration. A substrate (tetramethylbenzidine) was subsequently added to produce a 
fluorescent product, the intensity of which was proportional to sample insulin concentration. 
After incubating for 15 minutes at room temperature this reaction was stopped by adding 
sulphuric acid. The absorbance at each well was determined using a microtiter plate reader 
at a wavelength of 450 nm (Anthos 2010, Anthos GmbH, Germany). The sensitivity of the 
assay according to manufacturer instructions was 1.76 µIU∙ml-1. 
 
A standard curve was created from the known concentration and mean absorbance values of 
the duplicate standards using Prism 5 software (Graphpad Software, USA). Sample 
concentrations in μIU∙ml-1 were calculated from sample absorbance values by interpolation 
from the standard curve, and subsequently converted to SI units (pmol∙l-1) by multiplying by 
a conversion factor of 6 (Staten et al., 2010). In Chapters 5 and 6 samples were diluted 1:3 
using zero standard after initial analysis produced values outside of the assay range. 
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All samples from a participant were analysed on a single plate where possible in order to 
minimise inter-assay variation. The majority of samples were assayed in singlet, with at least 
one sample per trial measured in duplicate. Reference samples were assayed on each plate to 
calculate inter-assay variation. All standards were assayed in duplicate. The intra- and inter-
assay coefficients of variation for all assays conducted were 6.9 ± 0.9% and 10.8 ± 0.7% 
respectively.  
 
3.6.4.3 Enzymatic colourimetric assays 
 
NEFA, glycerol and triglyceride concentrations were determined with an automated analyser 
(RX Daytona, Randox Laboratories, UK) using enzymatic colorimetric assays (Randox 
Laboratories, UK) according to manufacturer instructions. The analyser was calibrated daily 
with ready-to-use calibrators supplied within each kit. Quality control material was assayed 
on two levels for NEFA and triglyceride (Human Assayed Multi-Sera – Level 2 and Level 3, 
Randox Laboratories, UK) and on one level for glycerol (Glycerol Control, Randox 
Laboratories, UK). Assay sensitivity according to manufacturer instructions was 0.072 
mmol∙l-1, 14.5 µmol∙l-1 and 0.134 mmol∙l-1 for NEFA, glycerol and triglyceride respectively. 
Samples were analysed in singlet, and all samples from a participant were analysed on the 
same run where possible. Analyte concentrations were provided in SI units directly by the 
analyser software. Intra-assay coefficients of variation for all assays conducted were <7.2%.  
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3.6.5 Continuous glucose monitoring 
 
In Chapters 4a and 4b, participants were fitted with a continuous glucose monitor (CGM) to 
assess the impact of each intervention on longer-term glycaemia (i.e. 24 hours). The CGM 
gives continuous (every 5 minutes) measures of interstitial glucose concentration which 
allows the capturing of high resolution data and thus information regarding both postprandial 
excursions and glycaemic variability, which are associated with adverse metabolic effects if 
elevated above normal levels (Ceriello et al., 2008; Fava, 2008). The CGM device used 
(G4 Platinum, Dexcom, USA) compares favourably to other systems in terms of accuracy 
(Kropff et al., 2015), and consists of a small indwelling sensor, a transmitter which attaches 
to the sensor and a handheld receiver which displays the glucose readings (Figure 3.4). The 
sensor principally utilises the glucose oxidase method described in section 3.6.4.1 to generate 
an electrical current proportional to the glucose concentration in the interstitium. The 
transmitter sends a signal via wireless radio frequency to the receiver which displays and 
records the concentration. Close agreement between capillary glucose and interstitial 
concentrations recorded by CGM systems has previously been found throughout the 
glycaemic range (Caplin et al., 2003; Maia & Araújo, 2007).  
 
The sensor was implanted into the subcutaneous tissue of the anterior-medial aspect of the 
abdomen using the insertion device provided, and placement was replicated across trials. 
This was carried out at least 48 hours prior to commencement of the first trial, allowing a 
period of stabilisation to occur following sensor initiation. The CGM was calibrated by the 
participant inputting a minimum of four capillary blood glucose readings per day, obtained 
from a blood glucose meter (Accu-Chek Mobile, Roche, Switzerland) using the finger-prick 
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technique described in section 3.6.3. As a consequence of the potential for a physiological 
time delay between blood and interstitial concentrations, participants were instructed to 
calibrate prior to meals in order to ensure that interstitial fluid glucose was in equilibrium 
with capillary glucose (Bequette, 2010). Data was captured for 24 hours pre-trial and for 24 
hours post-test breakfast, after which the sensor was removed.  
 
 
 
 
 
Figure 3.4 Dexcom G4 Platinum continuous glucose monitoring system. 
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3.7 Data processing 
 
Serial measures of blood analytes, subjective appetite responses and CGM data were used to 
calculate AUC using the trapezoidal method, which involves addition of the areas under the 
graph between each pair of consecutive observations. The resultant total AUC includes all 
area below the response curve in order take account of situations where concentration fell 
below baseline (Matthews et al., 1990). CGM data were analysed for 24 hours following 
initiation of breakfast consumption, with a total of 288 sample points recorded during each 
experimental condition. Data were split into 6 hour epochs for analysis of glycaemic 
exposure (AUC) and variability. Relative glycaemic variability was expressed as the overall 
glucose coefficient of variation (%CV), calculated by dividing the standard deviation (SD) 
with the mean and multiplying by 100. Previous studies have indicated a high degree of 
correlation between the SD and other parameters of glycaemic variability, such as mean 
amplitude of glucose excursions (Rodbard, 2009). 
 
Fasting levels of insulin resistance were characterised for participants across all chapters by 
utilising the homeostatic model assessment of insulin resistance (HOMA-IR) which was 
calculated using the following equation (Matthews et al., 1985): 
 
HOMA-IR =
Fasting Plasma Glucose (mmol∙l-1) x Fasting Plasma Insulin (µIU∙ml-1)
22.5
 
 
Insulin sensitivity was assessed across chapters using the Matsuda Insulin Sensitivity Index 
(ISI), calculated using fasting and postprandial concentrations of plasma glucose (mg∙dl-1) 
and plasma insulin (µIU∙ml-1) using the following equation (Matsuda & DeFronzo, 1999): 
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Matsuda-ISI =
10000
√(Fasting Glucose x Fasting Insulin) x (Mean Glucose x Mean Insulin)
 
 
In order to combine the four separate aspects of subjective appetite assessment detailed in 
3.6.2 into a summary measure of perceived appetite, the equation below was applied to 
calculate combined appetite score (CAS), as used previously (Gonzalez & Stevenson, 2014):  
 
CAS =
hunger + prospective consumption + (100 - fullness) + (100 - satisfaction)
4
 
 
This composite measure is reported alongside individual appetite ratings in Chapters 4-6.  
 
3.7.1 Statistical analysis 
 
Statistical analysis was conducted using the Statistical Package for the Social Sciences (SPSS 
version 21, IBM, USA). Matsuda ISI, baseline values and AUC (all variables measured over 
time) were assessed using one-way repeated measures analysis of variance (ANOVA). Blood 
and plasma analyte concentrations and subjective appetite responses were tested for 
differences between conditions over time using two-way (condition x time) repeated 
measures ANOVA. Mauchly’s test was used to check the assumption of sphericity for 
repeated measures analysis, and the degrees of freedom were adjusted using the appropriate 
correction if this assumption was violated. Post hoc analysis was performed upon 
identification of significant main effects and the Bonferroni correction was used to correct 
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the level of alpha for multiple comparisons. The level of statistical significance was set at 
p < 0.05 and data are presented as mean ± standard error of the mean (SEM).  
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CHAPTER 4a 
 
Acute and second-meal metabolic and appetite responses following co-
ingestion of whey protein with a carbohydrate-rich breakfast in normal-
weight males 
 
 
 
 
4  
4.1.1 Introduction 
 
It is widely acknowledged that obesity predisposes individuals to increased risk of disorders 
including metabolic syndrome, T2DM and CVD (Wang et al., 2011), characterised by insulin 
resistance, which is positively correlated with BMI (Shakher & Barnett, 2009). However, 
postprandial hyperglycaemia, independent of weight status, has an increasingly recognised 
role in metabolic impairment and contribution to CVD risk (Bianchi et al., 2008; Gerich, 
2006; Monnier et al., 2012), even when fasting glucose is in the normal range (Ning et al., 
2012). It may therefore be appropriate for interventions aimed at ameliorating postprandial 
glycaemic excursions, and improving metabolic health in general, to be targeted at the wider 
population rather than just ‘at risk’ groups, i.e. those with obesity or IFG.  
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A growing body of evidence implicates manipulation of meal macronutrient content, 
including protein ingestion, on markers of metabolic health (Leidy et al., 2015b; Mateo-
Gallego et al., 2016; Westerterp-Plantenga et al., 2012). Dairy proteins in particular, have 
been investigated extensively (Bjørnshave & Hermansen, 2014; Pasin & Comerford, 2015), 
and recent studies point to whey protein as having potentially advantageous effects including 
reduced postprandial glycaemia (Akhavan et al., 2010; Frid et al., 2005) and lipaemia 
(Mortensen et al., 2009; Pal et al., 2010b), potentially mediated by an increased insulin 
response (Gunnerud et al., 2013; Nilsson et al., 2007). Whey proteins promote insulin 
secretion to a greater extent than other proteins sources in lean individuals (Pal & Ellis, 2010), 
with a high concentration of BCAAs, particularly leucine, and fast rate of appearance as 
likely integral mediators (Esteves de Oliveira et al., 2011; Pal & Radavelli-Bagatini, 2013). 
The subsequent synthesis and secretion of the incretin hormones GIP and GLP-1, due to the 
presence of amino acids and peptides derived from whey protein digestion (Ricci-Cabello et 
al., 2012), also likely play an important role in the enhanced insulinaemic response. Incretin 
hormones increase both fasting and postprandial insulin release (Sousa et al., 2012) and their 
presence, in concert with increased plasma insulin concentrations, may also lead to appetite 
suppressive effects (Jakubowicz & Froy, 2013).  
 
Previous studies have investigated the effects of whey protein when consumed prior to, or 
alongside, a meal on postprandial glycaemia in normal-weight (Gunnerud et al., 2012b; Pal 
& Ellis, 2010), overweight (Bowen et al., 2007; Pal et al., 2010b) or diabetic populations 
(Frid et al., 2005; Ma et al., 2009). When whey protein (18.2 g) is ingested at the same time 
as a high GI lunch meal, a 21% reduction in glucose AUC was reported in participants with 
T2DM (Frid et al., 2005). A dose-dependent reduction in glucose AUC has also been shown 
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in healthy individuals (Gunnerud et al., 2013). Studies have regularly prescribed large doses 
of whey protein which may not be practical to consume alongside a meal and involves intake 
of relatively high amounts of additional energy. Typically, doses between 45 and 50 g have 
been employed (Anderson et al., 2004; Bowen et al., 2007; Ma et al., 2009). Furthermore, 
these studies characteristically involve short observation periods, e.g. 120 minutes 
(Chungchunlam et al., 2015; Nilsson et al., 2007), and the observation of single meal 
responses (Hoefle et al., 2015).  
 
The influence on subsequent feeding and metabolism is of importance as the macronutrient 
composition of a breakfast meal has been demonstrated to influence the metabolic response 
following subsequent feeding in healthy individuals (Frape et al., 1997) and those with 
T2DM (Park et al., 2015). It is currently unclear whether the potential beneficial effects of 
whey protein on the acute postprandial milieu extend beyond a single breakfast meal to have 
protective effects at lunch or later during the day. Thus, investigating the potential second 
meal effects of whey protein on glycaemia, insulinaemia, lipaemia and appetite may be 
important in identifying efficacious strategies to prevent metabolic deterioration in currently 
healthy individuals, while providing further insights into the supplemental use of whey 
protein for health. Therefore, the aim of this study was to determine the acute postprandial 
metabolic and appetite responses in normal-weight individuals following a carbohydrate-rich 
breakfast, with and without co-ingestion of whey protein, in addition to responses following 
subsequent feeding.  
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4.1.2 Methods 
 
4.1.2.1 Participants 
 
Ten normal-weight male participants who were free from metabolic disease (age: 
24 ± 1 years; mass: 79.7 ± 1.2 kg; stature: 1.81 ± 0.02 m; BMI: 24.5 ± 0.7 kg∙m-2, 
HOMA-IR: 2.1 ± 1.1 arbitrary units), were recruited as described in section 3.1, and 
according to the criteria listed in Table 3.1. All participants provided written informed 
consent prior to inclusion. This study was registered at clinicaltrials.gov as NCT02414061.  
 
4.1.2.2 Experimental design 
 
A crossover design was implemented with three experimental conditions consisting of a 
carbohydrate breakfast (CHO), carbohydrate breakfast with supplemental whey protein 
(CHO+WP) and no breakfast control (NB). Participants attended the laboratory on three 
separate occasions, separated by at least 72 hours, and underwent all three conditions in a 
randomised and counterbalanced order (section 3.2). The study involved both a laboratory 
protocol and a home-based element, where interstitial glucose concentrations were 
continuously sampled for 18 hours after leaving the laboratory on each occasion. Prior to 
each visit, physical activity and dietary intake was standardised (section 3.3) and a meal was 
provided which participants were instructed to consume 12 hours before arrival at the 
laboratory (Table 3.2).  
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Upon arrival at ~0800 hours, a cannula was inserted into an antecubital vein and a baseline 
blood sample collected (see section 3.6.3). Subjective appetite sensations were also sampled 
at baseline through completion of VAS as described in section 3.6.2. Participants 
subsequently consumed one of two test breakfasts (CHO or CHO+WP) or ingested a 
reference bolus of water (NB), with the remainder of the protocol being identical under all 
conditions (Figure 4.1). Participants remained in a rested state for 180 minutes, after which 
the same standardised, mixed-macronutrient lunch meal was provided under all conditions. 
After a further 180 minutes, the cannula was removed and participants could leave the 
laboratory. Dietary intake for the following 18 hours was replicated on each occasion as 
described in section 3.3.  
 
 
 
Figure 4.1 Schematic layout of laboratory experimental protocol. CHO, high carbohydrate breakfast trial; CHO+WP, high-
carbohydrate breakfast with added whey protein trial; NB, no breakfast trial. 
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4.1.2.3 Test meals 
 
The energy content and macronutrient composition of the test meals provided in each 
condition are displayed in Table 4.1. The breakfast meal administered in CHO and CHO+WP 
consisted of white wheat bread (95 g) and strawberry jam (48 g) with an orange juice 
beverage (200 ml) which had a GI of 63. Water (250 ml) was provided in an opaque bottle 
and flavoured with 0.5 ml energy-free vanilla flavouring (FlavDrops, Myprotein, UK) in the 
CHO trial. This process was repeated for CHO+WP, with the addition of 24 g whey protein 
isolate powder dissolved in the flavoured water. The whey powder had a protein content of 
83% (Appendix F1), providing 20 g protein per serving, which has previously been identified 
as an efficacious dose for reducing glycaemia (Abou-Samra et al., 2011). These beverages 
were matched for flavour, however the difference in viscosity due to the presence of the 
protein was not accounted for. No reference was made to which trial was being conducted 
throughout, and participants were therefore blinded to the condition in breakfast consumption 
trials. Further water was provided alongside breakfast, the volume of which was trial-
dependent in order to standardise meal volumes across conditions. In the NB trial, an 
isovolumetric bolus (675 ml) of water was consumed by participants at the applicable time 
point. Further water was not administered during the postprandial period in order to maintain 
standardisation and control for any potential effects of gastric volume on appetite suppression 
(Wang et al., 2008). A timer was started upon initiation of consumption in all trials, and 
participants were encouraged to consume the meal within 5 minutes. An identical pasta meal 
was served at lunch in all conditions, which was prepared as described in section 3.4. Water 
(350 ml) was also served alongside the lunch meal, and was withheld in the post lunch period.  
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Table 4.1 Energy and macronutrient composition of breakfast and lunch test meals. 
  
Energy 
kJ (kcal) 
Carbohydrate 
g (E%) 
Fat 
g (E%) 
Protein 
g (E%) 
 CHO 1799 (430) 93 (88) 2 (4) 9 (8) 
Breakfast CHO+WP 2172 (519) 95 (75) 2 (3) 29 (22) 
 NB 0 (0) 0 (0) 0 (0) 0 (0) 
      
Lunch  3446 (824) 104 (50) 33 (36) 29 (14) 
E%: percentage of total meal energy; CHO: high-carbohydrate breakfast trial; CHO+WP: high-carbohydrate breakfast with 
added whey protein trial; NB: no breakfast trial. 
 
 
 
4.1.2.4 Blood sampling and analysis 
 
Venous blood samples were collected at regular intervals throughout (baseline, 15, 30, 45, 
60, 90, 120, 150 and 180 minutes post-breakfast, and corresponding post lunch time points 
(Figure 4.1)). Samples were collected with subjects in a seated position as described in 
section 3.6.3, and were analysed for concentrations of blood glucose and plasma insulin, 
triglyceride, NEFA and glycerol as described in section 3.6.4.  
 
4.1.2.5 Subjective appetite 
 
Subjective appetite ratings were recorded at baseline and at 30 minute intervals following 
both breakfast and lunch meals using 100 mm paper-based VAS as described in section 3.6.2.  
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4.1.2.6 Continuous glucose monitoring 
 
Participants were fitted with a CGM (G4 Platinum, Dexcom, USA) at least 48 hours prior to 
their first trial (see 3.6.5 for detailed information regarding CGM methodology) to allow 
stabilisation before trial commencement. Interstitial glucose concentrations were continually 
recorded throughout the laboratory protocol and for a further 18 hours until 24 hours post-
breakfast.  
 
4.1.2.7 Statistical analysis 
 
Blood and VAS derived data were analysed over both the post-breakfast (0-180 min) and 
post-lunch (180-360 min) periods. The time point at 180 minutes post-breakfast was used as 
the baseline value for the post-lunch period. Due to its delayed appearance in plasma, 
triglyceride data were also assessed over the full 360 minute laboratory protocol. Total AUC 
values were calculated using the trapezoidal method and CGM data were processed as 
described in section 3.7. Statistical analysis was conducted as described in section 3.7.1. 
 
4.1.3 Results 
 
4.1.3.1 Post-breakfast responses 
 
There were no differences between trials at baseline for all measures (p > 0.05). Blood 
glucose concentrations displayed a significant condition x time interaction (p < 0.001) and 
time effect (p < 0.001) following breakfast consumption. Postprandial concentrations were 
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increased in CHO+WP (p = 0.006) and CHO (p = 0.011) compared to NB at 15 minutes, and 
remained elevated above NB in the CHO condition at 30 minutes post-breakfast (p = 0.029; 
Figure 4.2a). Comparison of postprandial peak glucose in the breakfast trials revealed a trend 
for a reduction following the addition of whey protein, however this did not reach 
significance (CHO+WP: 5.5 ± 0.2, CHO: 6.4 ± 0.3 mmol∙l-1; p = 0.059). Blood glucose 
concentrations were not different between conditions at 45-180 minutes post-breakfast 
(p > 0.05). Furthermore, there were no differences in glucose AUC between conditions 
across the postprandial period (p = 0.247; Table 4.2).  
 
Post breakfast plasma insulin concentrations are displayed in Figure 4.2b. There was a 
significant condition x time interaction (p < 0.001), condition effect (p < 0.001) and time 
effect (p < 0.001). Concentrations peaked 30 minutes after breakfast consumption under 
CHO+WP and CHO, with both similarly elevated above NB at 15-120 minutes post-
breakfast, before returning to baseline levels. Insulinaemia across this period was increased 
by 24.8% with the addition of whey protein to breakfast (CHO+WP vs CHO, p = 0.033; 
Table 4.2), and was greater under both breakfast trials than NB (both p < 0.001). Insulin 
sensitivity during the post-breakfast period, as assessed by Matsuda-ISI, did not differ 
between breakfast trials (CHO+WP: 10 ± 2, CHO: 10 ± 2 arbitrary units; p = 0.656). 
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Figure 4.2 Mean ± SEM temporal changes in blood glucose (a) and plasma insulin (b) during the post-breakfast period (0-
180 minutes), and blood glucose (c) and plasma insulin (d) during the post-lunch period (180-360 minutes). Significant 
differences (p < 0.05) between trials at individual time points are defined as follows; *NB vs CHO+WP and CHO, ** NB 
vs CHO+WP, ***NB vs CHO. CHO+WP: high-carbohydrate breakfast with added whey protein trial; CHO: high-
carbohydrate breakfast trial; NB: no breakfast trial. 
 
 
 
 
 
 
 
Post-breakfast Post-lunch 
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Table 4.2 Area under the curve for blood and plasma variables during post-breakfast (0-180 minutes) and post-lunch (180-
360 minutes) postprandial periods. 
  Area under the curve 
  CHO+WP CHO NB 
     
Glucose 
(mmol∙min-1∙l-1) 
Post-breakfast 690.5 ± 27.6 756.8 ± 42.0 760.6 ± 25.7 
Post-lunch 745.4 ± 24.2 718 ± 26.8 744.2 ± 28.3 
     
Insulin 
(pmol∙min-1∙l-1) 
Post-breakfast 34760 ± 4726a 27849 ± 3333b 8306 ± 1446c 
Post-lunch 23522 ± 3387 24646 ± 2824 19935 ± 3349 
     
NEFA 
(mmol∙min-1∙l-1) 
Post-breakfast 22.7 ± 5.4a 24.0 ± 5.3a 79.7 ± 14.1b 
Post-lunch 23.0 ± 2.6a 31.6 ± 4.3a,b 37.5 ± 3.9b 
     
Glycerol 
(µmol∙min-1∙l-1) 
Post-breakfast 6675 ± 1248 7469 ± 924 10244 ± 1702 
Post-lunch 6659 ± 1143 8048 ± 566 7243 ± 1193 
     
Triglyceride 
(mmol∙min-1∙l-1) 
Post-breakfast 137.7 ± 23.3 121.2 ± 13.2 118.8 ± 12.2 
Post-lunch 208.2 ± 29.0a 178.2 ± 19.5a 146.8 ± 17.4b 
Total 345.9 ± 51.7 299.4 ± 32.0 265.6 ± 29.1 
     
Data presented as mean ± SEM. Different superscript letters within a row indicates significant difference between conditions 
(p < 0.05). CHO+WP: high-carbohydrate breakfast with added whey protein trial; CHO: high-carbohydrate breakfast trial; 
NB: no breakfast trial; NEFA: non-esterified fatty acids. 
 
 
 
Plasma concentrations of NEFA and glycerol are presented in Figure 4.3. NEFA 
concentrations were similarly suppressed under CHO+WP and CHO in comparison to NB at 
90-180 minutes post-breakfast (p < 0.05), while glycerol was significantly lower following 
CHO+WP than NB at 90-120 minutes post-breakfast (p ≤ 0.013). Analysis of AUC across 
the post-breakfast period indicated that NEFA was lower following both breakfast meals 
compared to NB (p ≤ 0.019; Table 4.2) without differing between CHO+WP and CHO, and 
glycerol responses were not different between conditions (p = 0.092).   
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Figure 4.3 Mean ± SEM temporal changes in NEFA (a) and glycerol (b) during the post-breakfast period (0-180 minutes), 
and NEFA (c) and glycerol (d) during the post-lunch period (180-360 minutes). Significant differences (p < 0.05) between 
trials at individual time points are defined as follows; *NB vs CHO+WP and CHO, **NB vs CHO+WP. CHO+WP: high-
carbohydrate breakfast with added whey protein trial; CHO: high-carbohydrate breakfast trial; NB: no breakfast trial; 
NEFA: non-esterified fatty acids. 
 
 
Temporal changes in subjective appetite following breakfast consumption are indicated by 
time course responses for combined appetite scores (Figure 4.4a). There was a significant 
condition x time interaction (p < 0.001), condition effect (p < 0.001) and time effect 
(p < 0.001) in the post-breakfast period. Appetite was suppressed similarly under CHO+WP 
and CHO, with combined appetite scores significantly lower than baseline levels at 30 
minutes post-breakfast in both conditions (p ≤ 0.001), whereas appetite was increased above 
baseline levels from 60 minutes in NB (p ≤ 0.016). Appetite scores for CHO+WP and CHO 
Post-breakfast Post-lunch 
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remained below NB from 30-180 minutes post-breakfast (p < 0.05). Combined appetite score 
AUC was greater under NB than CHO+WP and CHO (p ≤ 0.001; Table 4.3), with similar 
suppression observed under both breakfast trials (p = 0.974). This observation is replicated 
for the component measures of hunger, fullness, PFC and satisfaction (Table 4.3).  
 
 
 
Figure 4.4 Mean ± SEM temporal changes in combined appetite score during the post-breakfast (a) and post-lunch (b) 
periods. Significant differences (p < 0.05) between trials at individual time points are defined as follows; *NB vs CHO+WP 
and CHO. CHO+WP: high-carbohydrate breakfast with added whey protein trial; CHO: high-carbohydrate breakfast trial; 
NB: no breakfast trial. 
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Table 4.3 Area under the curve for subjective appetite responses during the post-breakfast (0-180 minutes) and post-lunch 
(180-360 minutes) postprandial periods. 
  Area under the curve 
  CHO+WP CHO NB 
     
Combined appetite 
(mm∙min-1) 
Post-breakfast 9542 ± 709a 9966 ± 834a 14768 ± 443b 
Post-lunch 9391 ± 866 10338 ± 943 10971 ± 1024 
     
Hunger 
(mm∙min-1) 
Post-breakfast 8756 ± 682a 9442 ± 770a 13406 ± 570b 
Post-lunch 8760 ± 846 9870 ± 898 10307 ± 969 
     
Fullness 
(mm∙min-1) 
Post-breakfast 8571 ± 716a 8291 ± 822a 2853 ± 431b 
Post-lunch 8849 ± 809 7892 ± 981 7061 ± 1033 
     
PFC 
(mm∙min-1) 
Post-breakfast 10463 ± 900a 10880 ± 1082a 15296 ± 435b 
Post-lunch 10224 ± 1140 11151 ± 1028 11780 ± 1143 
     
Satisfaction 
(mm∙min-1) 
Post-breakfast 8479 ± 629a 8168 ± 782a 2775 ± 454b 
Post-lunch 8570 ± 732 7779 ± 912 7139 ± 986 
     
Data presented as mean ± SEM. Different superscript letters within a row indicates significant difference between conditions 
(p < 0.05). CHO+WP: high-carbohydrate breakfast with added whey protein trial; CHO: high-carbohydrate breakfast trial; 
NB: no breakfast trial; PFC: prospective food consumption. 
 
 
 
4.1.3.2 Post-lunch responses 
 
Following lunch insulinaemic and glycaemic responses did not differ between trials (Figure 
4.2c-d), with no effect of condition or time x condition interaction on blood glucose or plasma 
insulin concentrations observed (p > 0.05). Postprandial AUC also indicated that glycaemia 
and insulinaemia (Table 4.2; p = 0.283) were not different across the 180 minute period 
following consumption of a subsequent meal. Post lunch assessments of insulin sensitivity 
were similar across conditions (CHO+WP: 12 ± 2, CHO: 11 ± 2, NB: 16 ± 3 arbitrary units; 
p = 0.075).  
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A condition x time interaction effect was observed for post-lunch NEFA concentrations 
(p < 0.001). Levels did not significantly differ from pre-lunch concentration in CHO+WP or 
CHO (p > 0.05), but decreased following lunch consumption in NB, with similar 
concentrations maintained between trials from 45-180 minutes post-lunch (p > 0.05; Figure 
4.3c). Post-lunch NEFA AUC was reduced in CHO+WP compared with NB (p = 0.050), but 
did not differ significantly from CHO (p = 0.206; Table 4.2). There were no differences in 
plasma glycerol concentrations between trials throughout the post-lunch period (p > 0.05; 
Figure 4.3d).  
 
Deviations in subjective appetite responses between CHO+WP and CHO were not found 
following lunch (p > 0.05; Figure 4.4b). A trend for reduced appetite in CHO+WP compared 
to NB was detected, however the difference in combined appetite AUC observed was not 
significant (p = 0.076; Table 4.3). This trend may be more closely related to differences in 
levels of hunger (AUC: CHO+WP vs NB, p = 0.052) than other subjective appetite 
components (all p ≥ 0.099).  
 
4.1.3.3 Plasma triglyceride 
 
Plasma triglyceride displayed a significant condition x time interaction (p < 0.001) over the 
course of the laboratory protocol. Plasma concentrations did not differ significantly from 
baseline following breakfast omission (p > 0.05), however they were raised above NB in 
CHO+WP at 270-360 minutes (p ≤ 0.041) and in CHO at 270-330 minutes post-breakfast 
(Figure 4.5; p ≤ 0.035). Triglyceride AUC responses were not different between trials across 
the full postprandial period (p > 0.05), however when analysed over just the post-lunch period 
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AUC was reduced following prior breakfast omission compared to both CHO+WP (p = 
0.010) and CHO (p = 0.028; Table 4.2). 
 
 
 
Figure 4.5 Mean ± SEM temporal changes in plasma triglyceride concentrations throughout the full experimental protocol 
(0-360 minutes). Significant differences (p < 0.05) between trials at individual time points are defined as follows; *NB vs 
CHO+WP and CHO, **NB vs CHO+WP. CHO+WP: high-carbohydrate breakfast with added whey protein trial; CHO: 
high-carbohydrate breakfast trial; NB: no breakfast trial. 
 
 
 
4.1.3.4 Continuous glucose monitoring 
 
Interstitial glucose concentrations over 24 hours are displayed in Figure 4.6. Glycaemia and 
glycaemic variability were similar between CHO+WP and CHO over the 24 hour recording 
period (Table 4.4; p > 0.05). There were no differences in glycaemia between breakfast trials 
throughout, and glycaemia was similar between all trials over 24 hours and during the post-
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laboratory period (6-24 hours AUC, Table 4.4; p > 0.05). During the laboratory protocol (0-
6 hours), interstitial glucose AUC was significantly lower in NB than CHO+WP (p = 0.043), 
also appearing lower than CHO, although this comparison was not significant (p = 0.182). 
Glycaemic variability during the same laboratory period was greater in the CHO trial than 
NB (p = 0.003), however this measure did not differ between CHO+WP and CHO or NB (p 
≥ 0.273).  
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Figure 4.6 Interstitial glucose concentrations for 24 hours following test breakfast consumption. Data are presented as mean ± SEM. Shaded area indicates time during laboratory protocol. 
Dotted lines indicate test meals. CHO+WP: high-carbohydrate breakfast with added whey trial; CHO: high-carbohydrate breakfast trial; NB: no breakfast trial. 
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Table 4.4 Area under the curve and coefficient of variation for interstitial glucose concentrations. 
  
 
Total 
(0-24 hours) 
Post- 
Laboratory 
(6-24 hours) 
 
Laboratory 
(0-6 hours) 
 
Late afternoon 
(6-12 hours) 
 
Night Time 
(12-18 hours) 
 
Early Morning 
(18-24 hours) 
        
Area under the 
curve 
(mmol*min∙l-1) 
CHO+WP 7393 ± 340 5406 ± 279 1987 ± 94a 1974 ± 103 1845 ± 111 1587 ± 107 
CHO 7420 ± 333 5480 ± 249 1940 ± 109a,b 2027 ± 104 1856 ± 91 1598 ± 80 
NB 7141 ± 512 5429 ± 405 1712 ± 115b 1897 ± 134 1888 ± 152 1644 ± 129 
        
        
Coefficient of 
variation (%) 
CHO+WP 16.7 ± 1.9 16.6 ± 1.9 11.9 ± 1.2a,b 13.5 ± 1.2 11.8 ± 2.3 6.5 ± 0.8 
CHO 16.6 ± 1.4 15.8 ± 1.6 14.6 ± 1.3a 11.9 ± 0.6 10.3 ± 1.3 12.1 ± 2.3 
NB 13.3 ± 0.8 12.9 ± 1.1 9.9 ± 1.3b 11.7 ± 0.8 10.8 ± 1.5 7.6 ± 0.6 
        
Data presented as mean ± SEM. Different superscript letters within a column indicates significant difference between conditions (p < 0.05) for each parameter presented. CHO+WP: 
high-carbohydrate breakfast with added whey trial; CHO: high-carbohydrate breakfast trial; NB: no breakfast trial. 
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4.1.4 Discussion 
 
The aim of this study was to investigate the effect of supplementing a carbohydrate breakfast 
with whey protein on metabolic and appetite responses acutely and following a subsequent 
meal. The study was designed to reflect practical application, thus the amount of whey 
protein, the timing of supplementation and composition of meals were realistic in the context 
of habitual eating habits. Addition of 20 g whey protein to breakfast increased the acute 
insulin response, without significantly influencing glycaemia, lipaemia or appetite sensations 
compared to an identical meal without additional whey in healthy young males. Furthermore, 
for the first time it is shown that addition of whey protein to breakfast does not alter 
glycaemic, insulinaemic and appetite responses to a subsequent lunch meal, or glycaemia 
beyond this time, compared to breakfast without whey or fasting. 
 
The observation of increased circulating insulin with whey protein supplementation reflects 
the effect observed in several studies (Gunnerud et al., 2013; Nilsson et al., 2007; Pal & Ellis, 
2010). Potential mechanisms may centre on the amino acid profile of whey itself, and its 
consequent incretin hormone stimulatory properties (Jakubowicz & Froy, 2013). The 
synergistic effect of protein and carbohydrate co-ingestion is also well established (Nuttall et 
al., 1985). Although a ~25% increase in post-breakfast (0-180 min) insulin AUC with the 
addition of whey to a carbohydrate breakfast was observed, this did not augment a significant 
effect on postprandial glycaemia. This is contrary to the findings of previous studies, where 
various doses of whey protein have elicited positive effects on glycaemia in both healthy 
(Akhavan et al., 2014; Gunnerud et al., 2013) and diabetic (Frid et al., 2005; Ma et al., 2009) 
populations. This may partly be explained by insulin resistance being greater early in the 
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morning following an overnight fast (Plat et al., 1996), indicating that the insulinotrophic 
effect was not strong enough to offset this. In addition, in contrast to the pure glucose loads 
used in previous whey supplementation studies (Gunnerud et al., 2013; Nilsson et al., 2007), 
a combination of carbohydrate sources was used in the present study as the test meal was 
designed to reflect habitually consumed carbohydrate-rich breakfast foods, resulting in a 
lower GI. The challenge to glucose tolerance may therefore not have been sufficiently large 
for a significantly augmented response to be observed. Whey protein ingestion has also been 
shown to induce acute insulin resistance through impaired glucose disposal at whole body 
level and across the leg (Smith et al., 2015), albeit in obese post-menopausal female 
participants, however assessments of post-meal Matsuda-ISI were similar between breakfast 
trials in the current study. Whilst the mechanisms responsible for such an observation remain 
unclear, it is likely that any effects are counterbalanced by the promotion of insulin secretion 
by protein ingestion.  
 
It is possible that the dose of whey protein was insufficient to elicit a significant reduction in 
glycaemia in healthy males, however the efficacious dose to affect insulin and post-meal 
glycaemic response has previously been reported to be as low as 10 g in healthy individuals 
(Akhavan et al., 2010). Although post-breakfast glycaemia (in terms of AUC) was not 
significantly affected by whey protein addition to breakfast, the trend for reduced peak 
glucose, although not statistically significant in this participant group, may be indicative of 
a beneficial effect. The amplitude of postprandial glycaemic excursions, rather than simply 
mean glucose exposure, is recognised as an important factor in the advancement of declining 
metabolic health (Service, 2013), potentially via activation of oxidative stress (Monnier et 
al., 2012). Following lunch, both glycaemia and insulinaemia were unaffected by prior whey 
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consumption, indicating the priming effect of elevated pre-lunch insulin on pancreatic beta 
cells may not have been substantial enough to alter post lunch metabolism (Lopez et al., 
2011). Glycaemia remained similar between all trials for 18 hours after leaving the 
laboratory. The lack of a second meal effect, or of any prolonged effect on glycaemia 
suggests that any influence of whey protein on postprandial metabolism is transient in nature, 
however further research may be required to establish whether this is the case in other 
populations. 
 
In the present study, whey protein supplementation did not affect subjective appetite. Several 
studies have previously reported no effect of whey protein consumption on satiety and 
subsequent energy intake (Bowen et al., 2007; Potier et al., 2010). This contrasts with other 
published observations, where consumption of whey has enhanced satiety through a variety 
of proposed mechanisms, including increases in peak amino acid, GLP-1 and cholecystokinin 
(CCK) concentrations in healthy females (Hall et al., 2003; Zafar et al., 2013). As energy 
intake was not measured in the current study, it is difficult to infer any direct effect that 
appetite sensations may have had on subsequent intake (Blundell et al., 2010). 
 
Cross-sectional studies have associated regular breakfast consumption with improved health 
outcomes such as lower BMI and improved glycaemic control (Deshmukh-Taskar et al., 
2012; Kapantais et al., 2011), however few randomised trials exist to support the causality 
of such associations. In the current study, breakfast omission did not affect postprandial 
glucose or insulin concentrations following lunch. With regards to satiety, breakfast omission 
did not significantly affect subjective appetite indices in the post lunch period and similar 
circulating concentrations of insulin, which is considered a satiety hormone (Tremblay & 
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Bellisle, 2015), reflected this. Further research is required to establish whether participants 
would overcompensate in terms of energy intake at a following meal regardless of subjective 
appetite ratings. 
 
Measures of postprandial lipaemia were similar between both breakfast trials throughout, 
however the omission of breakfast appeared to impact on post meal lipid metabolism. NEFA 
was significantly higher following breakfast omission, likely mediated by the antilipolytic 
effects on HSL of insulin released in response to breakfast (Bano, 2013), and returned to 
similar levels to both breakfast trials 45 minutes after lunch. Elevated NEFA levels are 
associated with metabolic dysregulation and cardiovascular disease risk (Carlsson et al., 
2000). Plasma triglyceride concentrations were significantly lower 90-150 minutes post-
lunch following breakfast omission. The very low fat content of the breakfast (2 g) would 
suggest that the handling of dietary fat from lunch (33 g) was affected by breakfast omission, 
or that fat stored in the enterocyte from the previous meal (evening before) was mobilised 
following subsequent glucose consumption (Lambert & Parks, 2012; Robertson et al., 2003). 
This may have implications when considering the current swathe of public opinion 
suggesting that breakfast is the most important meal of the day. Our findings suggest that 
skipping breakfast on a single occasion may not be detrimental to the response to foods 
consumed later that day, and may provide beneficial effects on plasma triglyceride profile. 
Whether subsequent energy intake would be influenced remains to be established, however 
recent data indicates that the frequency, timing and composition of meals consumed later in 
the day are not different during 6 weeks of breakfast omission compared to regular breakfast 
consumption (Betts et al., 2014).  
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The primary findings of the current study are contrary to the body of evidence which suggests 
whey protein can provide acute advantages in postprandial handling of meals. Acutely, the 
promotion of greater insulin secretion following whey protein consumption may lead to a 
glucose lowering effect (Gunnerud et al., 2013; Nilsson et al., 2007; Pal & Ellis, 2010). 
Chronically however, prolonged hyperinsulinaemia in normoglycaemic conditions may 
decrease insulin sensitivity (Del Prato et al., 1994). The acute increase in circulating insulin 
observed in the present study may therefore be of benefit to individuals with type 2 diabetes, 
however the chronic effects in healthy, insulin sensitive individuals is less clear.  
 
The breakfasts provided in the present study were not matched for energy content, and this 
may limit the validity of direct comparisons between each meal. This was a consequence 
however, of the effort to ensure that this experimental manipulation had practical application 
by mimicking the effect of ‘adding’ a supplement to a meal, rather than replacing or 
substituting different components of a meal. Such a strategy may be easier for a layperson to 
implement. 
 
In summary, an ecologically valid protocol was implemented to assess the effect of 
supplementing a carbohydrate-rich breakfast with whey protein on metabolic and appetite 
responses, acutely and following a subsequent meal. Whey protein addition to breakfast 
increased the insulinaemic response to that meal, without significantly influencing metabolic 
or appetite responses to a subsequent mixed-macronutrient lunch. Breakfast omission 
induced glycaemic, insulinaemic and combined appetite responses to a subsequent meal that 
did not differ from breakfast consumption, while maintaining lower circulating triglyceride 
concentrations.  
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CHAPTER 4b 
 
Acute and second-meal metabolic and appetite responses following co-
ingestion of whey protein with a fat-rich breakfast in normal-weight 
males 
 
 
 
 
 
4.2.1 Introduction 
 
As discussed in Chapter 4a, the importance of the postprandial milieu in the assessment of 
CVD risk is increasingly recognised and, in addition to the clinically important risks 
associated with postprandial hyperglycaemia (Fonseca, 2003), postprandial hyperlipidaemia 
is considered an important independent determinant of CVD risk (Kolovou et al., 2011; Silva 
et al., 2005). The proatherogenic products of triglyceride-rich lipoprotein lipolysis are 
thought to mediate this risk (Ansar et al., 2011), while elevated postprandial NEFA may 
contribute to the insulin resistant state (Frape et al., 2000). Given that people spend the vast 
majority of non-sleeping hours in the postprandial state, it is important to investigate 
strategies which may reduce repeated exposure to exaggerated postprandial lipaemia. 
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It is well established that addition of carbohydrate to a fatty meal causes both a delay and a 
reduction in postprandial lipaemia, via alterations in absorption kinetics and modification of 
the endocrine response (Cohen & Berger, 1990; Westphal et al., 2002). The influence of 
dietary protein in a fat-rich meal, in the context of postprandial lipaemia, is less well 
established (Westphal et al., 2004). Epidemiological studies have indicated an inverse 
association between dairy protein intake and risk of developing CVD and metabolic disorders 
(Tremblay & Gilbert, 2009), however acute studies investigating this relationship are lacking. 
 
The insulinotrophic effect of whey protein supplementation has been established in previous 
studies (Gunnerud et al., 2012a; Nilsson et al., 2007) and was indicated in Chapter 4a. This 
property encourages speculation that addition of whey to high fat meals may have a beneficial 
effect on postprandial lipid exposure, initially through inhibition of NEFA mobilisation 
(Saponaro et al., 2015) and subsequently via stimulated LPL-induced hydrolysis of 
triglyceride for metabolism or storage (Czech et al., 2013). Currently, evidence from acute 
trials where high fat or mixed meals have been supplemented with whey protein is limited, 
and has shown inconsistency in findings. Consumption of 45 g whey protein isolate alongside 
a mixed macronutrient meal reduced the postprandial triglyceride AUC by 21% and 27% 
compared with glucose or casein supplementation respectively, in obese post-menopausal 
females (Pal et al., 2010b). Whey has also been reported to decrease postprandial lipaemia 
compared with other protein sources when added to a fat-rich meal in participants with 
T2DM (Mortensen et al., 2009). In overweight but otherwise healthy males, addition of whey 
to the same high fat breakfast increased triglyceride AUC compared with casein 
supplementation in one study (Mariotti et al., 2015), but had a similar response to casein and 
favourable affects compared to non-dairy proteins in another study by the same group 
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(Holmer-Jensen et al., 2013). To the author’s knowledge, the effect of whey protein 
supplementation on postprandial lipaemia in normal-weight participants has not been 
investigated.  
 
These studies have generally used test meals with an unrealistically high fat content (~80 g) 
to exceed the normal lipoprotein capacity (Holmer-Jensen et al., 2013), along with relatively 
high supplemental doses of whey protein (45 g). However, to apply any findings to future 
dietary guidance, there is a need for studies investigating the efficacy of realistic doses of 
whey protein on levels of fat found within typical meals. Current studies have manipulated 
the macronutrient content of fat-rich test meals to compare the action of whey with other 
protein sources or energy-matched carbohydrate ingestion. It is unclear if the action of adding 
a dose of whey protein alongside a high fat meal to compare against the effect of just the 
meal itself, a potentially more pragmatic approach, would induce beneficial postprandial 
responses. Furthermore, studies have typically investigated responses to an isolated meal by 
evaluating postprandial markers of lipaemia over extended evaluation periods of six (Mariotti 
et al., 2015; Pal et al., 2010b) or eight (Holmer-Jensen et al., 2013; Mortensen et al., 2009) 
hours. However, given that a mean interval between eating episodes of ~3 hours has been 
documented in cross-sectional analysis of American adults (Kant & Graubard, 2015), it is 
unlikely that such an extended period is commonplace in a free-living setting. Thus the use 
of sequential meal testing is of interest, particularly regarding triglyceride metabolism, where 
it remains to be established if prior whey protein supplementation with a fat-rich meal 
influences metabolic responses to subsequent meals. In addition, it is unclear whether the 
potential of whey protein to increase satiety (documented previously (Luhovyy et al., 2007; 
Veldhorst et al., 2009) but not in Chapter 4a) is observed when co-ingested with high-fat 
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rather than high-carbohydrate test meals. Therefore, this study aimed to determine the acute 
and second meal postprandial metabolic and appetite responses in normal-weight individuals 
following a fat-rich breakfast, with and without co-ingestion of whey protein. 
 
4.2.2 Methods 
 
4.2.2.1 Experimental design 
 
The experimental protocol described in this sub-chapter is a replication of that detailed in 
Chapter 4a. As described in section 3.2, analysis of two additional experimental trials is 
presented here, together with data from the control trial. The same ten normal-weight male 
participants (age: 24 ± 1 years; mass: 79.7 ± 1.2 kg; stature: 1.81 ± 0.02 m; BMI: 24.5 ± 
0.7 kg∙m-2, HOMA-IR: 2.1 ± 1.1 arbitrary units) consumed a fat-rich breakfast with 
(FAT+WP) or without (FAT) supplemental whey protein, or omitted breakfast (NB). Other 
than the difference in test breakfast content, all other protocols are as described in Chapter 
4a. A schematic of the laboratory protocol is presented in Figure 4.7. 
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Figure 4.7 Schematic layout of laboratory experimental protocol. FAT, high fat breakfast trial; FAT+WP, high-fat breakfast 
with added whey protein trial; NB, no breakfast trial. 
 
 
4.2.2.2 Test meals 
 
The energy content and macronutrient composition of the test meals provided during each 
trial are displayed in Table 4.5. The breakfast meal given under FAT and FAT+WP consisted 
of egg yolk (60 g) mixed with single cream (75g) and butter (10g) until homogenous, and 
heated in a microwave (1,000 W) for 150 seconds, resulting in a semi-solid portion of cooked 
eggs. A beverage containing 20 g available protein (FAT+WP) or isovolumetric flavoured 
water (FAT) was served alongside the breakfast meal as described in section 4.1.2.3. 
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Table 4.5 Energy and macronutrient composition of breakfast and lunch test meals. 
  Energy 
kJ (kcal) 
Carbohydrate 
g (E%) 
Fat 
g (E%) 
Protein 
g (E%) 
 FAT 1831 (438) 4 (4) 41 (85) 12 (11) 
Breakfast FAT+WP 2205 (527) 6 (5) 41 (71) 32 (24) 
 NB 0 (0) 0 (0) 0 (0) 0 (0) 
      
Lunch  3446 (824) 104 (50) 33 (36) 29 (14) 
E%: percentage of total meal energy; FAT: high-fat breakfast trial; FAT+WP: high-fat breakfast with added whey protein 
trial; NB: no breakfast trial. 
 
 
 
4.2.2.3 Statistical analysis 
 
Data were analysed as described in Chapter 4a (section 4.1.2.7). 
 
4.2.3 Results 
 
4.2.3.1 Plasma triglyceride 
 
Plasma triglyceride did not differ between conditions at baseline (p > 0.05). There were 
significant main effects of time (p < 0.001), condition (p = 0.001), and a condition x time 
interaction (p < 0.001) on triglyceride responses. Post hoc analysis revealed that 
concentrations were higher for  FAT+WP (p = 0.008) and FAT (p = 0.017) compared to NB 
(Figure 4.8), also reflected in significantly higher peaks for the breakfast trials (FAT+WP: 
2.59 ± 0.35, FAT: 2.24 ± 0.29 vs NB: 1.05 ± 0.13 mmol∙l-1; both p = 0.001), with no 
difference between FAT+WP and FAT throughout (p > 0.05). Concentrations rose over time 
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during FAT+WP and FAT, peaking at 225 minutes post-breakfast under both conditions, but 
did not significantly differ from baseline in NB (p > 0.05).  
 
 
 
Figure 4.8 Mean ± SEM (n = 10) temporal changes in plasma triglyceride concentrations throughout the full experimental 
protocol (0-360 minutes). Significant differences (p < 0.05) between trials are denoted as follows; *NB vs FAT+WP and 
FAT, **NB vs FAT+WP, ***NB vs FAT; Dotted line indicates time of lunch meal; FAT+WP: high-fat breakfast with 
added whey protein trial; FAT: high-fat breakfast trial; NB: no breakfast trial. 
 
 
 
Post-breakfast triglyceride AUC in the FAT+WP condition was significantly greater than NB 
(p = 0.039) but not FAT (p > 0.05), while FAT AUC displayed a trend to be higher than NB 
(p = 0.071), but was not significant after correcting for multiple comparisons (Table 4.6). 
Following lunch, and over the entire evaluation period, AUC was greater for FAT+WP and 
FAT conditions compared with NB (all p ≤ 0.018).  
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Table 4.6 Area under the curve for blood and plasma variables during post-breakfast (0-180 minutes) and post-lunch (180-
360 minutes) postprandial periods. 
  Area under the curve 
  FAT+WP FAT NB 
     
Triglyceride 
(mmol∙min-1∙l-1) 
Post-breakfast 204.2 ± 36.1a 184.4 ± 30.5a,b 118.8 ± 12.2b 
Post-lunch 345.0 ± 56.2a 291.6 ± 48.4a 146.8 ± 17.4b 
Total 549.2 ± 91.6a 476.0 ± 78.3a 265.6 ± 29.1b 
     
NEFA 
(mmol∙min-1∙l-1) 
Post-breakfast 50.6 ± 6.1 68.5 ± 9.2 79.7 ± 14.1 
Post-lunch 88.8 ± 6.5a 92.7 ± 10.7a 37.5 ± 3.9b 
     
Glycerol 
(µmol∙min-1∙l-1) 
Post-breakfast 9445 ± 1336 8180 ± 918 10244 ± 1702 
Post-lunch 11697 ± 1116a 12376 ± 1572a,b 7243 ± 1193b 
     
Glucose 
(mmol∙min-1∙l-1) 
Post-breakfast 702.8 ± 17.9 726.7 ± 17.6 760.6 ± 25.7 
Post-lunch 817.2 ± 21.9a 815.8 ± 29.8a 744.2 ± 28.3b 
     
Insulin 
(pmol∙min-1∙l-1) 
Post-breakfast 16475 ± 2085a 13186 ± 1792a 8306 ± 1446b 
Post-lunch 29946 ± 2556a 25560 ± 2887b 19935 ± 3349c 
     
Data presented as mean ± SEM. Different superscript letters within a row indicates significant difference between conditions 
(p < 0.05). FAT+WP: high-fat breakfast with added whey protein trial; FAT: high-fat breakfast trial; NB: no breakfast trial; 
NEFA: non-esterified fatty acids. 
 
 
 
4.2.3.2 Post-breakfast responses 
 
Plasma NEFA displayed a main effect of time (p < 0.01) and a condition x time (p < 0.01) 
interaction indicating a differential time response between trials. Concentrations did not 
differ significantly from baseline levels in FAT and NB trials (p > 0.05), but were supressed 
at 45-90 minutes post consumption of whey protein with breakfast (p ≤ 0.029), before 
returning to pre-breakfast levels (Figure 4.9a). There were no between-condition differences 
in plasma NEFA at individual time points or in AUC across the post-breakfast period (Table 
4.6; p > 0.05). Plasma glycerol was significantly affected by time (p = 0.001), such that 
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concentrations were suppressed in the postprandial period in all conditions, before returning 
to baseline levels (Figure 4.9b). No between-condition differences were observed, and AUC 
was similar across trials during this period (Table 4.6; p > 0.05).  
 
 
 
Figure 4.9 Mean ± SEM temporal changes in NEFA (a) and glycerol (b) during the post-breakfast period (0-180 minutes), 
and NEFA (c) and glycerol (d) during the post-lunch period (180-360 minutes). Significant differences (p < 0.05) between 
trials at individual time points are defined as follows; *NB vs FAT+WP and FAT. FAT+WP: high-fat breakfast with added 
whey protein trial; FAT: high-fat breakfast trial; NB: no breakfast trial; NEFA: non-esterified fatty acids. 
 
 
 
Post-breakfast Post-lunch 
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Post-breakfast glucose concentrations displayed a significant main effect of time (p < 0.001) 
and a condition x time interaction effect (p = 0.001). Concentration did not change 
significantly from baseline level in the NB trial (p > 0.05), however levels were reduced 
compared with baseline at 45-120 minutes following breakfast consumption in FAT+WP (all 
p ≤ 0.011) and at 60 minutes post in FAT (p = 0.004), before returning to pre-breakfast levels 
(Figure 4.10a). Glucose was significantly lower in the whey protein trial than FAT and NB 
at 45 minutes following breakfast (p ≤ 0.031), and remained lower than NB at 60 minutes 
post (p = 0.019). Differences between trials in blood glucose AUC were not observed, 
although the main effect approached significance (Table 4.6; p = 0.83).  
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Figure 4.10 Mean ± SEM temporal changes in glucose (a) and insulin (b) during the post-breakfast period (0-180 minutes), 
and glucose (c) and insulin (d) during the post-lunch period (180-360 minutes). Significant differences (p < 0.05) between 
trials at individual time points are defined as follows; *NB vs FAT+WP and FAT, **NB vs FAT+WP, ***NB vs FAT, 
****All trials differ, #FAT+WP vs FAT and NB. FAT+WP: high-fat breakfast with added whey protein trial; FAT: high-
fat breakfast trial; NB: no breakfast trial. 
 
 
 
Two-way ANOVA revealed significant main effects of condition (p < 0.001), time (p < 
0.001) and an interaction effect (p < 0.001) on plasma insulin levels (Figure 4.10b). Peak 
concentration was significantly greater following breakfast with (FAT+WP) compared to 
without (FAT) whey protein (p = 0.004), and greater in both breakfast conditions compared 
to NB (FAT+WP: 157.9 ± 18.8; FAT: 105.9 ± 17.1 vs NB: 65.8 ± 9.3 pmol∙l-1; both 
Post-breakfast Post-lunch 
111 
 
p ≤ 0.009). Insulin was unchanged throughout this period in NB (p > 0.05), but rose after 
breakfast in FAT+WP and FAT, remaining elevated above NB at 15-120 minutes in 
FAT+WP (all p ≤ 0.006) and 15-90 minutes in FAT (all p ≤ 0.013). A significant difference 
in AUC across the postprandial period was observed, such that insulinaemia was greater in 
FAT+WP (p = 0.003) and FAT (p = 0.001) compared to NB (Table 4.6). During the first 60 
minutes post-breakfast, insulin AUC was also greater in FAT+WP (6984 ± 829 pmol∙min-1∙l-
1) than FAT (5170 ± 793 pmol∙min-1∙l-1; p = 0.008). Matsuda-ISI was similar between 
breakfast conditions in the post-breakfast period (FAT+WP: 13 ± 2, FAT: 14 ± 2 arbitrary 
units; p = 0.356). 
 
Combined appetite score showed significant main effects for time (p < 0.001) and condition 
(p < 0.001), and a condition x time interaction effect (p < 0.001) was present. In FAT+WP 
and FAT conditions, combined appetite decreased to similar levels at 30 minutes following 
breakfast consumption, indicating greater satiety, before increasing similarly at 30-180 
minutes (Figure 4.11a). In NB, combined appetite was similar to other trials at baseline and 
increased steadily over the postprandial period, with levels significantly greater than 
FAT+WP (p = 0.001) and FAT (p < 0.001). Appetite AUC was significantly different 
between NB and both FAT+WP and FAT (all p < 0.05) for all aspects measured (hunger, 
fullness, PFC, satisfaction), with breakfast consumption impacting positively on appetite 
perceptions (Table 4.7). There were no differences between FAT+WP and FAT throughout 
(p > 0.05). 
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Figure 4.11 Mean ± SEM temporal changes in combined appetite score during the post-breakfast (a) and post-lunch (b) 
periods. Significant differences (p < 0.05) between trials at individual time points are defined as follows; *NB vs FAT+WP 
and FAT. FAT+WP: high-fat breakfast with added whey protein trial; FAT: high-fat breakfast trial; NB: no breakfast trial. 
 
 
Table 4.7 Area under the curve for subjective appetite responses during the post-breakfast (0-180 minutes) and post-lunch 
(180-360 minutes) postprandial periods. 
  Area under the curve 
  FAT+WP FAT NB 
     
Combined appetite 
(mm∙min-1) 
Post-breakfast 10093 ± 697a 9781 ± 702a 14768 ± 443b 
Post-lunch 10142 ± 1142a,b 8691 ± 912a 10971 ± 1024b 
     
Hunger 
(mm∙min-1) 
Post-breakfast 9241 ± 644a 9163 ± 718a 13406 ± 570b 
Post-lunch 9494 ± 1031a,b 8046 ± 976a 10307 ± 969b 
     
Fullness 
(mm∙min-1) 
Post-breakfast 8209 ± 691a 8447 ± 726a 2853 ± 431b 
Post-lunch 8186 ± 1224a,b 9447 ± 898a 7061 ± 1033b 
     
PFC 
(mm∙min-1) 
Post-breakfast 11125 ± 890a 10771 ± 923a 15296 ± 435b 
Post-lunch 11241 ± 1258a,b 9741 ± 1080a 11780 ± 1143b 
     
Satisfaction 
(mm∙min-1) 
Post-breakfast 7785 ± 632a 8365 ± 608a 2775 ± 454b 
Post-lunch 7982 ± 1129a,b 9578 ± 785a 7139 ± 986b 
     
Data presented as mean ± SEM. Different superscript letters within a row indicates significant difference between conditions 
(p < 0.05). FAT+WP: high-fat breakfast with added whey protein trial; FAT: high-fat breakfast trial; NB: no breakfast trial; 
PFC: prospective food consumption. 
 
Post-breakfast Post-lunch 
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4.2.3.3 Post-lunch responses 
 
Post-lunch NEFA levels were influenced significantly by time (p < 0.01) and trial (p < 0.01), 
with two-way ANOVA also indicating an interaction effect of these two factors (p < 0.01). 
A suppression of plasma NEFA was observed following lunch in NB, such that values were 
significantly lower than baseline at 30-60 minutes post-lunch (p ≤ 0.014), however levels 
remained unchanged in FAT+WP and FAT (Figure 4.9c; p > 0.05). Post hoc analysis showed 
that plasma NEFA concentrations were greater in both breakfast trials in comparison to NB 
at 30-150 minutes post-lunch (p < 0.05). Furthermore, post-lunch AUC was greater for 
FAT+WP (p < 0.001) and FAT (p = 0.001) in comparison to NB (Table 4.6).  
 
There was a significant effect of trial on post-lunch plasma glycerol concentrations (p = 
0.044). Post hoc analysis revealed that glycerol was reduced in NB in comparison to 
FAT+WP (Figure 4.9d; p = 0.032). Post-lunch AUC was also significantly lower in NB 
compared to FAT+WP (p = 0.01), while the difference between FAT and NB approached 
significance (Table 4.6; p = 0.089). There were no differences between FAT+WP and FAT 
throughout (p > 0.05).  
 
Time (p < 0.001), condition (p = 0.021) and time x condition interaction (p = 0.031) effects 
were observed on blood glucose concentrations following lunch. Glucose peaked similarly 
at 30 minutes post-lunch (p > 0.05), however responses were divergent later in the 
postprandial period such that glucose was reduced in NB compared to FAT at 120-180 
minutes (p ≤ 0.043), and compared to FAT+WP at 120-150 minutes post-lunch (Figure 4.10c; 
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p ≤ 0.023). Blood glucose AUC was similar between FAT+WP and FAT (p > 0.05), both 
significantly greater over the post-lunch period than NB (Table 4.6; p ≤ 0.019).  
 
Post-lunch analysis revealed main effects of both time (p < 0.001) and condition (p < 0.001) 
on plasma insulin concentrations. Levels peaked at 30 minutes post-lunch and remained 
elevated above baseline throughout the postprandial period in all trials (Figure 4.10d). 
Concentrations were higher following both breakfast trials compared to NB (both p ≤ 0.028), 
and the increase in FAT+WP compared with FAT was close to significance (p = 0.058). 
Analysis of post-lunch AUC revealed that insulinaemia was greater in FAT+WP than FAT 
(p = 0.035), and higher in both compared with NB (Table 4.6; p ≤ 0.005). Greater insulin 
sensitivity was observed in the non-whey breakfast trial (Matsuda-ISI: FAT+WP: 9 ± 1, FAT: 
11 ± 2 arbitrary units; p = 0.037). After prior breakfast omission, post-lunch insulin 
sensitivity (NB: 16 ± 3 arbitrary units) was greater than FAT+WP (p = 0.043) and tended to 
be greater than FAT (p = 0.079) although this comparison was not significant after correcting 
for multiple comparisons. 
 
Subjective appetite responses were influence by time (p < 0.001), such that appetite was 
supressed under all conditions at 30 minutes post-lunch, rising steadily thereafter, with 
responses back at similar levels to baseline by 150 minutes (Figure 4.11b). A main effect of 
trial was observed (p = 0.002), with subjective appetite suppressed to a greater extent in FAT 
compared to NB (p = 0.002), but not FAT+WP (p = 0.351). Post hoc analysis of significant 
differences in AUC for component measures of appetite (hunger, fullness, PFC, satisfaction) 
and combined appetite revealed more positive perceptions of appetite in the FAT trial 
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compared with NB (p < 0.05), with no differences between FAT and FAT+WP (Table 4.7; 
p > 0.05). 
 
4.2.3.4 Continuous glucose monitoring 
 
Due to technical issues with a CGM device for one participant during the FAT trial, the 
following data are presented as n = 9. Interstitial glucose concentrations over 24 hours are 
displayed in Figure 4.12. Glucose AUC over 24 hours was similar between FAT+WP and 
FAT (p > 0.05), however glycaemia during this period was lower when breakfast was omitted 
in comparison to both breakfast trials (both p ≤ 0.043; Table 4.8). When analysis was 
conducted on separate 6 hour epochs, no between-trial differences in glycaemia were 
observed (p > 0.05), however there were trends for glycaemia to be reduced during the 6 hour 
laboratory period in NB compared to FAT+WP (p = 0.077), as well as over the 18 hour post-
laboratory period in NB compared to both FAT+WP (p = 0.081) and FAT (p = 0.061) trials. 
Glycaemic variability was similar between conditions throughout.  
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Figure 4.12 Interstitial glucose concentrations for 24 hours following test breakfast consumption. Data are presented as mean ± SEM. Shaded area indicates time during laboratory 
protocol. Dotted lines indicate test meals. FAT+WP: high-fat breakfast with added whey protein trial; FAT: high-fat breakfast trial; NB: no breakfast trial. 
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Table 4.8 Area under the curve and coefficient of variation for interstitial glucose concentrations.  
  
 
Total 
(0-24 hours) 
Post- 
Laboratory 
(6-24 hours) 
 
Laboratory 
(0-6 hours) 
 
Late afternoon 
(6-12 hours) 
 
Night Time 
(12-18 hours) 
 
Early Morning 
(18-24 hours) 
        
Area under the 
curve 
(mmol*min∙l-1) 
FAT+WP 7502 ± 536a 5642 ± 429 1859 ± 114 1993 ± 138 1933 ± 137 1717 ± 171 
FAT 7601 ± 592a 5742 ± 485 1859 ± 118 2069 ± 172 1968 ± 201 1705 ± 149 
NB 7040 ± 561b 5335 ± 441 1705 ± 128 1872 ± 147 1854 ± 166 1609 ± 139 
        
        
Coefficient of 
variation (%) 
FAT+WP 14.6 ± 1.5 15.5 ± 1.8 9.5 ± 1.0 12.6 ± 0.9 14.5 ± 2.2 7.9 ± 1.3 
FAT 16.8 ± 1.6 17.1 ± 1.7 11.6 ± 1.1 12.6 ± 0.9 13.1 ± 2.1 10.7 ± 2.2 
NB 13.2 ± 0.8 13.0 ± 1.2 9.7 ± 1.4 11.4 ± 0.8 10.9 ± 1.6 7.2 ± 0.6 
        
Data presented as mean ± SEM. Different superscript letters within a column indicates significant difference between conditions (p < 0.05) for each parameter presented. FAT+WP: high-
fat breakfast with added whey protein trial; FAT: high-fat breakfast trial; NB: no breakfast trial. 
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4.2.4 Discussion 
 
The main findings of the current study are that a 20 g dose of whey protein augmented the 
insulin response both acutely (within the first hour) and following a second meal, however 
postprandial lipaemia was not significantly affected by the intervention. In addition, 
glycaemia was similar between breakfast conditions over the course of the laboratory 
protocol and during the rest of the day, while perceptions of appetite were unaffected by 
whey protein supplementation.  
 
Postprandial triglyceride responses peaked at 3-4 hours following a fat-rich breakfast, 
emphasising the relatively slow appearance of dietary fat into the plasma (Lambert & Parks, 
2012), with a greater response in breakfast trials compared to breakfast omission, as would 
be expected. In contrast to the findings of Pal et al. (2010b), where supplemental whey 
protein induced a 21% reduction in postprandial triglyceride AUC following a high fat meal, 
there was no modulation of postprandial lipaemia following consumption of whey with 
breakfast in the present study. The magnitude of this reduction reported by Pal et al. (2010b) 
may be considered clinically significant since a 20-24% reduction in triglyceride reduces the 
progression of CVD (Miller, 2000), and similar decrements have been observed in further 
studies (Holmer-Jensen et al., 2013; Mortensen et al., 2009).  
 
The discrepancy when comparing such findings to the present study may be explained by 
fundamental differences in study design. This study was the first to investigate the effect of 
whey protein on postprandial lipaemia in healthy, normal-weight individuals, whereas 
previous investigations have involved obese (Holmer-Jensen et al., 2013; Pal et al., 2010b) 
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or diabetic (Mortensen et al., 2009) participants. The negative effects of a high fat meal that 
are associated with postprandial hypertriglyceridaemia, including oxidative stress, low-grade 
inflammation and endothelial dysfunction, are considerably more pronounced when 
participants present with risk factors for metabolic disease such as obesity (Mariotti et al., 
2015). Indeed, both the increment and duration of postprandial lipaemia are exaggerated in 
obese compared to lean individuals (van Wijk et al., 2003), and it may therefore be the case 
that plasma triglyceride is not as sensitive to such an intervention when responses are already 
in the normal range. Moreover, a recent meta-analysis of longer term interventions of chronic 
whey protein supplementation reported that significant reductions in triglyceride were not 
observed in participants with a BMI < 30 kg∙m-2 (Zhang et al., 2016). Interestingly, the same 
study reported that effects were not observed when less than 30 g whey protein was 
supplemented per day, indicating that protein amount may be significant when investigating 
the beneficial effects of whey protein on triglyceride concentrations. The studies mentioned 
above all supplemented meals with 45 g whey protein, however the current study was 
designed to assess the effects of a more realistic dose (20 g) of whey protein. This amount 
has been shown to be efficacious in reducing glycaemia in previous studies (Abou-Samra et 
al., 2011; Akhavan et al., 2010), however a greater stimulus may be required to positively 
influence lipid metabolism. Fat content of test meals (80 g) implemented by Holmer-Jensen 
et al. (2013) and Mortensen et al. (2009) was also approximately double that used in the 
present study, indicating that the fat-rich meal administered may not have challenged fat 
tolerance in healthy individuals to a sufficient extent for beneficial effects to be observed.  
 
Previous studies have assessed the effectiveness of whey protein to reduce postprandial 
lipaemia compared to other proteins or energy-matched amount of glucose. The current study 
120 
 
was designed to assess the metabolic response when whey was added to a fat-rich meal 
compared to the response of the meal itself. Such an approach using casein protein has 
previously induced beneficial effects on postprandial lipid metabolism in healthy individuals, 
including marked suppression of NEFA and moderate reduction in postprandial triglyceride 
(Westphal et al., 2004). The reduction in lipaemia was only observed when casein was 
supplemented to the high-fat meal in the presence of carbohydrate, an effect also observed 
by Brader et al. (2010) in diabetic participants. This is suggestive of a role of carbohydrate 
coingestion with dairy protein on postprandial lipaemic responses, indeed studies that have 
supplemented whey in this context have all included carbohydrate (25-45 g) in the high-fat 
test meals (Holmer-Jensen et al., 2013; Mortensen et al., 2009; Pal et al., 2010b). The test 
meal in this study included a low carbohydrate content (4 g) to isolate the effects of whey 
protein on subsequent metabolism following a fat-rich meal. Carbohydrate and protein act 
synergistically to augment the postprandial insulin response (Nuttall et al., 1985). Although 
insulin was increased following whey consumption, the stimulus may not have been great 
enough to influence lipaemia or other aspects of postprandial metabolism including 
glycaemia and appetite.  
 
Proposed mechanisms by which whey protein may modulate the postprandial lipaemic 
response relate to enhanced insulinaemia. The inhibitory effect of insulin on intracellular 
HSL markedly suppresses the release of NEFA into the circulation (Saponaro et al., 2015), 
limiting the supply of NEFA to the liver and subsequently slowing hepatic triglyceride 
synthesis and very low density lipoprotein (VLDL) secretion (Westphal et al., 2004). The 
hydrolysis of triglyceride in chylomicrons and VLDL is augmented by the activity of LPL 
which may be stimulated by insulin (Czech et al., 2013), resulting in accelerated clearance 
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of triglyceride-rich lipoproteins. Post-breakfast insulin AUC was significantly greater in the 
first hour following breakfast and, although not significant, ~25% greater over 3 hours when 
whey was added to the fat-rich breakfast. This is indicative of the insulinotrophic effect of 
whey (Nilsson et al., 2007). Despite this increase, the macronutrient composition of the 
breakfast ensured relatively low absolute postprandial insulin concentrations across both 
breakfast conditions. Post-breakfast peak insulin was 158 pmol∙l-1 in the FAT+WP condition, 
considerably lower than when carbohydrate was co-ingested with whey protein in Chapter 
4a (447 pmol∙l-1), while AUC was approximately 2-fold higher following the mixed 
macronutrient lunch in comparison with the fat-rich breakfast. Post-breakfast insulinaemia 
may therefore have been insufficient to augment significant changes in lipid metabolism.  
 
Post-breakfast NEFA was transiently suppressed from baseline concentration following 
whey consumption, however levels were not significantly different to the other trials 
throughout, indicating that the increased insulin effect observed during this period did not 
markedly influence NEFA suppression. Following lunch, NEFA concentrations were similar 
in both breakfast trials, despite greater insulinaemia following whey consumption. A similar 
effect was observed in post-lunch glycaemia, which may be indicative of temporary 
peripheral insulin resistance, indeed Matsuda-ISI differed significantly between these 
conditions following lunch, thus it cannot be ruled out that the greater insulin levels observed 
were a result of amino acid induced insulin resistance (Smith et al., 2015). Insulin resistance 
is associated with impaired clearance and increased production of chylomicrons (Pal et al., 
2010b) which may increase triglyceride exposure. Although a non-significant observation, 
total triglyceride AUC was ~15% greater in the FAT+WP condition in comparison with FAT, 
which may be explained by this phenomenon.  
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Greater post-lunch insulin sensitivity was observed following omission of breakfast, 
illustrated by reduced glycaemia with concomitantly lower insulin in comparison to breakfast 
trials. Insulin remained elevated above baseline for the entire 3 hour period in all trials 
however, and in line with the findings of Westphal et al. (2004), glucose levels were not 
responsive to this increase, since it is clear that concentrations were rising at the end of the 
experimental protocol which is confirmed in interstitial glucose data. Post-lunch NEFA 
appeared to be suppressed similarly in breakfast trials, however there was a marked delay in 
suppression when compared to breakfast omission. It may be concluded that the effect of 
elevated post-lunch NEFA after a fat-rich breakfast is a result of spillover of NEFA into the 
plasma from hydrolysis of chylomicrons, since only approximately half is taken up by 
adipocytes (Karpe et al., 2011). However, the lack of suppression of glycerol, a marker of 
adipocyte lipolysis, would suggest a lack of insulin action on adipose lipolysis following the 
second meal, independent of protein supplementation.  
 
The findings of the present study appear to present a mixed picture surrounding the effects 
of whey protein on postprandial metabolic responses following a high-fat meal. Previous 
studies have outlined potentially beneficial effects on postprandial lipaemia in obese 
individuals or those with T2DM, however similar observations were not found in healthy 
normal-weight young males in the present study, potentially due to the lack of a challenge to 
the already greater fat tolerance in such individuals. The omission of breakfast had a greater 
effect on post-lunch metabolic responses than the modulation of meal macronutrient intake. 
Post-lunch glucose, insulin and NEFA concentrations were reduced following prior breakfast 
omission, despite similar pre-lunch levels to breakfast trials. Triglyceride was also 
significantly lower during this period due to the post-breakfast peak occurring within this 
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time in breakfast trials, also accentuated by the second meal effect, whereby appearance of 
fat from a previous meal is accelerated by consumption of a subsequent meal (Lambert & 
Parks, 2012). Such findings appear to counter the negative connotations associated with 
breakfast skipping (Brown et al., 2013), however such a conclusion may not be appropriate 
as it is unlikely that breakfast comprising 85% energy from fat would regularly be consumed. 
Combined subjective appetite responses also indicated that a fat-rich breakfast was more 
effective in reducing appetite following lunch than breakfast omission, although it cannot be 
directly interpreted that this would lead to a difference in energy intake. Supplementation 
with whey protein did not appear to significantly augment the appetite response, which 
contrasts with some previous observations (Solah et al., 2010; Zafar et al., 2013), although 
neither of these studies included high-fat test meals. 
 
In conclusion, the addition of whey protein to a fat-rich meal does not positively augment the 
postprandial triglyceride response in healthy young males, despite a moderate increase in 
acute and second meal insulinaemia, while acute and longer term glycaemic responses were 
unaffected. Further investigation of postprandial lipaemia in overweight or obese individuals 
may be warranted, particularly in the context of a mixed-macronutrient test meal.  
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CHAPTER 5 
 
The effect of timing of whey protein supplementation around breakfast 
on acute and second-meal metabolic and appetite responses in 
centrally-obese males 
 
 
 
 
5  
5.1 Introduction 
 
Evidence from the previous two sub-chapters demonstrated the insulinotrophic effects of 
whey protein consumption, however this did not appear to significantly augment postprandial 
glycaemia in normal-weight, healthy individuals. Whether an effect would be observed in 
centrally-obese individuals is unclear however. Despite the growing number of studies in 
normal-weight populations or individuals with T2DM, relatively few studies have been 
conducted with overweight/obese participants who are free from metabolic disease. This is 
surprising given that such individuals are likely to be exposed to elevated postprandial 
glycaemic excursions (Grundy, 2012) and their associated adverse metabolic effects (Gerich, 
2006). The accumulation of excessive adipose tissue, particularly in the abdominal region, a 
condition known as central obesity, is associated with insulin resistance and increased risk 
of developing T2DM and CVD (Item & Konrad, 2012; O'Neill & O'Driscoll, 2015).  Thus, 
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such individuals may benefit the most from strategies to ameliorate postprandial 
hyperglycaemia. 
 
In the studies that have been conducted, a significant reduction in glycaemia was observed 
following consumption of whey protein in obese, but otherwise healthy, female participants 
(Pal et al., 2010b), and whey produced a lower glucose response compared with a glucose 
preload in obese males (Bowen et al., 2006b). The relatively large doses of whey used, 45g 
and 55 g respectively, mean it is unclear whether such an effect would be replicated after 
administering a more realistic amount of protein, while it is also unclear if participants were 
centrally obese, as elevated BMI is the only reported obesity criteria.  
 
Previous studies have demonstrated beneficial effects of whey protein consumption on 
glycaemia with various supplementation approaches. Akhavan et al. (2010) reported 
significant reductions in glycaemia when whey (10-40g) was consumed 30 minutes prior to 
a pre-set pizza meal in lean participants. Similar benefits have been observed when whey 
protein is ingested alongside a meal (Petersen et al., 2009). Thus, it is unclear based on the 
literature whether it is most advantageous to consume whey protein prior to or alongside a 
meal to promote the greatest acute health benefits. When designs have allowed a preload vs 
no preload comparison to be made, no significant differences were observed in metabolic 
(Ma et al., 2009) or subjective appetite (Potier et al., 2010) responses. Nevertheless, Abou-
Samra et al. (2011) reported that the appetite suppressing effects of other protein sources 
(casein and pea) after a preload was administered 30 minutes prior to a meal disappeared 
when consumed immediately prior to the meal.  
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Many studies have used a preload design, administering whey protein at a set time before a 
standardised or ad libitum meal under all conditions, while fewer studies have administered 
whey protein alongside or immediately prior to a test meal, as detailed in Chapters 4a and 
4b. A large variation in preload timings (15-180 minutes) makes determination of the most 
efficacious supplementation strategy difficult. To the author’s knowledge, the study of Ma et 
al. (2009) is the only one to have directly compared the effect of consuming whey protein 
before or alongside a meal on subsequent metabolic responses. It should be noted that 
consuming a preload 30 or more minutes prior to a meal is not analogous to conventional 
eating habits (Popkin & Duffey, 2010). To have the greatest impact upon public health, 
interventions should be replicable in a free-living setting, and it may therefore be that 
tailoring an intervention to enhance its application is of more significance than attaining the 
greatest changes in certain metabolic responses in the laboratory. In this context, a strategy 
that appears to have been overlooked is the consumption of whey protein after a meal. 
Although not representative of a breakfast eating behaviour, such a strategy could potentially 
mimic the effect of consuming a high-protein dessert. 
 
In addition, there are currently no studies that have investigated the effects of whey protein 
consumption on postprandial responses beyond a single isolated meal. A second meal effect 
was not observed in normal-weight participants in Chapters 4a and 4b, however it remains 
unclear whether whey may have a more prolonged effect in centrally obese participants.  
Given that a high protein breakfast attenuated postprandial glucose excursions following a 
standard lunch meal in participants with T2DM (Park et al., 2015), this may be an appropriate 
area to investigate. This study therefore investigated the effect of timing of whey protein 
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supplementation on postprandial metabolic and appetite responses in centrally obese males, 
using timings that reflect habitual eating behaviours.  
 
5.2 Methods 
 
5.2.1 Participants 
 
Participants were recruited as described in section 3.1. Fourteen sedentary centrally-obese 
male participants, free from metabolic disease, were screened against the inclusion/exclusion 
criteria listed in Table 3.1. Data from one participant were removed from analysis (see section 
5.3), thus participant characteristics are presented in Table 5.1 as n = 13. All participants 
provided written informed consent. This study was registered at clinicaltrials.gov as 
NCT02658110. 
 
Table 5.1 Participant characteristics. 
 
All Participants 
(n = 13) 
Characteristics    
Age (years) 39 ± 3 
Body mass (kg) 117.9 ± 3.7 
Stature (cm) 181.3 ± 2.8 
BMI (kg∙m-2) 36.0 ± 1.1 
Waist circumference (cm) 121.3 ± 2.6 
Waist/hip ratio 1.00 ± 0.01 
Fasting variables    
Blood glucose (mmol∙l-1) 5.0 ± 0.1 
Plasma insulin (pmol∙l-1) 122.0 ± 24.8 
HOMA-IR 4.6 ± 1.0 
Plasma triglyceride (mmol∙l-1) 1.91 ± 0.17 
Fasting values are presented as mean of fasting samples for 
each main trial. 
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5.2.2 Experimental design 
 
Participants completed four experimental trials in a randomised, counterbalanced fashion as 
part of a single-blind, crossover design. Trial order was determined as described in section 
3.2. On all visits participants consumed a standardised mixed-macronutrient breakfast meal, 
followed 180 minutes later by consumption of a standard lunch meal. The timing of 
additional protein supplementation varied by trial, with participants consuming 20 g whey 
protein as a preload 15 minutes prior to breakfast (PRE), during the breakfast meal (DUR), 
or 15 minutes post-breakfast consumption (POST). A control trial was also completed 
without additional protein supplementation (CON). Prior to each visit, diet and physical 
activity were standardised as described in section 3.3, and a mixed-macronutrient evening 
meal (Table 3.2) was provided for participants to consume 12 hours before each trial 
commenced.  
 
Participants arrived at the laboratory at the same time (~0800 hours) on each occasion 
following an overnight fast. After insertion of a cannula in an antecubital vein, baseline 
venous and capillary blood samples were collected (see section 3.6.3), and subjective appetite 
was assessed using VAS. In the PRE condition, participants subsequently consumed a 
beverage containing 20 g whey protein, whereas a flavoured water beverage was provided in 
all other conditions. After 15 minutes, breakfast was consumed in all conditions, 
accompanied by either a whey protein (DUR) or placebo beverage. At 15 minutes post-
breakfast consumption, a further test beverage was provided, with whey protein administered 
in the POST trial and flavoured water during all other trials. The remainder of the protocol 
was identical under all experimental conditions, with blood samples and appetite ratings 
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collected at regular intervals (Figure 5.1). Participants rested in a seated position for 180 
minutes following breakfast consumption, after which the same standardised lunch meal was 
consumed on all occasions. After a further 180 minutes, the cannula was removed and 
participants could leave the laboratory.  
 
 
 
Figure 5.1 Schematic representation of experimental trials. 
 
 
 
5.2.3 Test meals 
 
At each test drink time point (15 minutes before, during or 15 minutes after breakfast) either 
a whey protein or placebo drink was consumed which was condition-dependent. The protein 
drink consisted of 23g whey protein isolate powder (see section 3.5) mixed with 150 ml water 
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and 0.5 ml energy-free strawberry flavouring (FlavDrops, Myprotein, UK). The protein 
content of the supplement was 87% (Appendix F2), providing a 20 g dose of whey protein 
with a 344 kJ (82 kcal) energy content. The placebo drink consisted of an isovolumetric bolus 
of similarly flavoured water. All drinks were provided in opaque bottles and no reference 
was made to which trial was being conducted. An additional 200 ml drinking water was 
administered after each test beverage to eliminate any after taste.  
 
A standardised breakfast of rolled porridge oats with semi-skimmed milk and honey was 
provided as under all conditions. This was prepared as described in section 3.4, and provided 
1960 kJ (468 kcal) of energy (70% carbohydrate, 17% fat, 13% protein) with a GI of 63. 
Participants were encouraged to consume this meal within 10 minutes, and 200 ml drinking 
water was provided alongside the porridge. Porridge was selected to represent a habitually 
consumed breakfast food amongst the UK population (Reeves et al., 2013) which, in contrast 
to the test breakfasts administered in Chapters 4a and 4b, provided a more mixed 
macronutrient breakdown, enhancing the ecological validity of any findings. 
 
A standardised mixed-macronutrient lunch meal was administered in all conditions, 
consisting of pasta in a cheese and tomato sauce. This was prepared as described in section 
3.4, providing 3446 kJ (824 kcal) of energy (50% carbohydrate, 36% fat, 14% protein). Water 
(500 ml) was also served alongside the lunch meal, and was withheld in the post lunch period.  
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5.2.4 Blood sampling and analysis 
 
Venous and capillary blood samples were collected at regular intervals (Figure 5.1) while the 
participant was in a seated position (see section 3.6.3). Additional capillary samples were 
taken at 5 and 10 minutes post-breakfast and post-lunch in order to increase the resolution of 
the blood glucose response curve. Samples were processed and analysed for concentrations 
of glucose, insulin, triglyceride and NEFA as described in section 3.6.4. Due to technical 
difficulties with the automated analyser (RX Daytona, Randox Laboratories, UK) used for 
determination of plasma glycerol concentrations, data for this analyte are not presented. 
 
5.2.5 Subjective appetite 
 
Subjective appetite ratings were assessed at regular intervals throughout the protocol (Figure 
5.1) using VAS as described in section 3.6.2. Scales assessed perceptions of hunger, fullness, 
PFC and satisfaction, and a combined appetite score was calculated (section 3.7). 
 
5.2.6 Statistical analysis 
 
Total AUC was calculated using the trapezoidal method (see section 3.7). Data were analysed 
over both the post-breakfast (0-180 min) and post-lunch (180-360 min) periods. The time 
point at 180 minutes post-breakfast was used as the baseline value for the post-lunch period. 
Due to its delayed appearance in plasma, triglyceride data were also assessed over the full 
360 minute laboratory protocol. Statistical analysis was conducted as described in section 
3.7.1. 
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5.3 Results 
 
Fasting values did not differ between conditions for all physiological and appetite variables 
assessed (p > 0.05). Analysis revealed that one participant did not adhere to the pre-trial 
fasting protocol prior to one visit. Data from this participant was subsequently removed from 
analysis, thus data are presented as n = 13. 
 
5.3.1 Post-breakfast responses 
 
Blood glucose responses displayed a significant condition x time interaction effect 
(p < 0.001) in addition to main effects of condition (p < 0.001) and time (p < 0.001). Glucose 
peaked at 30 minutes post-breakfast under all conditions (Figure 5.2a), with the magnitude 
of the peak significantly reduced when whey protein was consumed as a preload or alongside 
breakfast compared with whey after the meal or no supplementation (PRE: 7.2 ± 0.3, DUR: 
7.8 ± 0.3 vs POST: 8.6 ± 0.3, CON: 8.6 ± 0.2 mmol∙l-1; all p ≤ 0.046). A tendency for peak 
to be reduced in PRE compared to DUR was also observed, however this was not statistically 
significant (p = 0.076). Compared to CON, glucose was lower in PRE at 10-45 minutes 
(p ≤ 0.017), and in DUR at 30-60 minutes post-breakfast (p ≤ 0.041). Concentrations returned 
to baseline levels at 90 minutes post-breakfast under all conditions, with no further between-
trial differences observed (p > 0.05). Glycaemia across the post-breakfast period was 
significantly lower following whey preload compared with POST and CON conditions 
(AUC0-180min: PRE: 982 ± 30 vs POST: 1031 ± 36 and CON: 1065 ± 37 mmol∙min-1∙l-1; 
p ≤ 0.042), but not significantly different from the whey with meal condition (DUR: 1013 ± 
32 mmol∙min-1∙l-1; p = 0.77; Figure 5.2b).  
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Figure 5.2 Time course changes in glucose (a), insulin (c) and NEFA (e) concentrations during the post-breakfast period 
(0-180 minutes). Significant differences (p < 0.05) between trials at individual time points are defined as follows: a, PRE 
vs CON; b, PRE vs POST; c, DUR vs CON; black dotted line indicates time of breakfast consumption; grey dotted lines 
indicate time of whey protein consumption during PRE and POST trials; Area under the curve for glucose (b), insulin (d) 
and NEFA (f) responses. Bars not sharing a common superscript letter differ significantly from one another (p < 0.05). Data 
are presented as mean ± SEM. PRE: pre-meal protein trial; DUR: during meal protein trial; POST: post-meal protein trial; 
CON: no additional protein trial; AUC: area under the curve; NEFA: non-esterified fatty acids.  
 
134 
 
Postprandial plasma insulin concentrations were influenced by both time (p < 0.001) and 
condition (p = 0.047). Concentrations rose following breakfast consumption, remaining 
significantly elevated above baseline level at 15-120 minutes post-breakfast (p ≤ 0.007; 
Figure 5.2c). Post hoc analysis of the main effect of condition indicated that concentrations 
were lower during PRE than DUR (p = 0.019) with a trend for insulin to be lower compared 
to POST (p = 0.053), however concentrations did not differ between PRE and CON 
(p > 0.05). Insulin AUC across this period showed a reduced insulin response when whey 
was supplemented before breakfast compared with other supplementation times 
(AUC0-180min: PRE: 96340 ± 10807 vs DUR: 112344 ± 10310 and POST: 121997 ± 
15862 pmol∙min-1∙l-1; p ≤ 0.032; Figure 5.2d), and was similar to the response following 
breakfast without additional protein (CON: 99115 ± 14656 pmol∙min-1∙l-1; p > 0.05). When 
whey was supplemented after the meal, insulinaemia was ~23% greater than control 
(p = 0.049). Insulin sensitivity did not significantly differ between conditions during the post-
breakfast period (Matsuda-ISI; PRE: 3.8 ± 0.6, DUR: 2.9 ± 0.5, POST: 2.8 ± 0.4, CON: 
3.3 ± 0.5 arbitrary units; p = 0.161).  
 
Post-breakfast NEFA concentrations were significantly affected by time (p < 0.001) such that 
levels were immediately suppressed following breakfast consumption under all conditions, 
and remained significantly below baseline levels from 15-180 minutes post-breakfast 
(p ≤ 0.006; Figure 5.2e). There was no effect of condition (p = 0.611) and NEFA AUC was 
similar between conditions across this period (p = 0.517; Figure 5.2f).  
 
An effect of time (p < 0.001), but not condition (p = 0.26) or condition x time interaction 
(p = 0.423), was observed on appetite perceptions following breakfast. Combined appetite 
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ratings were similarly suppressed under all conditions following breakfast consumption, 
reaching their nadir at 15-30 minutes post-consumption, the magnitude of which was not 
different between conditions (PRE: 14 ± 4, DUR: 15 ± 4, POST: 17 ± 4, CON: 20 ± 4 mm; 
p = 0.344; Figure 5.3a). Appetite subsequently increased gradually, reaching similar levels 
to baseline at 120-180 minutes post-breakfast in all conditions (p > 0.05). There were no 
significant differences in AUC between conditions for combined appetite score (Figure 5.3b) 
or individual subjective appetite components (Table 5.2) across this period (p > 0.05).  
 
 
 
Figure 5.3 Time course changes (a) and area under the curve (b) for combined appetite score during the post-breakfast 
period (0-180 minutes). Data are presented as mean ± SEM; black dotted line indicates time of breakfast consumption; grey 
dotted lines indicate time of whey protein consumption during PRE and POST trials; PRE: pre-meal protein trial; DUR: 
during meal protein trial; POST: post-meal protein trial; CON: no additional protein trial; AUC: area under the curve. 
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Table 5.2 Area under the curve for components of subjective appetite during post-breakfast (0-180 minutes) and post-lunch 
(180-360 minutes) postprandial periods. 
  Area under the curve 
  PRE DUR POST CON 
      
Hunger 
(mm∙min-1) 
Post-breakfast 6033 ± 801 6070 ± 911 6461 ± 887 7641 ± 1095 
Post-lunch 6046 ± 734 5651 ± 954 6378 ± 1012 6649 ± 929 
      
Fullness 
(mm∙min-1) 
Post-breakfast 11350 ± 885 11553 ± 964 11107 ± 965 9963 ± 1139 
Post-lunch 11347 ± 824 11980 ± 974 11130 ± 1080 11003 ± 1007 
      
PFC 
(mm∙min-1) 
Post-breakfast 7303 ± 1034 6642 ± 1086 7448 ± 1094 8761 ± 1288 
Post-lunch 7499 ± 1069 6882 ± 1187 7423 ± 1165 7707 ± 1201 
      
Satisfaction 
(mm∙min-1) 
Post-breakfast 11203 ± 929 11194 ± 966 10767 ± 969 10411 ± 982 
Post-lunch 10941 ± 881 11548 ± 1018 11313 ± 979 10767 ± 980 
      
Data presented as mean ± SEM. PRE: pre-meal protein trial; DUR: during meal protein trial; POST: post-meal protein trial; 
CON: no additional protein trial; PFC: prospective food consumption. 
 
 
 
5.3.2 Post-lunch responses 
 
Following consumption of a standardised lunch meal, both glucose and insulin 
concentrations displayed a significant effect of time (p < 0.001), with no condition or 
interaction effects present (p > 0.05). Concentrations peaked similarly across all conditions 
before returning to pre-lunch levels at 60 and 90 minutes post-lunch for glucose and insulin 
respectively (Figure 5.4). Post-lunch AUC revealed no differences between conditions in 
glycaemia (p = 0.262) or insulinaemia (p = 0.271; Figure 5.4).  
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Figure 5.4 Time course changes in glucose (a), insulin (c) and NEFA (e) concentrations during the post-lunch period (180-
360 minutes) and area under the curve for glucose (b), insulin (d) and NEFA (f) responses. Data are presented as mean ± 
SEM; black dotted line indicates time of breakfast consumption; grey dotted lines indicate time of whey protein consumption 
during PRE and POST trials; PRE: pre-meal protein trial; DUR: during meal protein trial; POST: post-meal protein trial; 
CON: no additional protein trial; AUC: area under the curve; NEFA: non-esterified fatty acids. 
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Post-lunch NEFA concentrations were not influenced by condition (p = 0.346), with similar 
AUC observed between trials (p = 0.587; Figure 5.4e). Concentrations were moderately 
suppressed at 15-60 minutes post-lunch under all conditions, before returning to pre-lunch 
levels at 90-180 minutes (Figure 5.4f). Appetite was similarly affected by consumption of 
lunch in all conditions (p = 0.423). An effect of time was present (p < 0.001), such that there 
was an immediate reduction in combined appetite score following lunch, before gradually 
returning to pre-lunch levels at 150-180 minutes post-consumption across all trials (Figure 
5.5a). There were no significant differences observed in post-lunch AUC for combined 
appetite score (Figure 5.5b) or its constituent components of hunger, fullness, PFC and 
satisfaction (Table 5.2) between conditions (p > 0.05). 
 
 
 
Figure 5.5 Time course changes (a) and area under the curve (b) for combined appetite score during the post-lunch period 
(180-360 minutes). Data are presented as mean ± SEM; black dotted line indicates time of breakfast consumption; grey 
dotted lines indicate time of whey protein consumption during PRE and POST trials; PRE: pre-meal protein trial; DUR: 
during meal protein trial; POST: post-meal protein trial; CON: no additional protein trial; AUC: area under the curve. 
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5.3.3 Plasma triglyceride 
 
Triglyceride concentrations increased similarly over the course of the experimental protocol 
in all conditions. Post hoc analysis of the main effect of time (p < 0.001) indicated that levels 
were elevated above baseline concentration from 60 minutes post-breakfast onwards 
(p ≤ 0.018), and continued to rise throughout (Figure 5.6a). There was no effect of condition 
on triglyceride concentrations (p = 0.653), and AUC was similar between conditions for 
triglyceride response across the full postprandial period (p = 0.64; Figure 5.6b).  
 
 
 
Figure 5.6 Mean ± SEM temporal changes in plasma triglyceride concentrations throughout the full experimental protocol 
(0-360 minutes); black dotted line indicates time of breakfast consumption; grey dotted lines indicate time of whey protein 
consumption during PRE and POST trials;  PRE: pre-meal protein trial; DUR: during meal protein trial; POST: post-meal 
protein trial; CON: no additional protein trial; AUC: area under the curve. 
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5.4 Discussion 
 
The findings of the current study demonstrate that consumption of whey protein, either before 
or alongside a mixed-macronutrient breakfast, attenuates peak postprandial glucose 
excursions in centrally obese, but otherwise healthy, males. Furthermore, consuming whey 
as a preload appears to confer the greatest beneficial effect, manifested by a reduction in 
glycaemia over 3 hours compared to the same breakfast devoid of additional protein, without 
augmenting the postprandial insulin response. In agreement with findings in normal-weight 
participants described in Chapters 4a and 4b, the addition of 20 g whey protein to a breakfast 
meal did not significantly affect postprandial lipaemic responses or subjective perceptions of 
appetite, acutely or following a subsequent lunch meal.  
 
Both peak glucose and mean postprandial glycaemia following meal consumption are 
significant outcomes in non-diabetic populations presenting with metabolic risk factors such 
as central obesity. Postprandial hyperglycaemia is a greater risk factor for CVD than 
increased fasting glucose in non-diabetics (Bianchi et al., 2008; Gerich, 2003), where its 
contribution to overall glycaemia is particularly marked. Furthermore, postprandial 
glycaemic excursions have been established as the main causative factor in glycaemic 
variability in non-insulin treated individuals with IGT (Monnier et al., 2012), and such 
excursions manifest adverse metabolic effects via activation of oxidative stress and 
endothelial dysfunction (Ceriello et al., 2008). Thus, evidence supports recommending 
reductions in postprandial hyperglycaemia as a relevant clinical goal in delaying or 
preventing the onset of T2DM (Monnier & Colette, 2015).  
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The reduction in peak glucose observed following a whey preload in the present study 
(1.4 mmol∙l-1) is comparable with those demonstrated in previous studies in both healthy and 
diabetic populations. Akhavan et al. (2010) reported a mean peak decrement of 1.8 mmol∙l-1 
following a mixed-macronutrient meal preceded by 20 g whey protein, albeit with a longer 
duration between preload and meal (30 minutes). In prediabetic individuals and those with 
T2DM, Clifton et al. (2014a) observed a 2.1 mmol∙l-1 reduction in peak blood glucose when 
a high GI breakfast was consumed 15 minutes after 17 g whey protein. The addition of 5 g 
guar fibre to this preload, known to delay gastric emptying (Sah et al., 2016) may explain the 
greater effect. Significantly reduced glucose peaks were also observed when whey protein 
was supplemented at the same time as breakfast consumption in the present study, however 
the magnitude of this reduction compared to control (~9%) was lower than during the preload 
condition (~14%), with the difference between these conditions approaching significance. 
This is suggestive of a greater beneficial effect when whey is administered at least 15 minutes 
prior to a meal. Indeed, the finding that total AUC was significantly reduced over the full 
postprandial period in the preload trial, compared to both control (~8%) and post-meal 
supplementation (~5%), whereas glycaemia did not differ significantly from other conditions 
in the with-meal trial, appears to confirm this.  
 
Several mechanisms are likely to have interacted to bring about such an effect. The 
insulinotrophic effect of whey protein has previously been established (Gunnerud et al., 
2013; Nilsson et al., 2007), and may be amplified by a possible inhibitory effect of whey on 
DPP-IV, which acts to degrade the incretins (Jakubowicz & Froy, 2013). Plasma insulin was 
significantly greater when supplemented after breakfast in the current study, however this 
did not lead to a significant lowering of blood glucose compared to control. When whey was 
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administered as a preload however, glycaemia was significantly lower than control in the 
absence of a differential insulin response, indicative of an insulin-independent effect. An 
effect on gastric emptying is a likely mediator for an insulin-independent effect (Akhavan et 
al., 2010). It is well established that the rate of gastric emptying is a major determinant of 
postprandial blood glucose excursions, particularly in the early postprandial phase (Marathe 
et al., 2013; Mignone et al., 2015). Consumption of a whey protein preload has previously 
been reported to slow gastric emptying (Akhavan et al., 2014) and, although this was not 
measured in the current study, it could be speculated that such an effect was responsible for 
the observed reduction in glycaemia. In addition, the fact that glycaemia was greater when 
whey was consumed 15 minutes after the meal compared with the preload trial, despite 
significantly greater insulinaemia, suggests that consumption was too late to significantly 
affect the rapid absorption of exogenous glucose (Frayn, 2010), which peaked in the blood 
just 15 minutes later.  
 
The efficacy of both fat (Gentilcore et al., 2006) and protein (Hall et al., 2003) preloads in 
slowing gastric emptying has been shown previously, however the greater energy density of 
fat may limit its application. Nutrient intake initiates the release of the incretin hormones, 
while GLP-1 also acts to slow gastric emptying and suppress glucagon release (Mignone et 
al., 2015). In addition, other gut peptides such as CCK and PYY, released due to the presence 
of nutrients in the gastrointestinal tract, act to slow gastric emptying (Marathe et al., 2013). 
The fact that pre-meal protein reduced post-meal glycaemia in the present study, whereas the 
same amount of protein with the meal did not have a significant effect, contrasts with the 
findings of Ma et al. (2009). In this study in a T2DM population, protein slowed gastric 
emptying to a greater extent after a preload, however glycaemia was reduced significantly 
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under both conditions without an effect of preload. The considerably larger dose of protein 
used (55 g) and high GI nature of the test meal may explain this difference, as a 3-fold 
increase in insulin concentration was observed 90 minutes after consumption of the test meal 
in supplementation conditions.  
 
The ability of whey protein to improve glycaemia without a concomitant increase in plasma 
insulin has been reported previously (Akhavan et al., 2010), and may be indicative of 
transient changes in insulin sensitivity due to whey protein ingestion. Enhanced insulin 
sensitivity has been shown following chronic whey protein supplementation in both rats 
(Belobrajdic et al., 2004) and humans (Pal et al., 2010a). However this contrasts with the 
reported promotion of insulin resistance with increased amino acid availability (Tremblay et 
al., 2005) following acute whey protein ingestion (Smith et al., 2015). The composite index 
of insulin sensitivity (Matsuda-ISI) did not differ significantly between conditions in the 
current study, indicating that insulin-independent mechanisms such as delayed gastric 
emptying may have had a greater influence on postprandial glycaemia.  
 
The effects of whey protein ingestion, independent of timing of consumption, were limited 
to glucose and insulin responses in the current study. Postprandial lipaemia was not affected 
by co-ingestion of whey protein with breakfast, which differs from the findings of Pal et al. 
(2010b). This group observed a 21% reduction in triglyceride appearance in plasma following 
supplementation of 45 g whey, compared with glucose, alongside a mixed-macronutrient 
meal in obese females. Such a difference is perhaps unsurprising due to the considerably 
lower fat content of the breakfast administered in the present study (9 g) compared to the 
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aforementioned study (32 g), whilst the amount of supplemental whey administered by Pal 
et al. (2010b) was over 2-fold greater.  
 
Subjective appetite responses were also similar across conditions in the present study, 
regardless of the addition of whey or its timing. Although post-breakfast appetite appeared 
to be elevated in the control condition, this difference was not significant and may be a 
consequence of the fact that this study was powered to detect differences in the primary 
outcome of glycaemia. The lack of a timing effect supports the findings of a previous study 
where the consumption of carbohydrate, fat and protein preloads had similar effects on both 
food intake and subjective appetite whether ingested immediately or 1 hour before a lunch 
meal (Potier et al., 2010). In contrast, Abou-Samra et al. (2011) reported that food intake was 
reduced following casein and pea preloads (30 minutes prior to ad libitum  meal) compared 
to a water control, however this effect was not present when preloads were consumed 
immediately prior to the meal. Such an effect may be limited to other proteins however, as 
whey did not significantly affect food intake or appetite in this comparison. A positive effect 
of whey protein on subjective appetite responses has previously been shown in overweight 
males after a 55 g preload (Bowen et al., 2006b), however such a comparison with glucose 
does not easily compare with the response following the addition of 20 g whey to a mixed-
macronutrient breakfast meal consisting of habitually consumed ingredients. A mixed effect 
of whey on subjective appetite in healthy individuals has previously been shown.  Several 
studies have reported reductions in appetite (Hall et al., 2003; Solah et al., 2010; Zafar et al., 
2013), although the mechanisms remain to be elucidated. Others have failed to show an effect 
(Abou-Samra et al., 2011; Astbury et al., 2010; Chungchunlam et al., 2015), however these 
responses did not necessarily correlate with energy intake.  
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Whey protein at breakfast did not affect post-lunch responses across all outcomes assessed 
in the present study. This appears to confirm the findings of Chapter 4a in normal-weight 
individuals, and suggests that any effects of whey protein on postprandial glycaemia are 
transient, and may provide rationale for researchers to investigate the supplementation of 
whey protein at multiple sequential meals.  
 
This study aimed to investigate the effect of timing of whey protein supplementation on 
postprandial metabolic and appetite responses. It is unclear if the beneficial effects on 
glycaemia would have been greater with a longer duration between preload and test meal, 
however the timings used in the present study were designed to reflect an approach that does 
not deviate markedly from typical eating habits. As such, consuming a small nutrient load 15 
minutes before a meal is analogous to consuming a starter prior to a main meal, and may 
therefore be more easily replicated in the free-living setting.  
 
In summary, consumption of whey protein alongside a mixed-macronutrient meal attenuated 
postprandial glucose excursions in centrally-obese males. In addition, consumption of whey 
as a preload had a similar effect on peak glucose, also attenuating glycaemia over the 
subsequent 3 hours, with a simultaneously reduced insulin response. Reductions in 
postprandial glycaemia may be beneficial in preventing or delaying the progression from 
NGT to IGT or T2DM. The addition of whey protein, independent of timing, did not affect 
postprandial responses to a subsequent lunch meal. 
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CHAPTER 6 
 
Metabolic and appetite responses to a whey protein preload following 
prior low-moderate intensity exercise in sedentary centrally-obese males 
 
 
 
 
6  
6.1 Introduction 
 
Obesity, particularly of the abdominal region, is associated with dysregulation of a number 
of metabolic processes including glucose and lipid metabolism, and thus increased risk of 
developing T2DM and CVD (Misra & Khurana, 2008). Lifestyle intervention is an effective 
strategy in the prevention of chronic diseases (Hays et al., 2008) and dietary interventions 
that aim to reduce body mass via energy restriction are common (Andersen & Fernandez, 
2013). However, adherence to such interventions and maintenance of improvements are often 
areas of concern (Alhassan et al., 2008; Anderson et al., 2001). Thus, additional strategies to 
reduce the risks associated with central obesity are important, including modulating 
postprandial responses to reduce the adverse metabolic effects associated with elevated 
postprandial glycaemia and lipaemia (Gerich, 2006; Kolovou et al., 2011).  
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In chapter 5 it was found that consumption of whey protein 15 minutes prior to a meal can 
attenuate postprandial glycaemia in obese males. Furthermore, this effect was observed using 
a smaller supplemental whey protein dose (20 g vs 45-55 g) than previous studies showing 
the same effect in obese, but otherwise healthy participants (Bowen et al., 2006b; Pal et al., 
2010b). Subjective appetite was unaffected by the same intervention, however as subsequent 
intake was not measured it is unclear if energy intake is influenced at a later meal. Whey may 
also influence postprandial energy expenditure through an increase in diet-induced 
thermogenesis (Acheson et al., 2011; Hursel et al., 2010). Evidence therefore indicates the 
potential of whey protein supplementation to positively influence post-meal responses.  
 
Physical activity and exercise are also important aspects of chronic disease prevention. The 
UK Government recommends achieving at least 30 minutes of moderate or greater intensity 
physical activity (such as brisk walking) on five or more days a week (National Institute for 
Health and Care Excellence, 2014), and a joint position stand of the American College of 
Sports Medicine and the American Diabetes Association affirms this goal for reduction of 
T2DM risk (Colberg et al., 2010). Evidence suggests that greater amounts of physical activity 
are required to influence central obesity and maintenance of fat loss (Slentz et al., 2009), 
however such targets may not be sustainable in the free-living setting for the majority of 
obese individuals who currently perform very little physical activity (Bray et al., 2016). 
Moreover, exercise training does not result in weight loss for the majority of obese 
individuals (Hays et al., 2008), and compliance is often poor (Johnson & Jebb, 2009). In this 
context, and given that the effects of exercise on cardiometabolic risk factors are often found 
to be transient (Boulé et al., 2005; Colberg et al., 2010), investigating the acute effects of a 
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single bout of exercise on postprandial metabolism may be relevant in populations that are 
unlikely to undertake frequent training.  
 
Acute endurance-type exercise is a potent regulator of postprandial lipid metabolism, with 
studies consistently reporting a reduction in postprandial triglyceride response following a 
high-fat meal after prior exercise (Freese et al., 2014). Evidence also suggests that acute 
exercise does not increase hunger or food intake in normal-weight (Martins et al., 2008) and 
overweight/obese individuals (Martins et al., 2015). This underlines the potential for an acute 
bout of exercise to induce an energy deficit, however laboratory-based studies have revealed 
a large degree of inter-individual variation in post exercise compensatory eating in lean 
(Finlayson et al., 2009) and obese (Hopkins et al., 2013) individuals. A single bout of 
moderate-intensity aerobic exercise is sufficient to increase insulin sensitivity in habitually 
inactive obese adults (Nelson & Horowitz, 2014). The effect on acute post-exercise 
glycaemic responses is equivocal however, with reported improvements (Hasson et al., 
2010), no change (Gonzalez et al., 2013) or decrements (Rose et al., 2001) in glucose 
tolerance. Glucose uptake tends to be elevated for several hours post-exercise (Colberg et al., 
2010), however the rate of exogenous glucose appearance from a post-exercise meal may 
also be augmented. The fitness and prior nutritional state of the participant are likely to 
influence post-exercise metabolism, however the effect of altering post-exercise nutritional 
intake is unclear.  
 
The vast majority of studies concerning post-exercise whey protein supplementation have 
been conducted following resistance-type exercise, with beneficial effects on muscle protein 
synthesis (Witard et al., 2014) and lean mass maintenance (Hayes & Cribb, 2008; Naclerio 
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& Larumbe-Zabala, 2015) previously described. However, the influence of whey protein 
supplementation following aerobic exercise on subsequent metabolic and appetite responses 
has received little attention. Reduced ad libitum energy intake has been observed 60 minutes 
after milk (Rumbold et al., 2015) or whey protein (Clayton et al., 2014) consumption 
following prior moderate-intensity cycling exercise in recreationally active participants. 
Whether postprandial metabolic and appetite responses would be influenced by post-exercise 
whey protein consumption in habitually inactive obese individuals remains unclear. Given 
that a single bout of exercise may produce divergent responses in subsequent glucose 
tolerance (Gonzalez, 2014), and that whey has been observed to influence postprandial 
glycaemia and insulinaemia within this thesis, the impact of post-exercise whey consumption 
on postprandial metabolic responses may be of significance.  
 
Acute endurance-type exercise and whey protein supplementation have previously been 
reported to affect acute metabolic and appetite responses to a subsequent meal independently, 
however it is unclear whether additional beneficial effects are present when these strategies 
are combined. This study therefore aimed to investigate the effect of fasted moderate-
intensity exercise and subsequent whey protein supplementation on postprandial metabolic 
and appetite responses.  
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6.2 Methods 
 
6.2.1 Participants 
 
Twelve sedentary centrally-obese male participants, free from metabolic disease, took part 
in the study (see Table 6.1 for participant characteristics). Participant recruitment methods 
are detailed in section 3.1, and participants were screened against the inclusion/exclusion 
criteria listed in Table 3.1. All participants provided written informed consent. This study 
was registered at clinicaltrials.gov as NCT02714309.  
 
 
 
Table 6.1 Participant characteristics. 
 
All Participants 
(n = 12) 
Characteristics    
Age (years) 41 ± 9 
Body mass (kg) 121.9 ± 10.9 
Stature (cm) 179.5 ± 5.9 
BMI (kg∙m-2) 37.8 ± 2.1 
Waist circumference (cm) 123.4 ± 9.9 
Waist/hip ratio 1.01 ± 0.07 
V̇O2peak (ml∙kg-1∙min-1) 25.5 ± 3.9 
Fasting variables    
Blood glucose (mmol∙l-1) 5.2 ± 0.6 
Plasma insulin (pmol∙l-1) 122.6 ± 56.7 
HOMA-IR 4.7 ± 2.4 
Plasma triglyceride (mmol∙l-1) 1.50 ± 0.63 
Fasting values are presented as mean of fasting samples for each main trial. 
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6.2.2 Experimental design 
 
Participants completed three trials in a randomised, counterbalanced fashion, separated by at 
least 7 days as part of a single-blind, crossover design. Randomisation of trial order was 
determined as described in section 3.2. Pre-trial diet and physical activity was standardised 
as described in section 3.3. A 30 minute bout of steady-state brisk treadmill walking was 
completed on two separate occasions, followed by consumption of a whey protein 
(EX+PRO) or placebo (EX) preload beverage. On a third occasion, participants remained in 
a sedentary position for the same duration followed by consumption of the placebo beverage 
(CON). A standardised, carbohydrate-rich, breakfast meal was provided 15 minutes after 
consumption of test preloads (whey protein or placebo) under all conditions. Participants 
remained sedentary for a further 240 minutes, followed by consumption of an ad libitum 
mixed-macronutrient lunch meal. 
 
The efficacy of supplemental whey protein in reducing acute postprandial glycaemia was 
observed to be greater when whey was given as a preload, rather than alongside, the same 
standardised breakfast in Chapter 5, therefore this strategy has been replicated in the current 
study. In previous chapters, a standardised lunch meal has been administered to assess second 
meal metabolic and appetite responses following whey protein supplementation at breakfast. 
Having confirmed that prior whey does not influence subsequent meal responses, an ad 
libitum lunch meal was administered in the current study, enabling assessment of between-
condition differences in energy intake at this time point. 
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6.2.3 Preliminary exercise test 
 
Prior to experimental visits, participants completed a treadmill walking test to determine their 
prescribed walking speed during the main trials. Due to the sedentary nature of participants, 
a submaximal test was conducted, where linear relationships between walking speed and 
oxygen consumption, and between heart rate and oxygen consumption, were established. 
This enabled estimation of V̇O2peak for each participant, and subsequently calculation of 
walking speed of the desired relative intensity. Participants warmed up for 3 minutes at a 
self-selected comfortable walking speed, enabling habituation with the motorised laboratory 
treadmill (Pulsar 3p, h/p/cosmos, Germany). The test began with the participant walking at 
3-4 km∙h-1, with four steady-state walking stages completed in total. Each stage lasted for 3 
minutes, and the speed of the treadmill was increased by 0.5 or 1 km∙h-1 at the end of each 
stage, unless heart rate exceeded 85% age-predicted maximum (220 – age) or the participant 
reported any undue side-effects, at which point the test was terminated. The increase in speed 
was determined according to the discretion of the researcher, and based on the rating of 
perceived exertion (RPE) which the participant indicated in the final 30 seconds of each stage 
using the scale of Borg (1990) (Appendix H).  
 
Throughout the test, expired gas was sampled using a breath by breath gas analyser (Oxycon 
Pro, CareFusion, USA) and heart rate was recorded using short-range telemetry (Polar 
RS400, Polar Electro, Finland). Data were averaged over 30 second intervals to plot the 
relationship between oxygen consumption and heart rate, which was extrapolated to age-
predicted maximum heart rate in order to estimate V̇O2peak for each participant. The walking 
speed eliciting an intensity of 50% V̇O2peak was determined from the relationship between 
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oxygen consumption and walking speed, and selected as the prescribed walking speed for 
exercise bouts during main trials.  
 
6.2.4 Main trial procedures 
 
Participants arrived at the laboratory following an overnight fast, and body mass was 
recorded to the nearest 0.05 kg using a digital scale (Seca 704, Seca Ltd, Germany) after 
voiding. Following insertion of a cannula into an antecubital vein, venous and capillary blood 
samples were taken (see section 3.6.3), and baseline measures of subjective appetite and 
expired gas were collected. During CON participants remained rested and during EX+PRO 
and EX a 30 minute bout of steady-state brisk walking was performed on a motorised 
treadmill. Participants began walking at their predetermined speed, which was subsequently 
adjusted during the first visit if a significant deviation from the desired value of oxygen 
consumption was observed during expired gas analysis. Any adjustments were recorded and 
replicated in the second exercise trial. Heart rate was monitored throughout, and RPE was 
recorded at 5 minute intervals. The mode, intensity and duration of exercise was designed to 
be achievable for habitually sedentary individuals, while also conforming to current 
recommendations for prescribed levels of daily physical activity for health (National Institute 
for Health and Care Excellence, 2014).  
 
Within 5 minutes of exercise completion, participants consumed a test beverage containing 
whey protein during EX+PRO, and a placebo beverage during EX. During CON, a placebo 
beverage was consumed at the corresponding time point. The remainder of the trial procedure 
was identical under all conditions. A standardised breakfast was consumed 15 minutes after 
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test beverage ingestion, and participants subsequently remained in a sedentary position with 
access to reading material or a laptop computer. After 240 minutes had elapsed, a lunch meal 
was provided to assess energy intake. Upon completion, the cannula was removed and 
participants were free to leave the laboratory. Blood, expired gas and VAS were sampled at 
regular intervals throughout (see Figure 6.1).  
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Figure 6.1 Schematic representation of experimental trials. WP, whey protein.
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6.2.5 Test meals 
 
During EX+PRO, the test beverage consisted of 23 g whey protein isolate powder (see 
section 3.5) combined with 150 ml water and 0.5 ml energy-free strawberry flavouring 
(FlavDrops, Myprotein, UK). The protein content of the supplement was 87% (Appendix 
F2), providing a 20 g dose of whey with a 344 kJ (82 kcal) energy content. During EX and 
CON an isovolumetric bolus of similarly flavoured water was consumed as a placebo. All 
test drinks were provided in opaque bottles. An additional 200 ml drinking water was 
administered after each test beverage to eliminate any after taste. 
 
A standardised portion of rolled porridge oats with semi-skimmed milk and honey was 
provided as breakfast under all conditions. This was prepared as described in section 3.4, and 
provided 1960 kJ (468 kcal) of energy (70% carbohydrate, 17% fat, 13% protein). 
Participants were encouraged to consume this meal within 10 minutes, and 250 ml drinking 
water was provided alongside the porridge. A timer was starter upon completion of this meal. 
 
A homogenous pasta meal was provided ad libitum at lunch to record energy intake. This 
consisted of dried pasta, a tomato-based sauce, cheddar cheese and olive oil (Tesco Stores 
Ltd, UK) as used previously (Gonzalez et al., 2015; Gonzalez et al., 2013) providing 53%, 
14% and 33% energy from carbohydrate, protein and fat respectively. Participants were 
initially provided with a 400 g (2845 kJ, 680 kcal) portion of the pasta and were instructed 
to eat until they felt ‘comfortably full’ on each occasion. The serving bowl was topped up 
with fresh pasta prior to completion, thus removing the effect of bowl clearance as a stimulus 
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for food intake termination. All cooked pasta (served or unserved) was weighed immediately 
before and after consumption to determine energy intake.  
 
6.2.6 Indirect calorimetry 
 
Expired gas was sampled at regular intervals throughout resting and exercise portions of the 
protocol (Figure 6.1) using an online gas analyser (Oxycon Pro, CareFusion, USA) which 
was calibrated prior to each use with 3 litre syringe and gasses of known concentrations. 
Participants wore a facemask (model 7940, Hans-Rudolph, USA) which was connected to 
the analyser, and remained in a seated position throughout resting samples. Samples were 
collected at baseline, immediately after test beverage, 20 minutes post breakfast, and every 
subsequent 30 minutes until the end of the protocol. Expired gas was collected for 10 minute 
periods, with data from the first and last minute of each period discarded. During treadmill 
walking, expired gas was collected for 5 minute periods at 5, 15 and 25 minutes into the bout, 
with the first and last minutes discarded.  
 
Values of oxygen consumption and carbon dioxide production were used to calculate rates 
of substrate oxidation using stoichiometric equations as follows: 
 
Carbohydrate oxidation at rest (g∙min-1)  =  4.55 V̇CO2  –  3.21 V̇O2   
Carbohydrate oxidation during exercise (g∙min-1)  =  4.210 V̇CO2  –  2.962 V̇O2   
Lipid oxidation (g∙min-1)  =  1.67 V̇CO2  –  1.67 V̇O2   
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The methods of Frayn (1983) were used to calculate lipid oxidation and carbohydrate oxygen 
at rest, which assumes exclusive use of glucose for carbohydrate metabolism. The method of 
Jeukendrup and Wallis (2005) was used to calculate carbohydrate oxidation during exercise 
which adjusts for the increase in glycogen contribution to carbohydrate metabolism during 
moderate intensity exercise. Energy expenditure was calculated based on lipids, glucose and 
glycogen providing 37.7, 15.5 and 17.2 kJ∙g-1 (9.0, 3.7 and 4.1 kcal∙g-1), respectively. Urine 
was collected throughout each visit to determine urinary nitrogen excretion as a marker of 
protein oxidation. Due to technical difficulties with the automated analyser (RX Daytona, 
Randox Laboratories, UK), these determinations were not achieved. Protein oxidation 
contributes least to total energy expenditure, and intake at the level supplemented in the 
current study (20 g) does not increase protein oxidation above basal levels (Moore et al., 
2009; Witard et al., 2014). Therefore, calculations were based on the assumption of 
negligible contribution of protein oxidation, which reflects the method used in the vast 
majority of studies utilising indirect calorimetry. 
 
6.2.7 Blood sampling and analysis 
 
Venous and capillary blood samples were collected at regular intervals (baseline, post-
exercise/control [-15], 0, 15, 30, 45, 60, 90, 120, 150, 180, 210 and 240 minutes post-
breakfast (Figure 6.1)) while the participant was in a seated position, as described in section 
3.6.3. Additional capillary samples were taken at 5 and 10 minutes post-breakfast in order to 
increase the resolution of the blood glucose response curve. Samples were processed and 
analysed for concentrations of glucose, insulin, triglyceride and glycerol as described in 
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section 3.6.4. Due to unforeseen complications with the analysis of plasma samples for 
NEFA concentration, levels of this analyte are not reported in the current study.  
 
6.2.8 Subjective appetite 
 
Subjective appetite ratings were assessed using VAS (section 3.6.2) and a combined appetite 
score was subsequently calculated, as described in section 3.7. Ratings for hunger, fullness, 
PFC and satisfaction were collected at corresponding time points to venous blood samples 
(Figure 6.1), with a final VAS completed following termination of the lunch meal.  
 
6.2.9 Statistical analysis 
 
Total AUC was calculated for subjective appetite and blood analyte data using the trapezoidal 
method as described in section 3.7. Baseline comparisons between trials, AUC for all 
variables, measures of energy balance and substrate metabolism were assessed using one-
way repeated measures ANOVA. Two-way repeated measures ANOVA (condition x time) 
was used to test for differences between conditions over time as described in section 3.7.1.  
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6.3 Results 
 
6.3.1 Exercise responses 
 
Exercise intensity, oxygen consumption, heart rate, perceived exertion, substrate oxidation 
and energy expenditure were similar between bouts of brisk treadmill walking during 
EX+PRO and EX conditions (all p > 0.05) (Table 6.2). 
 
 
Table 6.2 Physiological responses during 30 minutes of treadmill walking. 
 EX+PRO EX 
       Walking Speed (km∙h-1) 5.1 ± 0.5 5.1 ± 0.5 
%V̇O2peak 51.5 ± 1.4 49.7 ± 1.0 
V̇O2 (ml∙kg-1∙min-1) 13.0 ± 0.5 12.6 ± 0.4 
Heart rate (b∙min-1) 103 ± 12 103 ± 11 
RPE 11 ± 2 11 ± 2 
CHO oxidation (g) 31.4 ± 2.6 30.1 ± 2.7 
Lipid oxidation (g) 10.7 ± 1.3 10.7 ± 1.3 
Energy expenditure (kJ) 938 ± 48 914 ± 43 
       RPE, Rating of perceived exertion; CHO, carbohydrate; EX+PRO, exercise with 
whey protein preload trial; EX, exercise trial. 
 
 
 
6.3.2 Blood glucose and plasma insulin 
 
There were no between-trial differences in blood glucose concentration at baseline (p > 0.05). 
Glucose displayed a significant condition x time interaction effect (p < 0.001), time effect 
(p < 0.001) and main effect of condition (p = 0.009; Figure 6.2a). The post-breakfast increase 
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in glucose was reduced after whey protein supplementation compared with placebo trials at 
15-30 minutes post-breakfast, and a significantly reduced peak was observed in this condition 
(EX+PRO: 7.6 ± 0.4 vs EX: 8.4 ± 0.3, CON: 8.3 ± 0.3 mmol∙l-1, p ≤ 0.04). Glucose was 
significantly lower during CON than EX+PRO and EX at 90 minutes, and lower than 
EX+PRO at 120 minutes post-breakfast (all p < 0.05). Values declined significantly below 
baseline levels after 180 minutes in all conditions. Acute (0-60 minutes) postprandial glucose 
AUC was lower after exercise followed by whey protein consumption than exercise alone 
(Table 6.3; p = 0.011), but not significantly different from CON (p = 0.12) after correcting 
for multiple comparisons. Over the full postprandial period (0-240 minutes), glycaemia was 
greater during EX compared with CON (p = 0.002) but not significantly higher than 
EX+PRO (Table 6.3; p = 0.241).  
 
Plasma insulin concentrations were not different between trials at baseline or immediately 
post exercise, but were significantly greater following the whey protein beverage 
(immediately prior to breakfast) compared with CON (EX+PRO: 249 ± 32 vs CON: 118 ± 13 
pmol∙l-1, p < 0.001), but not EX (151 ± 44 pmol∙l-1, p = 0.379). Insulin displayed a significant 
interaction of condition and time (p = 0.006), and main effects for time (p < 0.001) and 
condition (p = 0.027; Figure 6.2b). A larger peak in insulin was observed during EX+PRO 
compared with CON (EX+PRO: 1374 ± 602 vs CON: 1050 ± 420 pmol∙l-1, p = 0.004) and 
insulin AUC was greater during EX+PRO than CON, but not EX, during the acute (0-60 
minutes), intermediate (0-120 minutes) and full (0-240 minutes) postprandial analyses (Table 
6.3). There were no differences observed between conditions in whole-body insulin 
sensitivity following breakfast consumption (Matsuda-ISI: EX+PRO: 2.3 ± 0.3, EX: 
2.3 ± 0.3, CON: 2.6 ± 0.4; p = 0.344).  
162 
 
 
Figure 6.2 Mean ± SEM (n = 12) temporal changes in blood glucose (a) and plasma insulin (b) concentrations. Significant 
differences (p < 0.05) between conditions at individual time points are defined as follows; a, EX+PRO vs CON; b, EX vs 
CON; c, EX+PRO vs EX. Dotted line indicates time of breakfast consumption. EX+PRO: exercise with whey protein 
preload trial; EX: exercise trial; CON: resting trial. 
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Table 6.3 Area under the curve responses during the post-breakfast period for blood and plasma analytes. 
 Time 
(minutes) 
Area Under the Curve 
 EX + PRO  EX  CON 
             
Glucose 
(mmol∙min-1∙l-1) 
0 – 60 405 ± 22a  446 ± 21b  430 ± 17a,b 
0 – 120 778 ± 41  811 ± 39  770 ± 34 
0 – 240 1291 ± 54a,b  1330 ± 51a  1276 ± 49b 
                          
Insulin 
(pmol∙min-1∙l-1) 
0 – 60 60725 ± 7076a  49121 ± 5417a.b  47536 ± 5955b 
0 – 120 109248 ± 15805a  86490 ± 11273a.b  77807 ± 9885b 
0 – 240 128173 ± 19097a  105374 ± 14341a.b  93313 ± 11013b 
                          
Triglyceride 
(mmol∙min-1∙l-1) 
0 – 60 90.4 ± 9.3  93.9 ± 10.0  89.6 ± 6.1 
0 – 120 187.9 ± 18.8  195.7 ± 21.1  192.4 ± 13.7 
0 – 240 403.6 ± 38.1  412.7 ± 43.4  402.4 ± 29.3 
                          
Glycerol 
(µmol∙min-1∙l-1) 
0 – 60 3342 ± 288  3226 ± 154  3652 ± 261 
0 – 120 5966 ± 607a,b  5656 ± 324a  6912 ± 509b 
0 – 240 13254 ± 1281a  16074 ± 915b  15807 ± 1105b 
             Data presented as mean ± SEM. Different superscript letters within a row indicates significant difference between conditions 
(p < 0.05). EX+PRO: exercise with whey protein preload trial; EX: exercise trial; CON: resting trial. 
 
 
 
6.3.3 Plasma triglyceride and glycerol 
 
There were no differences between conditions at baseline, immediately post exercise, or 
immediately prior to breakfast in plasma triglyceride concentrations (p > 0.05). Following 
breakfast, responses were significantly affected by time (p < 0.001), such that triglyceride 
was significantly increased above baseline at 120-210 minutes post-breakfast in all 
conditions (Figure 6.3a; all p < 0.05). There was no effect of condition or a condition x time 
interaction effect on plasma triglyceride responses, and AUC was similar across conditions 
(Table 6.3; all p < 0.05).  
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Figure 6.3 Mean ± SEM (n = 12) temporal changes in plasma triglyceride (a) and glycerol (b) concentrations. Significant 
differences (p < 0.05) between conditions at individual time points are defined as follows; a, EX+PRO vs CON; b, EX vs 
CON; c, EX+PRO vs EX. Dotted line indicates time of breakfast consumption. EX+PRO: exercise with whey protein 
preload trial; EX: exercise trial; CON: resting trial. 
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Circulating glycerol concentrations did not differ between conditions at baseline, but were 
significantly greater in exercise trials than CON immediately post-exercise (Figure 6.3b; both 
p ≤ 0.004), remaining elevated immediately prior to breakfast in EX (p = 0.019). Post-
breakfast glycerol concentrations were influenced by condition (p = 0.004), time (p < 0.001) 
and a condition x time interaction effect (p < 0.001). Concentrations were similarly supressed 
below baseline in EX+PRO and EX at 15-120 minutes post-breakfast, after which EX+PRO 
remained below EX (p ≤ 0.013). Suppression of glycerol under CON was more delayed, with 
levels remaining below baseline at 30-90 minutes post-breakfast (p ≤ 0.006). AUC over 
0-120 minutes was lower in EX than CON (p = 0.01), while over the full postprandial period 
comparison of AUC indicated lower glycerol levels in EX+PRO compared to both EX 
(p = 0.023) and CON (p = 0.005; Table 6.3).  
 
6.3.4 Energy balance and substrate oxidation 
 
The rate of energy expenditure did not differ between conditions at baseline (p = 0.10). The 
amount of energy expended did not differ between EX+PRO and EX throughout (p > 0.05), 
but was understandably greater during the exercise period in EX+PRO and EX than CON, 
fully accounting for the significantly greater total energy expenditure in exercise trials 
compared with CON (both p < 0.001; Table 6.4). No differences were detected between 
conditions in absolute energy intake at the ad libitum lunch meal (p = 0.886), signifying that 
participants did not compensate for the excess energy expended in exercise trials at the 
subsequent lunch meal. When total intake over the whole trial (breakfast, test drink and 
lunch) was compared, no between-condition differences were present (p = 0.491). 
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Table 6.4 Energy intake, expenditure and substrate metabolism during the exercise period (30 minutes), post-breakfast 
period (240 minutes) or full protocol (~300 minutes). 
  EX+PRO EX CON 
     
Energy 
Intake (kJ) 
Lunch 4623 ± 356 4728 ± 385 4569 ± 343 
    Total 6925 ± 356 6686 ± 385 6527 ± 343 
          
Energy 
Expenditure 
(kJ) 
Exercise period 938 ± 48a 914 ± 43a 203 ± 14b 
    Post-Breakfast 1657 ± 87 1695 ± 83 1572 ± 73 
    Total 2690 ± 134a 2712 ± 122a 1866 ± 86b 
          
Carbohydrate 
Oxidation (g) 
Exercise period 31.4 ± 2.6a 30.1 ± 2.7a 6.1 ± 1.1b 
    Post-Breakfast 55.4 ± 4.3 56.2 ±5.7 57.1 ± 4.3 
    Total 89.3 ± 6.9a 89.0 ± 8.2a 65.5 ± 5.5b 
          
Fat Oxidation 
(g) 
Exercise period 10.7 ± 1.3a 10.7 ± 1.3a 2.9 ± 0.4b 
    Post-Breakfast 21.0 ± 2.0 21.7 ± 2.1 18.0 ± 2.1 
    Total 33.1 ± 3.3a 33.9 ± 3.5a 22.4 ± 2.6b 
     
Data presented as mean ± SEM. Different superscript letters within a row indicates significant difference between 
conditions (p < 0.05). EX+PRO: exercise with whey protein preload trial; EX: exercise trial; CON: resting trial. 
 
 
 
Rates of fat and carbohydrate oxidation did not differ between conditions at baseline 
(p = 0.593 and p = 0.879 respectively). Greater amounts of fat and carbohydrate were utilised 
over the course of each exercise trial in comparison to resting control (all p < 0.05), however 
substrate metabolism was not influenced by consumption of whey protein, with similar fat 
and carbohydrate oxidation observed between EX+PRO and EX throughout (all p > 0.05; 
Table 6.4). The greater substrate utilisation in exercise trials appears to be exclusively due to 
the contribution of the exercise bout, as no detectable differences were observed in fat or 
carbohydrate oxidation between conditions in the postprandial period following breakfast 
consumption (p = 0.127 and p = 0.969 respectively).  
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6.3.5 Subjective appetite ratings 
 
A significant effect of time on combined appetite responses was observed (p < 0.001), with 
appetite decreasing similarly following breakfast in all trials, returning to baseline levels at 
90-240 minutes post-breakfast, before decreasing similarly after the ad libitum lunch meal 
(Figure 6.4). There was no detectable difference in AUC for combined appetite score and 
individual components of subjective appetite under all conditions (all p > 0.05; Table 6.5). 
 
 
 
Figure 6.4 Mean ± SEM (n = 12) temporal changes in plasma combine appetite score. Dotted line indicates time of breakfast 
consumption. EX+PRO: exercise with whey protein preload trial; EX: exercise trial; CON: resting trial. 
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Table 6.5 Area under the curve responses during the post-breakfast period for subjective appetite responses. 
 Area under the curve 
 EX+PRO EX CON 
    
Combined appetite (mm∙min-1) 10725 ± 1354 11280 ± 1230 10545 ± 1417 
    Hunger (mm∙min-1) 9611 ± 1213 10654 ± 1173 9915 ± 1356 
    Fullness (mm∙min-1) 12931 ± 1399 12886 ± 1318 13870 ± 1423 
    PFC (mm∙min-1) 11019 ± 1487 11896 ± 1276 11590 ± 1570 
    Satisfaction (mm∙min-1) 12797 ± 1394 12545 ± 1247 13456 ± 1449 
    
Data presented as mean ± SEM. PFC: prospective food consumption; EX+PRO: exercise with whey protein preload trial; 
EX: exercise trial; CON: resting trial. 
 
 
 
6.4 Discussion 
  
The main finding from this study was that differential effects on postprandial glycaemia were 
observed when prior low-moderate intensity exercise was followed by supplemental whey 
protein, compared with the absence of a protein preload. In addition, neither exercise, nor its 
combination with post-exercise whey protein ingestion, affected postprandial triglyceride 
responses, subjective perceptions of appetite or the amount of food consumed at a subsequent 
lunch meal. Glucose tolerance was moderately impaired following prior exercise, indicated 
by a higher glucose AUC0-240 min when exercise was performed without additional protein 
compared to resting control, while insulin AUC remained unchanged. Glucose peak and 
acute AUC were not different between these conditions, indicating that this effect was 
manifested by a more prolonged elevation in blood glucose after prior exercise. When whey 
protein was ingested following exercise and prior to breakfast consumption, this impairment 
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appears to be negated, as glycaemia did not differ from control overall, and was ~9% lower 
in the acute (0-60 minutes) period following breakfast, with a significant reduction in peak 
glucose excursion.  
 
The observation of increased glycaemic response immediately following an acute bout of 
exercise is in accordance with previous findings in healthy trained males (Rose et al., 2001) 
and obese normoglycaemic males (Knudsen et al., 2014). Interestingly, the latter study 
reported that post-exercise glucose tolerance was preserved in age and BMI-matched 
participants with IGT and T2DM, indicating that this effect may be dependent on underlying 
glycaemic control. Although fasting glucose levels of participants in the current study were 
in the normal range, HOMA-IR levels indicated an underlying degree of insulin resistance 
(Geloneze et al., 2006), signifying that the effect observed may have been larger in 
participants with greater insulin sensitivity. Glucose disposal is increased during exercise in 
an insulin-independent manner (Goodyear & Kahn, 1998), due to muscle contraction-
induced translocation of GLUT4 (Borghouts & Keizer, 2000), an effect that persists for 
several hours after cessation of exercise (Colberg et al., 2010). Circulating insulin was similar 
between EX and CON throughout, indicating that increased post-exercise circulating glucose 
may be explained by greater exogenous and endogenous glucose appearance. Exercise-
induced elevation in catecholamine levels may increase hepatic glucose output (Frayn, 2010), 
and has been shown to enhance the appearance of orally ingested glucose in an animal model 
via stimulation of sodium-glucose linked transporter type 1 (SGLT1) (Aschenbach et al., 
2002). Increased postprandial splanchnic perfusion after exercise may also explain increased 
glucose absorption (Gonzalez, 2014). Evidence of greater glucose appearance following 
exercise was reported by Rose et al. (2001) who observed a 30% elevation in glucose 
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appearance during an OGTT following 30 minutes of cycling exercise, albeit at a higher 
intensity (70% V̇O2peak) than the current study.  
 
It is currently unclear how long this effect persists for, however it is likely to be transient in 
nature (Knudsen et al., 2014), and blood glucose levels were similar between exercise and 
control trials beyond 120 minutes post-breakfast in the current study. Exercise-induced 
improvements in insulin sensitivity may subsequently result in improved glucose tolerance 
for several hours after a single bout of exercise (Bonen et al., 1998), likely due to the drive 
for muscle glycogen replenishment (Horowitz, 2007). In addition, should obese individuals 
take part in regular exercise training, then improvements in aerobic fitness and potential 
weight loss are likely to have independent effects on improving glucose metabolism 
(Borghouts & Keizer, 2000; Coker et al., 2009). Nevertheless, knowledge of the acute effect 
of exercise on glucose tolerance when food is ingested immediately or shortly after exercise, 
is of significance when aiming to ameliorate the adverse effects of postprandial 
hyperglycaemia on metabolic health (Ceriello et al., 2008; Monnier & Colette, 2015).  
 
The observed reduction in acute glycaemia following post-exercise whey protein 
supplementation could be attributed to a combination of mechanisms, including the direct 
effects of amino acids, particularly leucine, on β-cell stimulation (Gao et al., 2003) and 
activation of the incretin response (Salehi et al., 2012). An increase in plasma insulin in the 
whey trial compared to control was observed 15 minutes after consumption of the whey 
preload, signifying greater circulating insulin coinciding with the timing of breakfast 
consumption. The post-breakfast rise in insulin secretion also occurred earlier in the 
EX+PRO trial, with higher concentrations observed at 15 minutes post-breakfast compared 
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with both non-protein conditions. The fact that the acute glucose response was attenuated in 
EX+PRO compared with EX, in the context of a potentially increased rate of post-exercise 
glucose absorption, is suggestive of delayed gastrointestinal transport of orally ingested 
glucose. As described in Chapter 5, the rate of gastric emptying exerts considerable influence 
in determining the magnitude of postprandial glucose excursions (Marathe et al., 2013; 
Mignone et al., 2015), accounting for ~35% of variance in glycaemic response to 
carbohydrate-containing meals in healthy individuals (Horowitz et al., 1993). Large 
fluctuations in circulating glucose concentrations have deleterious effects on endothelial 
function and oxidative stress in both healthy individuals and T2DM patients (Ceriello et al., 
2008). The attenuation of peak glucose excursion compared to both exercise and resting 
control conditions in the current study may therefore indicate a role for pre-meal 
supplementation of whey protein both at rest, and when consuming meals shortly after bouts 
of low-moderate intensity exercise, in obese individuals. The stimulus was not great enough 
to detect a reduction in glycaemia over the full postprandial period, however it was sufficient 
to negate the increase observed in post-exercise glycaemia without additional whey protein.  
 
There was no effect of whey protein supplementation on postprandial triglyceride in the 
current study. This reflects the findings of Chapter 5 where the same breakfast meal was 
administered, albeit without prior exercise, and is most likely due to the low fat content of 
the breakfast meal provided, which contrasts with previous investigations of whey protein 
and postprandial lipaemia (Holmer-Jensen et al., 2013; Mortensen et al., 2009; Pal et al., 
2010b). Elevated glycerol concentrations immediately post-exercise are indicative of 
increased lipolysis and lipid substrate availability for exercise, confirmed by the observed 
increase in fat oxidation during exercise. Increased fat oxidation is associated with the 
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postprandial triglyceride-lowering effects of exercise (Trombold et al., 2014), however 
postprandial substrate utilisation was not significantly different between exercise and control 
trials in the present study, and triglyceride responses were similar between conditions. A 
large body of evidence implicates exercise in the attenuation of postprandial lipaemia (Freese 
et al., 2014; Maraki & Sidossis, 2013), however the clear majority of studies have 
administered a test meal >4 hours after cessation of exercise, with those studies that have 
shown a more acute effect administering meals considerably greater in fat content (>95 g) 
and prescribing a greater workload during aerobic exercise bouts than the current study 
(Katsanos & Moffatt, 2004; Plaisance et al., 2008).  
 
The magnitude of postprandial triglyceride reduction appears to be related to the amount of 
energy expended during the most recent exercise bout (Gill et al., 2002). Participants 
expended ~926 kJ during 30 minutes brisk walking in the current study, which may be 
considered a relatively modest energy deficit. This was necessitated by the fact that 
participants were habitually inactive, obese individuals and the bout was designed to reflect 
a realistically achievable isolated exercise session within this population. Furthermore, 
replacement of the exercise-induced energy deficit via mixed-macronutrient (Burton et al., 
2008) or carbohydrate (Harrison et al., 2009) feeding attenuates or abolishes improvements 
in postprandial triglyceridaemia. In the current study, participants consumed breakfast 
containing more than double the amount of energy expended during treadmill walking, which 
may account for the similar lipaemic responses in exercise and resting conditions. It has also 
been observed that consumption of a meal immediately after exercise diminishes the shift 
from carbohydrate to fat oxidation that usually follows exercise (Dionne et al., 1999), which 
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may explain the lack of significant differences in substrate utilisation in resting and exercise 
conditions in this study.  
 
Appetite was unaffected by prior exercise in the current study, which appears to be consistent 
with previous evidence suggesting that appetite is not altered by acute moderate-intensity 
exercise (Blundell & King, 2000). In accordance with the comparable subjective appetite 
responses, lunch meal energy intake 4 hours post-breakfast was similar between conditions. 
The failure of participants to compensate for the deficit created by prior exercise reflects the 
findings of the majority of exercise studies (Martins et al., 2008) and brisk walking protocols 
(King et al., 2010). The moderate energy deficit created by the exercise bout in the present 
study, in addition to the short duration between exercise and consumption of a standardised 
breakfast, is likely to have influenced this response. It may also be a possibility that energy 
expenditure from exercise is gradually compensated for over several meals or even days, 
however such compensation is likely to only partially account for energy expended (Blundell 
et al., 2003). Nevertheless, the provision of standard breakfast meals, in addition to the lack 
of a difference in lunch intake, meant that participants maintained a difference in energy 
balance in the exercise control trial compared with resting control that was equivalent to the 
net amount expended during exercise. This highlights the potential efficacy of brisk walking 
to create acute energy deficits in obese individuals and, if repeated regularly, a potential 
application for weight control.  
 
A limitation of the current study is that a whey protein supplementation trial without prior 
exercise was not conducted, which may have allowed uncoupling of the interaction of these 
two factors on postprandial responses. However, having identified the effectiveness of a 
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whey protein preload to attenuate acute postprandial glycaemia in the previous chapter, the 
present study was designed to investigate the potential of whey protein to influence post-
exercise effects, rather than the effects of whey protein per se. In addition, implementation 
of a longer investigation period may have been warranted, as the transient effects of a single 
bout of exercise on insulin sensitivity may last for up to 72 hours (Colberg et al., 2010), 
indicating that these beneficial effects may occur beyond the time frame studied here. The 
timing of post-exercise feeding may have limited the ability to identify significant effects of 
exercise on postprandial lipaemia and subsequent intake, however the consumption of a meal 
or snack following fasted morning exercise is likely, ensuring that these findings hold 
relevance in a free-living setting. 
 
In summary, this study in sedentary, overweight males showed that an isolated bout of brisk 
walking exercise moderately impaired post-exercise glucose tolerance, and that a whey 
protein preload consumed immediately post-exercise negates this effect. Furthermore, acute 
postprandial glycaemia was attenuated following whey protein consumption, and energy 
intake at a later lunch meal was not influenced by the intervention. Caution should be applied 
when interpreting the acute effects of a single bout of exercise given the benefits associated 
with regular exercise training. 
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CHAPTER 7 
 
General Discussion 
 
7  
7.1 Introduction 
 
Chronic metabolic conditions such as T2DM currently place an unprecedented burden upon 
global health care systems (Diabetes UK, 2014; Wang et al., 2011), and vast swathes of 
scientific literature are devoted to understanding their aetiology and the development of 
strategies for prevention and treatment. In this context, the postprandial period is of 
significant interest to researchers due to the acute effects of meal handling on the metabolic 
and hormonal milieu, and the adverse health effects associated with chronic exposure to an 
impaired response. Given that western populations effectively spend most the day in the 
postprandial state, interventions aiming to adjust the acute meal response are pertinent to 
preventing the deterioration in metabolic health that may precede the onset of overt 
symptoms. Several studies have indicated potential health-promoting effects of whey protein 
supplementation, however a large degree of variation exists in the methodology used. The 
research presented in this thesis has built on existing knowledge by examining the impact of 
whey protein ingestion at breakfast on acute and subsequent meal postprandial metabolism 
and appetite, utilising practical supplementation strategies that provide the research with 
‘real-world’ application. The purpose of this chapter is to collate and reflect upon the main 
findings, consider the limitations of the methodology utilised and provide directions for 
future research.  
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7.2 Reflections on main findings 
 
7.2.1 Whey protein supplementation and glycaemia 
 
Based on previous literature, the potential for whey protein to positively influence 
postprandial blood glucose is clear. A variety of designs have reported reduced glycaemia 
following consumption of whey protein as a standalone supplement or as part of a test meal 
in normal-weight (Akhavan et al., 2010; Gunnerud et al., 2013), overweight (Bowen et al., 
2006b; Pal et al., 2010b) or T2DM populations (Jakubowicz et al., 2014; Ma et al., 2009) 
 
From this series of studies it would appear that 20 g whey protein is sufficient to reduce 
postprandial glycaemia in obese but not normal-weight males, however this may not be a fair 
comparison to make due to the different designs conducted in these populations. In Chapter 5 
the supplementation of whey as a preload 15 minutes prior to breakfast was the most effective 
intervention emphasised by reduced post-breakfast glucose AUC, while insulin remained at 
similar levels to control. This strategy was not tested in the normal-weight participants in 
Chapter 4, where whey was consumed at the same time as the breakfast meal. The use of a 
different breakfast meal also makes direct comparison difficult, however the GI of breakfast 
meals used in Chapters 4a and 5 were matched.  
 
The importance of the timing of supplementation is illustrated by the post-breakfast 
glycaemic responses in all three protein conditions in Chapter 5 (Figure 5.2b). Although not 
all significantly different from each other, glycaemia appears to increase in a stepwise fashion 
as whey supplementation progresses from -15 to 0 and +15 minutes in relation to the timing 
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of breakfast consumption, indeed a straight line could almost be drawn through the graphical 
representation to illustrate this. When comparing the with-meal whey protein trial from 
Chapter 5 with the equivalent condition in Chapter 4a, findings between normal-weight and 
obese participants do not differ markedly. Post-breakfast AUC did not differ from the non-
protein control in either comparison, and peak glucose excursion was significantly lower in 
obese participants while in normal-weight participants there was a non-significant trend for 
reduced peak glucose (p = 0.059). This makes it attractive to speculate that if the normal-
weight participants had completed the same protocol as that implemented in Chapter 5, 
significant reductions in glucose AUC and peak glucose may also have been observed. Only 
one acute study has focussed on the glycaemic response to whey protein in both normal-
weight and overweight participants (Zafar et al., 2013). Whey protein was effective in 
reducing postprandial glycaemia in both groups, although glucose was attenuated from a 
greater peak in overweight participants, with speculation that insulin sensitivity is enhanced 
following whey supplementation to a greater extent in overweight individuals, as observed 
following chronic whey protein consumption in both rats (Belobrajdic et al., 2004) and 
humans (Pal et al., 2010a).  
 
It may be argued that reducing postprandial glycaemia is of less importance in the normal-
weight cohort due to the healthy weight status and relative lack of insulin resistance exhibited 
by these participants (HOMA-IR: 2.1 ± 1.1). However, postprandial hyperglycaemia 
contributes to CVD risk independently of weight status, (Bianchi et al., 2008; Gerich, 2006; 
Monnier et al., 2012), even when fasting glucose is in the normal range (Ning et al., 2012). 
Ensuring that postprandial glycaemic excursions remain within a healthy range throughout 
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the life course may therefore be a significant strategy in averting the onset of metabolic 
disease.   
 
The finding that post-exercise whey protein negated the impairment observed in post-
exercise glycaemia in physically inactive obese males was a novel and interesting outcome. 
However, the lack of a non-exercise whey protein condition in this study made uncoupling 
of the effects of whey protein and prior exercise on glycaemia problematic. Whether the 
blood glucose response would be further reduced by consuming a whey protein preload in 
the absence of prior exercise cannot be answered with any degree of certainty, however 
overlaying the trace of this condition from Chapter 5 onto the glucose trace from Chapter 6 
(Figure 7.1) appears to confirm this conjecture. Only five participants took part in both 
studies, making this a speculative observation, however the breakfast meal, whey protein 
dose and blood sampling schedule were identical across studies, albeit participants were 
observed for an additional hour in Chapter 6. Examination of these responses confirms the 
moderate impairment in glucose tolerance following an acute bout of brisk walking exercise, 
and the subsequent abrogation of this effect by post-exercise whey protein consumption. 
Although this protocol was not completed by the normal-weight participants in Chapter 4, 
this effect may hold relevance, despite the greater level of fitness, as previous studies have 
reported higher post-exercise glycaemia in healthy trained males (Rose et al., 2001) and 
obese normoglycaemic males (Knudsen et al., 2014). Although this is likely to be a transient 
effect, this phenomenon may be of significance to those who undertake exercise infrequently, 
and when intake of a meal is likely in the immediate post-exercise period.  
 
 
179 
 
 
Figure 7.1 Mean ± SEM temporal changes in blood glucose concentrations. Dotted line indicates time of breakfast 
consumption. EX+PRO: exercise with whey protein preload trial; EX: exercise trial; CON: resting trial; CON+PRO: resting 
trial with whey protein preload. 
 
 
 
When assimilating the findings reported in this thesis in the context of postprandial 
glycaemia, the rationale for further investigation of the glucose reducing effects of whey 
protein is prominent, particularly in centrally-obese individuals. Although a whey preload 
has been observed to be particularly effective in reducing acute postprandial glycaemia, 
further investigation of the optimal timing of pre-meal ingestion may be warranted. To the 
author’s knowledge this was the first study to assess the effect of timing of whey protein 
consumption on post-meal glycaemia in a non-diabetic population. The modification of post-
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exercise glycaemia has also been observed following brisk walking in previously sedentary 
obese individuals, however it remains to be seen whether such a response would be observed 
when varying the modality or intensity of exercise, or in different populations. Furthermore, 
Chapters 4 and 5 appeared to confirm that supplementation of 20 g whey protein with a meal 
does not affect glycaemia at the next meal or later in the day, potentially providing a rationale 
for the investigation of supplementation with multiple sequential meals. 
 
 
7.2.2 Whey protein supplementation and lipaemia 
 
The importance of postprandial hypertriglyceridaemia as a determinant of CVD risk is 
increasingly recognised (Kolovou et al., 2011), and the beneficial effects of whey protein 
supplementation on post-meal triglyceride reported in some studies (Holmer-Jensen et al., 
2013; Mortensen et al., 2009; Pal et al., 2010b) is of interest for this reason. Nevertheless, 
evidence is currently limited to comparison of whey with glucose or other protein sources, 
and studies investigating this response in the absence of unrealistically high-fat meals have 
been lacking.  
 
The consumption of whey protein with a high-carbohydrate (Chapter 4a) or high-fat (Chapter 
4b) breakfast meal in normal-weight participants, or a mixed breakfast meal (Chapters 5 
and 6) in centrally-obese participants, did not modify postprandial triglyceride responses 
throughout this body of work. It could be speculated that the low-fat content of the breakfasts 
served in Chapter 4a (2 g) and Chapters 5 and 6 (9 g) would not be expected to augment a 
large enough postprandial response for any reduction to be apparent, and this was almost 
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certainly the case in these studies. When supplemented with a fat-rich meal (Chapter 4b), 
whey protein actually appeared to induce a moderately higher triglyceride response, however 
the difference in total AUC (~15%) was not significant. This may be explained by the reduced 
post-lunch insulin sensitivity observed in the whey protein trial, as insulin resistance is 
associated with impaired clearance and increased production of chylomicrons (Pal et al., 
2010b) thus increasing triglyceride exposure. Considering the higher fasting triglyceride and 
HOMA-IR levels of the centrally-obese cohorts from Chapters 5 and 6, differential responses 
may be exhibited compared with their normal-weight counterparts, and future research 
should investigate this response. Evidence from these studies adds to the mixed picture 
regarding the potential of whey protein to improve markers of dyslipidaemia. In addition, 
prior low-moderate intensity exercise did not appear to affect postprandial triglyceride levels, 
although delaying the consumption of the post-exercise meal may allow identification of this 
response in future work. 
 
7.2.3 Whey protein supplementation and appetite 
 
Although not measured in this body of work, whey protein has previously been reported to 
augment postprandial levels of gut hormones including GLP-1 and CCK in addition to 
supressing ghrelin (Bowen et al., 2006a), thus promoting satiety. The effect on subjective 
appetite in previous studies is equivocal, however whey protein has been shown to suppress 
subsequent food intake with greater consistency. In this thesis, whey protein did not influence 
subjective appetite regardless of the population studied or the interventions tested. In 
addition, subsequent energy intake at lunch was not affected by prior exercise or post-
exercise whey protein. These findings are perhaps surprising as whey has consistently been 
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shown to potentiate insulin secretion throughout the studies in this thesis, and the short-term 
satiating effect of insulin has previously been reported (Flint et al., 2007), however this effect 
may be blunted in obese individuals. Whether whey protein would influence satiety outside 
of the laboratory remains uncertain, and future work should investigate this response further 
in the context of preventing overconsumption and subsequent obesity. The exercise-induced 
energy deficit generated by participants in Chapter 6 was not compensated for at a subsequent 
lunch meal, independent of whey supplementation, which was consistent with previous 
research (Blundell & King, 2000). Brisk walking and post-exercise whey protein 
consumption may therefore be an effective combination in reducing chronic disease risk, 
enabling the creation of moderate energy deficits while controlling postprandial glycaemic 
excursions.  
 
7.3 Methodological limitations 
 
Several limitations have been addressed within the relevant experimental chapters of this 
thesis, however there are a number of common limitations which may apply across all 
chapters. In order to assess postprandial responses, studies were confined to the controlled 
environment of the laboratory. Whilst this allows thorough investigation of effects and 
mechanisms of interest without the confounding influence of many extraneous factors, it 
limits the application of findings in the free-living setting. Although interstitial glucose was 
recorded outside of the laboratory in Chapter 4, this did not constitute free-living conditions 
as participants were asked to replicate dietary intake across conditions. Efforts were made to 
increase the ecological validity of findings throughout, including administering doses of 
protein that could realistically be supplemented alongside a meal, and using foods that were 
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typical of those consumed at breakfast and lunch meals across the population. However, due 
to the influence of behavioural and environmental factors on satiety (Benelam, 2009), 
measures such as subjective appetite and ad libitum energy intake may still be affected by 
the unfamiliar environment. Care should therefore be taken when interpreting the relevance 
of these findings for individuals in the free-living setting.  
 
Extrapolation of findings may also be hindered by the relatively homogenous nature of the 
sample groups within each study. Typical of a number of studies conducted in this area of 
research, only male participants were used. This was a consequence of the desire to eliminate 
the confounding hormonal influence of the menstrual cycle upon metabolism (Brennan et al., 
2009) which, if controlled for, may have added considerably to the duration of each data 
collection period during these multiple-visit designs. In addition, although no screening for 
ethnicity was in place throughout this work, all participants were of European ethnicity 
except for two who were of South Asian ethnicity. It is well established that differences in 
disease risk exist between ethnicities, with higher prevalence of T2DM amongst South Asian 
populations (Khunti et al., 2013) a well-reported example. Thus, extrapolation of findings to 
other populations should be interpreted cautiously.  
 
The findings of this body of work may have been enhanced by the measurement of additional 
parameters to fully explain the mechanisms underlying the effects observed. Measurement 
of energy substrates and insulin enabled patterns of metabolic regulation to be detected, 
however this evidence was insufficient to fully explain the influence of whey protein on 
glycaemia observed in Chapters 5 and 6. Determination of circulating concentrations of 
amino acids, incretin hormones and DPP-IV, as well as rates of gastric emptying, may have 
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been beneficial in this respect. Implementation of such measures was limited by practical 
constraints in the studies described, however consideration should be given to incorporating 
these measures into future work.  
 
7.4 Future directions 
 
Acute trials such as those reported in this thesis, provide valuable information regarding the 
effects of whey protein consumption on immediate post-meal responses in a laboratory 
environment. As identified in Chapters 4 and 5, whey protein does not appear to significantly 
influence postprandial metabolism at a subsequent eating occasion. In order to identify the 
efficacy of whey to influence glycaemia and other markers over a longer period, studies 
should be conducted to investigate the effects of supplementation at multiple meals. Frid et 
al. (2005) reported the effects of supplementing breakfast and lunch meals with whey protein 
in individuals with T2DM however, to the author’s knowledge, no studies have been 
conducted in other populations or investigated supplementation at more than two consecutive 
meals.  
 
In addition, consideration should be given to the fact that prevention of deteriorating 
metabolic health may require chronic improvements in postprandial glycaemia and other 
markers which cannot be observed in the acute laboratory setting. Despite this, studies 
assessing the longer-term effects of whey supplementation are relatively few in number, with 
only one study having been carried out in normal-weight participants (Astbury et al., 2014) 
and a small number in overweight/obese (Baer et al., 2011; Gouni-Berthold et al., 2012; Pal 
et al., 2010a; Pal et al., 2014) or diabetic (Ma et al., 2015) individuals. Although some 
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inconsistencies are apparent, the limited evidence to date appears to show that chronic 
supplementation of the diet with whey protein is associated with metabolic health benefits 
including improved fasting lipid profile and insulin sensitivity, with possible effects on food 
intake and body mass. This work may be advanced through development of an optimal 
chronic supplementation strategy, while development of food products incorporating whey 
protein may enhance adherence to supplementation. The use of CGM technology would also 
enable assessment of the longer-term influence of whey protein supplementation on mean 
glycaemic exposure and glycaemic variability.  
 
Additionally, the implementation of longer-term supplementation protocols would allow 
assessment of potential negative consequences of whey protein supplementation on 
metabolic health. Increased postprandial insulinaemia in the absence of a reduction in 
glycaemia is suggestive of compromised insulin sensitivity, an effect that has previously been 
observed following acute whey protein ingestion (Smith et al., 2015). Thus there is potential 
for the chronic exposure to the insulinotrophic effects of whey protein to have a desensitising 
effect on sites of insulin action, which would have a detrimental effect on the prevention of 
metabolic disease.  
 
7.5 Conclusion 
 
In summary, the findings of this thesis indicate that addition of a practical dose of whey 
protein to a typical breakfast meal improves the glycaemic response to that meal in centrally-
obese males. This may add weight to previously observed inverse associations between 
consumption of dairy products and obesity, metabolic syndrome and T2DM. Pre-meal whey 
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protein may modify postprandial glycaemia to a greater extent than consumption during or 
after a meal, however beneficial effects do not persist past a subsequent meal. In addition, 
post-exercise whey protein is effective in abolishing the transient impairment in postprandial 
glycaemia observed following prior walking exercise in previously sedentary individuals. 
Further investigation is now required to determine the chronic and long-term effects of whey 
protein consumption and its role in the management of body mass and metabolic regulation. 
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APPENDICES 
 
APPENDIX A: Participant information form 
 
 
 
Faculty of Health & Life Sciences 
 
PARTICIPANT INFORMATION 
 
 
The purpose of this information sheet is to provide you with sufficient information so that you can then give 
your informed consent. It is thus very important that you read this document carefully, and raise any issues that 
you do not understand with the investigator.  
 
 
Project Title:  Metabolic and appetite responses to a whey protein preload following prior exercise 
                        in overweight and obese males 
 
Principal Investigator:  Dean Allerton 
 
Supervisor:  Dr. Penny Rumbold 
 
Email address:  d.allerton@northumbria.ac.uk 
 
 
INFORMATION FOR POTENTIAL PARTICIPANTS 
1. What is the purpose of the project? 
Consuming whey protein may have beneficial effects on health, principally by having an impact on blood 
sugar metabolism, but also by affecting appetite. The purpose of this project is to investigate the effect 
of consuming whey protein following a bout of low/moderate intensity exercise (brisk walking) on 
glucose and fats in the blood as well as on appetite. 
 
2. Why have I been selected to take part and what are the exclusion criteria? 
You have been asked to participate because you are male, aged between 18 and 55 years old, have a 
BMI above 25 kg/m2, have a waist circumference greater than 102 cm and currently have a low level of 
physical activity. 
You should NOT take part if you are a smoker or have any metabolic disorder (i.e. type 1 diabetes, type 
2 diabetes, thyroid disorders). If you have a food allergy/intolerance, eating disorder, current illness, 
regularly skip breakfast or are currently taking medication which may affect your metabolism you should 
also not take part. 
 
3. Do I have to take part? 
Participation is completely voluntary. Before you decide to take part we will discuss the study and you 
will have the opportunity to ask any questions. If you agree to take part, we will then ask you to sign a 
consent form. However, if at any time you decide you no longer wish to take part in the study you are 
free to withdraw at any time without giving a reason. 
222 
 
4. What will I have to do? 
 
After giving informed consent, you will be screened for eligibility to take part in the study. This will involve 
basic measures being taken (height/weight/waist) and completion of a screening questionnaire and 
physical activity questionnaire. If eligible, you will be required to visit the lab for 1 short preliminary visit 
(30 minutes) and 3 separate main trials, each separated by at least 5 days. Each trial will last 
approximately 6 hours, however you will have the opportunity to read or use a laptop during this time.  
 
Preliminary visit (30 minutes) 
 
The preliminary visit involves walking on a treadmill for 12 minutes, starting with a 3 minute warmup 
and then completing 3 stages (3 minutes each). At the end of each stage the speed will be increased 
slightly so that you will be walking at a brisk pace by the end of the test. Throughout the test, you will 
be required to wear a mask in order to collect the air that you breathe out and a chest strap to record 
heart rate. You will be provided with a ready meal to eat on the night before each trial.  
 
Main trials (3 x 6 hours) 
 
You will be asked to arrive at the laboratory at the same time of morning for all four trials, having not 
had breakfast, and having refrained from alcohol and caffeine on the previous day. A cannula will be 
inserted into a vein in the arm by a trained researcher and a blood sample will be taken. A very small 
fingertip sample will also be taken. We will also record the air you breathe for a 10 minute period while 
you rest, and will ask you to collect a sample of urine when you need to use the bathroom. 
 
After this you will be asked to remain seated for 30 minutes (in 1 of the trials) or walk for 30 minutes on 
a treadmill (in 2 of the trials). The speed will be set at a low/moderate intensity for the walking exercise. 
15 minutes after this you will be given a drink which will contain either flavoured water or whey protein, 
followed 15 minutes later by breakfast which will consist of porridge sweetened with honey. For the 
following 4 hours you will be required to rest, and at various points we shall collect blood from the 
cannula that is already placed in the arm and from a fingertip. We shall also ask you to answer questions 
about your appetite, and will ask you to put on the mask that collects your expired air for a short period 
every half an hour.  
 
After this you will be provided with lunch which shall consist of pasta in a cheese and tomato sauce, as 
well as water to drink. You will be asked to keep eating until you feel that you are comfortably full. The 
cannula will then be removed and you will be able to leave the lab. During the whole visit you will be 
able to read or use a laptop (Wi-Fi is provided) to pass the time. 
 
5. Will my participation involve any physical discomfort? 
The collection of blood via cannulation may result in a small amount of light bruising, however this is 
normal and will be minimised as this procedure will be carried out by trained personnel. Capillary blood 
sampling may cause very slight discomfort when the finger-prick technique is used, however this is 
extremely short-term in nature and usually relatively painless. 
 
6. Will my participation involve any psychological discomfort or embarrassment? 
No 
 
7. Will I have to provide any bodily samples (i.e. blood, saliva)? 
We will require venous blood samples taken from a cannula at various intervals throughout the day. 
The maximum amount of blood we will take during the whole day is 130ml, which falls well within safe 
guidelines for blood sampling, however this may affect your ability to donate blood in the weeks 
following the study. Capillary blood samples shall also be collected using the standard finger-prick 
technique. This involves collecting a small droplet of blood from the fingertip. Urine samples shall also 
be collected during each visit. 
 
8. How will confidentiality be assured and who will have access to the information that I provide? 
Upon participation you will be allocated a participant code that will be used to identify your data, 
therefore your name will not be associated with any data collected. All data will either be kept in a locked 
filing cabinet or accessed via a password-protected computer. This is in accordance with the Data 
Protection Act.  
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Only the principal investigator and their supervisory team will have access to information that you 
provide, and all records will remain confidential. Any published results will be anonymous, therefore 
your personal data will not be identifiable. 
 
9. How will my information be stored / used in the future? 
All identifiable data will be kept in a locked filing cabinet. In accordance with the Data Protection Act, 
data will not be kept longer than is necessary for the purposes of this study. Following this it will be 
destroyed appropriately. Blood samples collected and stored during this study will be disposed of 
following the conclusion of the study. 
 
10. What will happen to the results of the project? 
Data may be included as part of a thesis submission as well as used for publication in the form of a 
scientific paper or presented at a conference. 
 
11. Who has reviewed the project? 
This study has been approved by the Faculty of Health and Life Sciences Research Ethics Committee, 
Northumbria University. 
 
12. Will I receive any financial rewards / travel expenses for taking part? 
Yes. You will receive £150 in compensation for your time after participating fully in this research project. 
You will also be provided with breakfast and lunch during each trial of the study as well as evening 
meals the night before each trial.  
 
13. How can I withdraw from the project? 
You can withdraw from the project at any point without providing reasons for doing so, by contacting 
the principal investigator (contact details at the top of this form). If you have any concerns please feel 
free to discuss them with the principal investigator. If, for any reason, you wish to withdraw your 
data please contact a member of the research team who will facilitate this, and discuss with you how 
you want your data to be treated. Please bear in mind that if this may not always possible if the request 
is made after a long period following participation, as results may already have been published, however 
you will not be identifiable in any way from the published data. 
 
14. What happens if there is a problem? 
If you have a concern about any aspect of the study you should ask to speak to the researchers who 
will do their best to answer any questions you may have. If they are unable to resolve your concern, or 
you wish to make a complaint regarding the study, please contact the chair of the Faculty of Health and 
Life Sciences Ethics Committee:  
 
Chair of Faculty of Health and Life Sciences Ethics Committee,  
Northumberland Building,  
Northumbria University,  
Newcastle upon Tyne,  
NE1 8ST 
 
15. Who is funding and organising the project? 
The study is funded by the Faculty of Health and Life Sciences, and organised by researchers within 
the Department of Sport, Exercise and Rehabilitation at Northumbria University.  
 
16. If I require further information who should I contact and how? 
If you would like to ask questions or gain further information on the study please contact the principal 
investigator on the contact email address listed at the beginning of this form. If you would like to 
withdraw your data or register a complaint please contact the chair of the ethics committee on the 
address listed in section 14 of this form. 
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APPENDIX B: Informed consent form 
 
  
Faculty of Health & Life Sciences 
 
INFORMED CONSENT FORM 
 
Project Title:   Metabolic and appetite responses to a whey protein preload following prior    
                         exercise in overweight and obese males 
 
Principal Investigator:   Dean Allerton 
Participant Code:  _____________________________ 
                                                                                                                    
please tick 
where applicable 
 
I have read and understood the Participant Information Sheet.  
 
I have had an opportunity to ask questions and discuss this study and I have received 
satisfactory answers. 
 
 
I understand I am free to withdraw from the study at any time, without having to give a 
reason for withdrawing, and without prejudice. 
 
 
I agree to take part in this study.  
 
I would like to receive feedback on the overall results of the study at the email address 
given below. 
 
Email address…………………………………………………………………… 
 
 
 
 
Signature of participant.......................................................    Date.....……………….. 
 
(NAME IN BLOCK LETTERS)....................................................………………………. 
 
 
Signature of researcher.......................................................    Date.....……………….. 
 
(NAME IN BLOCK LETTERS)....................................................………………………. 
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APPENDIX C: Health screening questionnaire 
 
  
Faculty of Health & Life Sciences 
Participant Screening 
 
Strictly Confidential 
 
 
Please answer these questions truthfully and completely. The sole purpose of this questionnaire is to 
ensure that you are fit and healthy to follow the proposed research programme. 
 
For the participant to complete: 
 
Screening Number                                                                       
Date of Birth  
Age  
Gender Male  /  Female 
 
How often do you eat breakfast?   Always  /  Regularly  /  Sometimes  /  Rarely  /  Never 
 
Do you have any known allergies 
or intolerances? 
  Yes  /  No 
If yes please list:  
 
Do you have or suffer from: Details: 
History of heart disease (e.g. Heart attack, 
surgery, angina, etc.) 
Yes  /  No  
Problems with the circulation Yes  /  No  
High blood pressure Yes  /  No  
Diabetes Yes  /  No  
Lung disease/breathing problems (e.g. Asthma, 
COPD, etc.) 
Yes  /  No  
Kidney disease Yes  /  No  
Have you ever suffered from:   Details: 
Discomfort in the chest, jaw, neck, back or arms Yes  /  No  
Light headedness, dizziness or fainting Yes  /  No  
Shortness of breath at rest Yes  /  No  
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Have you had a recent illness? Yes  /  No 
If yes please list:  
 
Are you currently taking any medication?   Yes  /  No 
If yes please list:  
 
Do you have any injuries / joint problems 
which would make exercising difficult? 
  Yes  /  No 
If yes please list:  
 
Are you currently a smoker?   Yes  /  No 
Have you previously been a smoker?   Yes  /  No 
If yes: How long is it since you stopped?  
 
Is there anything that you feel would stop you from 
successfully completing the research study outlined to you? 
 
If yes please feel free to discuss with the research team 
 
  Yes  /  No 
 
 
For the researcher to complete: 
 
Height (cm)  
Body Mass (kg)  
BMI (kg/m2)  BMI Classification  
Waist Circumference (cm)  
Hip Circumference (cm)  
 
IPAQ physical activity level   Low  /  Moderate  /  High 
Adequate venous access   Yes  /  No 
 
 
The information I have given is correct to the best of my knowledge at the time of completion. 
 
Participant Signature  
Date  
Researcher Signature  
Date  
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APPENDIX D: International physical activity questionnaire (IPAQ) 
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APPENDIX E: Food diary 
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APPENDIX F: Whey protein isolate – product information 
 
APPENDIX F1: Chapters 4a and 4b 
 
 
 Material Whey Protein Isolate 
 Name PSNU27600 
 Solids (%) 95.26 
 Protein (%) 82.93 
 Carbohydrates (%) 9.264 
 Ash (%) 2.72 
 Fat (%) 0.15 
   
 Amino acids  
* Trp. (g/100 g protein) 2.64 
 Asp (g/100 g protein) 12.64 
* Thr(g/100g protein) 5.32 
 Ser(g/100g protein) 4.63 
 Glu(g/100g protein) 18.25 
 Pro(g/100g protein) 5.33 
 Gly(g/100g protein) 1.98 
 Ala(g/100g protein) 5.14 
* Val(g/100g protein) 5.78 
* Isoleu(g/100g protein) 6.21 
* Leu(g/100g protein) 13.40 
 Tyr(g/100g protein) 3.85 
* Phe(g/100g protein) 3.94 
* His(g/100g protein) 2.20 
* Lys(g/100g protein) 11.11 
 Arg(g/100g protein) 2.74 
 Cys + Cystine(g/100g protein) 3.20 
* Methionin(g/100 g protein) 2.43 
 *Essential amino acids  
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APPENDIX F2: Chapters 5 and 6 
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APPENDIX G: Visual analogue scales (VAS) 
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APPENDIX H: Rating of perceived exertion (RPE) scale 
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